DOCUMENT RESUME

ED 070 466 LI 004 018

AUTHOR	Schneider, John H.
TITLE	Cancer Therapy (Preclinical and Clinical): A Decimal Classification, (Categories 51.1, 51.2, and 51.3).
INSTITUTION	National Cancer Inst. (NIH), Bethesda, Md.
REPORT NO	NCI-STIO-7201
PUB DATE	24 Apr 72
NOTE	57p.; (0 References)
AVAILABLE FROM	National Technical Information Service, Springfield, Va., 22151. (PB-210 023, MF $.95, HC $3.00)
EDRS PRICE	MF-$0.65 HC-$3.29
DESCRIPTORS	*Classification; Information Dissemination; *Information Retrieval; *Information Storage; *Medical Research; *Organization
IDENTIFIERS	*Cancer; Decimal Classification

ABSTRACT

This hierarchical decimal classification of information related to cancer therapy in humans and animals (preceeded by a few general categories) is a working draft of categories taken from an extensive classification of biomedical information. Because the classification identifies very small areas of cancer information, it can be used for precise matching of cancer researchers with useful documents or data in information systems, and for detailed analysis of large cancer research programs. The use of this classification in an automated information system has been described in the following reference: J. H. Schneider, "Selective Dissemination and Indexing of Scientific Information." "Science" 173, 300-308, 1971. This paper describes the use of these classifications for precise matching of 103 cancer research scientists against a data base of 1,396 articles published in 12 leading cancer research journals. (ED 025 270 and LI 004 019-LI 004 020 are related documents.) (Author)

U.S. DEPARTMENT OF HEALTH, EDUCATION & WELFARE
OFFICE OF EDUCATION
THIS DOCUMENT HAS BEEN REPRODUCED EXACTLY AS RECEIVED FROM THE PERSON OR ORGANIZATION ORIGINATING IT. POINTS OF VIEW OR OPINIONS STATED DO NOT NECESSARILY REPRESENT OFFICIAL OFFICE OF EDUCATION POSITION OR POLICY

PB 210 623

CANCER THERAPY

(PRECLINICAL AND CLINICAL):

A DECIMAL CLASSIFICATION

(CATEGORIES 51.1, 51.2, AND 51.3)

FN 070466

ABSTRACT

This hierarchical decimal classification of information related to cancer therapy in humans and animals (preceeded by a few general categories) is a working draft of categories taken from an extensive classification of biomedical information.

Because the classification identifies very small areas of cancer information, it can be used for precise matching of cancer researchers with useful documents or data in information systems, and for detailed analysis of large cancer research programs.

John H. Schneider, Ph.D.
Scientific and Technical Information Officer
Office of Program Planning and Analysis
National Cancer Institute
Bethesda, Maryland

April 24, 1972

PUBLICATION NCI-STIO-7201

LT 004 018

The use of this classification in an automated information system has been described in the following reference:

J. H. Schneider, "Selective Dissemination and Indexing of Scientific Information", Science 173, 300-308, 1971.

This paper describes the use of these classifications for precise matching of 103 cancer research scientists against a data base of 1,396 articles published in 12 leading cancer research journals.

The development and publication of this classification would have been very difficult without the conscientious effort of Mrs. Kathleen McManus who has worked with these categories for the past six years.

Thanks are also due to Miss Patricia Gorman and Miss Cynthia Friedman who keypunched cards from very rough drafts of the classification, and to Miss Sylvia Daves for help in some of the final stages of computer programming and printing.

MOST OF THE CATEGORIES CONTAINED IN THIS CLASSIFICATION WERE DEVELOPED IN THE EARLY 60'S. LITTLE TIME WAS BEEN AVAILABLE FOR MODIFYING THE CLASSIFICATION SINCE 1968. AS A RESULT, FAST MOVING FIELDS (SUCH AS CANCER VIROLOGY) ARE NOW CONSIDERABLY OUT OF DATE IN THAT THEY DO NOT CONTAIN CATEGORIES FOR THE MOST RECENT FINDINGS AND DEVELOPMENTS, SUCH AS SPECIFIC ANTICANCER AGENTS, VIRUSES, CARCINOGENIC AGENTS, ETC.

ED 070400

CANCER THERAPY (PRECLINICAL AND CLINICAL): A DECIMAL CLASSIFICATION
(CATEGORIES 51.1, 51.2, AND 51.3)

PREFACE

Hierarchical classifications can be used for two different but related purposes:

1) In Information Systems:

Small areas of information can be precisely identified by categories in a detailed hierarchical decimal classification. These categories can be used to:

a) Index information in published documents,

b) Index information needs of individual scientists, and

c) Match scientists with indexed information and documents.

2) For Detailed Program Analysis:

Hierarchical decimal classifications can be used to organize the scientific content and substance of research programs.

This is accomplished by using categories from the classification to group related research projects together into:

a) Small research units consisting of several related projects,

b) Research areas consisting of several research units, and

c) Large program areas consisting of several research areas.

This clustering and "treeing" of research activities is an essential component of program analysis and program management activities. In addition, the hierarchical structure permits analysis at any desired level of detail -- ranging from broad summaries and overviews to individual research projects.

b.

CURRENT STATUS OF THIS CLASSIFICATION

A preliminary version of the entire cancer classification was published in 1968.* At that time, it consisted of typewritten pages which were subsequently modified by handwritten insertions and changes.

Since that time, it has been converted to punched cards, and an automated system called AUTOKLS has been written in PL/I to convert the cards to magnetic tape records. These records can be updated by another AUTOKLS program and can be printed out in indented, hierarchical format for use by indexers.

Still other parts of the AUTOKLS system are used for keeping track of cross-references between categories, for linking terms in alphabetic indexes to specific categories in the classification, and for updating the alphabetic index entries.

As mentioned in the abstract, this published version is a PRELIMINARY, WORKING DRAFT at a very early stage after the difficult conversion from typed and handwritten pages to punched cards.

For these reasons, there are some gaps and omissions in subject coverage, some topics covered only in broad outline with insufficient detail, some cases where several categories deal with the same topic in almost the same way, occasional cross-references that do not refer to the correct category number, and probably some spelling and simple clerical errors that have not yet been noticed. In addition, some cross-references refer to categories in portions of the classification which are not yet published.

However, because THIS CLASSIFICATION IS CONSTANTLY EVOLVING AND DEVELOPING it will never be available in final, fixed form. Instead, it will be published periodically to show current status. (Computer printouts of the most up-to-date version for use by indexers can easily be prepared weekly or monthly.) Most of the problems mentioned in the last paragraph will be corrected in the course of continuing updating and revision.

* John Schneider, Hierarchical Decimal Classification of Information Related to Cancer Research, (National Cancer Institute, Bethesda, Maryland). February 1968. 116 pp. (Available from National Technical Information Service, as PB-177-209.)

c.

OUTLINE OF MAJOR CATEGORIES IN THIS DOCUMENT

51. CANCER AND CANCER RESEARCH.

51.1 Very general information: History, Financial support, Information sources.

51.2 CLINICAL ASPECTS OF CANCER (GENERAL).

51.20 Clinical treatment of specific types of tumors.

51.21 General diagnostic and prognostic methods; prevention and control.

51.22 CLINICAL CANCER CHEMOTHERAPY.

51.23 Clinical use of hormones and antihormones.

51.24 Clinical use of radiation in cancer therapy.

51.25 Surgical removal of cancers from human patients; use of cryosurgery.

51.26 Clinical use of combination therapy; adjunct or adjuvant therapy: Use of chemotherapeutic agents and/or radiation and/or surgery and/or hormones.

51.27 Clinical immunotherapy: use of antibodies and other immunological prophylaxis to inhibit tumor growth in humans.

51.28 Novel methods of treatment not listed elsewhere.

51.3 PRE-CLINICAL ASPECTS OF CANCER THERAPY: Use of exogenous agents of all types:
Experiments in animals other than humans and
Experiments in vitro.

51.31 Selected general topics.

51.32 Pre-clinical aspects of cancer chemotherapy.

51.33 Pre-clinical studies of hormones, synthetic hormones, and hormone antagonists as therapeutic agents.
(Includes modification of normal hormonal environment by endocrine removal.)

51.34 Pre-clinical use of radiation in cancer therapy.

51.35 Surgical removal of cancers in experimental animals: Evaluation of this method for curing cancer: cryosurgery.

51.36 Pre-clinical studies of combination therapy: Adjunct or adjuvant therapy.

51.37 Pre-clinical immunotherapy: use of antibodies, vaccines, (and other immunological prophylaxis) to inhibit tumor growth in animals.

51.38 Novel methods of treatment not elsewhere classified.

(The complete list of all sub-divisions included in the outline above begins on page 1 and consists of 2,516 individual categories.)

d.

OUTLINE OF ALL MAJOR CATEGORIES FOR CANCER RESEARCH INFORMATION

51.1 Selected General Topics Related to Cancer Research

51.2 Clinical Aspects of Diagnosis and Treatment

51.3 Pre-Clinical Aspects of Diagnosis and Treatment

51.4 Cancer Epidemiology and Etiology, including all types of Carcinogenesis and Co-Carcinogenesis

51.5 Cancer Pathology; Related Physiology, Cytology, and Tissue Culture Studies

51.6 Biochemistry of Tumors and Tumor-Bearing Hosts

51.7 Host-Tumor Interactions

51.8 Cancer in Specific Types of Hosts

51.1 SELECTED GENERAL TOPICS.

51.11 HISTORICAL AND REFERENCE INFORMATION.
51.111 HISTORY OF CANCER RESEARCH AND ACCOMPLISHMENTS.
51.112 BOOKS, REVIEWS, AND SURVEY ARTICLES ON CANCER AND CANCER RESEARCH.

51.12 FINANCIAL SUPPORT OF CANCER RESEARCH.
51.121 GENERAL.
51.122 SPECIFIC ORGANIZATIONS SUPPORTING AND CONDUCTING CANCER RESEARCH (LIST IN ALPHABETICAL ORDER).
51.123 SUPPORT OF LARGE PROJECTS COVERING NUMEROUS DIFFERENT ASPECTS OF CANCER RESEARCH.
51.124 SUPPORT FOR TRAINING OF MANPOWER FOR CANCER RESEARCH AND TREATMENT OF CANCER PATIENTS.
SEE ALSO: 51.2114 FOR TRAINING OF MANPOWER FOR CANCER DETECTION AND CONTROL.
51.125 SUPPORT OF FACILITIES AND RESOURCES (INCLUDING EXPERIMENTAL ANIMALS) RELATED TO CANCER.

51.13 INFORMATION EXCHANGE RELATED TO CANCER.
51.131 GENERAL.
51.132 SCIENTIFIC COMMUNICATIONS (PRODUCTS AND SERVICES) RELATED TO CANCER.
51.1321 GENERAL.
51.1322 PRIMARY PUBLICATIONS IN CANCER.
51.1323 ABSTRACTING, INDEXING, TITLE LISTING SERVICES, AND OTHER SECONDARY INFORMATION SERVICES FOR CANCER.
51.1324 SYMPOSIA, CONGRESSES, AND OTHER MEETINGS RELATED TO CANCER AND REPORTS OF SUCH MEETINGS.
51.133 PUBLIC INFORMATION PRODUCTS AND SERVICES RELATED TO CANCER.

51.14 PLANNING AND ANALYSIS OF CANCER RESEARCH. RELATED THEORETICAL ASPECTS OF CANCER RESEARCH.

51.15 CANCER RESEARCH IN COUNTRIES OUTSIDE THE UNITED STATES.
51.15181 CANCER RESEARCH IN RUSSIA.
51.153 INTERNATIONAL CANCER RESEARCH AGENCIES.
51.15301 GENERAL.
51.15302 UICC.
51.15303 INTERNATIONAL AGENCY FOR CANCER RESEARCH.

51.2 CLINICAL DIAGNOSIS AND TREATMENT OF CANCER.

51.20 GENERAL CLINICAL ASPECTS OF CANCER.
51.200 FACILITIES, PROGRAMS, AND TRAINING RELATED TO CLINICAL ASPECTS OF CANCER.
51.2001 GENERAL.
51.2002 CANCER DIAGNOSIS, PREVENTION, AND THERAPY PROGRAMS AND THEIR OPERATION (GENERAL ASPECTS).
CANCER PART OF THE CANCER, HEART, AND STROKE PROGRAMS.
OTHER PUBLIC HEALTH ASPECTS RELATED TO CANCER PROGRAMS.
SEE ALSO: 51.2018 FOR COOPERATIVE GROUPS AND TASK FORCES.
51.2003 FACILITIES AND SPECIFIC CLINICAL CENTERS, INCLUDING FACILITIES FOR STUDYING PATHOLOGY AND DIAGNOSIS OF CANCER.
51.2004 TRAINING PROGRAMS RELATED TO CLINICAL ASPECTS OF CANCER.
51.201 GENERAL ASPECTS OF CLINICAL DIAGNOSIS, TREATMENT, AND MANAGEMENT OF CANCER PATIENTS.
SEE ALSO: 51.21 FOR SPECIFIC DIAGNOSTIC METHODS.
SEE ALSO: 51.22 TO 51.28 FOR SPECIFIC TYPES OF THERAPY.
51.2011 TREATMENT AND CARE OF CANCER PATIENTS IN GENERAL.
SEE ALSO: 51.202 THROUGH 51.209 FOR TREATMENT OF SPECIFIC TYPES OF CANCER.
SEE ALSO: 51.2233 FOR MOST SPECIFIC ASPECTS OF CANCER PATIENT MANAGEMENT.
51.20111 GENERAL. REVIEWS OF CANCER THERAPY (GENERAL).
51.20112 ATTITUDES TOWARD CANCER AND RELATED PSYCHOLOGICAL, SOCIAL, AND BEHAVIOURAL ASPECTS.
REHABILITATION OF CANCER PATIENTS.
PSYCHIATRIC THERAPY AND CARE OF CANCER PATIENTS.
51.2012 GENERAL PATHOLOGY OFTEN ACCOMPANYING DIFFERENT TYPES OF CANCER.
51.20121 GENERAL.
51.20122 GENERAL WASTING AND CACHEXIA OF CANCER PATIENTS.
SEE ALSO: 51.7512 FOR BASIC STUDIES ON TUMOR-INDUCED CACHEXIA.
51.20123 CAUSE OF PAIN AND TREATMENT OF PAIN IN CANCER PATIENTS.
PERIPHERAL NEUROPATHY ACCOMPANYING CANCER AND ITS TREATMENT.
SEE ALSO: 56.1814 FOR TREATMENT OF PAIN (GENERAL).

51.20124 CAUSE OF DEATH IN CANCER PATIENTS.
51.20125 MICROBIAL INFECTION AND SEPTICEMIA IN CANCER PATIENTS.
METHODS OF TREATING INFECTION IN CANCER PATEINTS.
51.2013 ETHICAL ASPECTS OF CANCER CARE AND CANCER RESEARCH IN HUMANS.
51.20131 GENERAL.
51.20132 ETHICAL ASPECTS OF CANCER THERAPY AND CARE.
INFORMED CONSENT OF CANCER PATIENTS IN CLINICAL TRIALS.
NOTIFICATION OF PATIENTS WHEN THEY HAVE CANCER.
51.20133 ETHICAL ASPECTS OF CANCER RESEARCH OTHER THAN THERAPY.
INJECTION OF CANCER CELLS INTO HUMANS.
51.2014 PATHOLOGICAL CLASSIFICATIONS USED TO DESCRIBE AND DIAGNOSE CANCER AND TO COLLECT STATISTICAL DATA.
SEE ALSO: 51.5 AND 51.7 FOR BASIC ASPECTS OF CANCER PATHOLOGY.
51.2015 END RESULTS OF TREATMENT OF CANCER.
SEE ALSO: 51.202 THROUGH 51.209 FOR END RESULTS OF SPECIFIC TYPES OF CANCER.
SEE ALSO: 51.40 FOR CANCER EPIDEMIOLOGY (GENERAL).
SEE ALSO: 51.40011 FOR CANCER INCIDENCE, SURVIVAL, AND MORBIDITY SURVEYS AND RELATED STATISTICAL METHODOLOGY.
51.20151 GENERAL.
51.20152 METHODS OF OBTAINING, PROCESSING, AND ANALYZING STATISTICAL DATA ON RESULTS OF CANCER THERAPY.
FOLLOW-UP STUDIES AND THEIR METHODOLOGY.
51.20153 METHODS OF DETERMINING AND EVALUATING TUMOR RESPONSE.
CRITERIA FOR DEFINING TUMOR REGRESSION, CANCER CURES, AND CANCER REMISSION.
USE OF THYMIDINE LABELING TECHNIQUES TO FOLLOW THERAPY.
51.20154 COMPARISON OF SURVIVAL AND MORTALITY RATES AFTER VARIOUS TYPES OF THERAPY (GENERAL REVIEWS ONLY).
SEE ALSO: 51.22013 FOR SUCCESS OF DIFFERENT TYPES OF CANCER CHEMOTHERAPY.
51.2016 DETERMINING PROGNOSIS AND END RESULTS. METHODS USED.
SEE ALSO: 51.22011 FOR INDICATORS USED TO SELECT PATIENTS FOR CANCER CHEMOTHERAPY.
SEE ALSO: 51.22012 FOR PREDICTING RESPONSE TO ANTICANCER AGENTS.
51.20161 GENERAL.
51.20162 METABOLIC AND BIOCHEMICAL METHODS OF PROGNOSIS.
51.20163 CYTOLOGICAL AND HISTOLOGIC METHODS OF PROGNOSIS.
51.20164 MATHEMATICAL MODELS RELATED TO PROGNOSIS.
51.2017 SPONTANEOUS REMISSION OF CANCER IN HUMANS.
51.201701 GENERAL.
51.201702 REMISSION OF PULMONARY METASTASIS OF RENAL CARCINOMAS AFTER NEPHRECTOMY.
51.2018 COOPERATIVE GROUPS AND TASK FORCES FOR CLINICAL CANCER THERAPY.
SEE ALSO: 51.22014 FOR COOPERATIVE CHEMOTHERAPY GROUPS.
51.202 CLINICAL DIAGNOSIS, THERAPY, AND END RESULTS OF CANCER OF THE CARDIOVASCULAR, LYMPHATIC, AND RETICULOENDOTHELIAL SYSTEM.
51.2021 GENERAL.
51.2022 CLINICAL DIAGNOSIS, THERAPY, AND END RESULTS OF CARDIAC CANCER.
51.2024 CLINICAL DIAGNOSIS, THERAPY, AND END RESULTS OF VASCULAR AND ENDOTHELIAL CANCERS.
51.2025 CLINICAL DIAGNOSIS, THERAPY, AND END RESULTS OF LEUKEMIAS, LYMPHOMAS, AND OTHER CANCER OF LYMPHATIC AND RELATED TISSUES.
SEE ALSO: 51.22025 FOR USE OF CHEMOTHERAPY FOR THESE CANCERS.
51.20251 GENERAL.
51.20252 DIAGNOSIS AND TREATMENT OF LEUKEMIAS.
51.202521 GENERAL.
51.202522 DIAGNOSIS AND TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIAS.
51.202523 DIAGNOSIS AND TREATMENT OF ACUTE MYELOGENOUS LEUKEMIAS.
51.202524 DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIAS.
51.202525 DIAGNOSIS AND TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIAS.
51.202526 DIAGNOSIS AND TREATMENT OF OTHER TYPES OF LEUKEMIAS. (PLASMACYTIC LEUKEMIAS, MENINGEAL LEUKEMIAS).
51.202527 PATIENT MANAGEMENT TECHNIQUES UNIQUE TO LEUKEMIAS.
USE OF LEUKOPHORESIS AND LEUKOCYTE REPLACEMENT THERAPY.
SEE ALSO: 51.2233 FOR MOST ASPECTS OF PATIENT MANAGEMENT.
51.20253 DIAGNOSIS AND TREATMENT OF HODGKINS DISEASE.
51.20254 DIAGNOSIS AND TREATMENT OF OTHER LYMPHOMAS, INCLUDING PLASMACYTIC AND MYELOCYTIC LYMPHOMAS, AND MULTIPLE MYELOMA.
51.2026 DIAGNOSIS AND TREATMENT OF HEMATOLOGIC AND RED BLOOD CELL-RELATED MALIGNANCIES.

51.20261 GENERAL.
51.20262 HEMATOLOGIC MALIGNANCIES OF THE SPLEEN.
51.20263 HEMATOLOGIC MALIGNANCIES OF THE BONE MARROW.
51.2027 DIAGNOSIS AND TREATMENT OF METASTASES GROWING IN LYMPH NODES.
51.2028 DIAGNOSIS AND TREATMENT OF OTHER TYPES OF RETICULOENDOTHELIAL TUMORS.
51.202801 DIAGNOSIS AND TREATMENT OF HISTIOCYTOSIS (LETTERER-SIWE DISEASE).
51.203 CLINICAL DIAGNOSIS AND THERAPY OF MUSCLE CANCER AND END RESULTS.
51.204 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE KIDNEY, BLADDER, AND URINARY SYSTEM AND END RESULTS.
51.2041 GENERAL.
51.2042 CLINICAL DIAGNOSIS AND THERAPY OF KIDNEY CANCER AND END RESULTS.
51.2043 CLINICAL DIAGNOSIS AND THERAPY OF BLADDER CANCER, CANCER OF THE URETER AND URETHRA, AND RELATED TISSUES OF THE URINARY SYSTEM.
51.205 CLINICAL DIAGNOSIS AND THERAPY OF NEOPLASIA OF SELECTED INTERNAL ORGANS AND END RESULTS.
51.2050 GENERAL. CLINICAL DIAGNOSIS AND THERAPY OF VISCERAL AND PERITONEAL CANCER.
51.2051 CLINICAL DIAGNOSIS AND THERAPY OF EXOCRINE GLAND CANCER AND END RESULTS.
DIAGNOSIS AND THERAPY OF SALIVARY GLAND CANCER.
51.2052 CLINICAL DIAGNOSIS AND THERAPY OF LUNG CANCER AND OTHER CANCERS OF THE PULMONARY SYSTEM INCLUDING TRACHEA AND BRONCHI, AND END RESULTS.
DIAGNOSIS AND TREATMENT OF BRONCHIOGENIC CANCER.
COOPERATIVE LUNG CANCER STUDY GROUPS.
SURVIVAL OF PATIENTS WITH LUNG CANCER. PROLONGED SURVIVAL OF FEMALE PATIENTS.
DETECTION OF MALIGNANT LUNG CANCER CELLS IN SPUTUM.
BRONCHIAL BIOPSY TECHNIQUES.
51.2053 CLINICAL DIAGNOSIS AND THERAPY OF LIVER CANCER AND END RESULTS.
51.20531 CLINICAL DIAGNOSIS AND THERAPY OF LIVER AND GALL BLADDER CANCER.
51.20532 CLINICAL DIAGNOSIS AND THERAPY OF GALL BLADDER CANCER AND CANCER OF RELATED TISSUES.
51.2054 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE GASTROINTESTTINAL TRACT AND END RESULTS.
51.20541 GENERAL
51.20542 DIAGNOSIS AND THERAPY OF SPECIFIC TYPES OF UNUSUAL GASTROINTESTINAL CANCER.
51.205421 DIAGNOSIS AND THERAPY OF CARCINOID TUMORS.
SEE ALSO: 51.2832 FOR TREATMENT BY DIETS LOW IN TRYPTOPHAN.
51.205422 DIAGNOSIS AND THERAPY OF NON-CANCEROUS MELANOMAS.
SEE ALSO: 51.20833 FOR CUTANEOUS MELANOMAS.
51.20543 DIAGNOSIS AND THERAPY OF ESOPHAGEAL CANCER AND END RESULTS.
51.20544 DIAGNOSIS AND THERAPY OF STOMACH CANCER AND END RESULTS.
USE OF GASTROSCOPES AND GASTRIC JUICE ANALYSIS TO DETECT CANCER.
51.20545 DIAGNOSIS AND THERAPY OF INTESTINAL CANCER IN SMALL OR LARGE INTESTINE OR BOWEL, AND END RESULTS.
51.20546 DIAGNOSIS AND THERAPY OF CANCER OF THE COLON, RECTUM, AND ANAL CANAL AND END RESULTS.
51.20547 DIAGNOSIS AND THERAPY OF CANCER OF THE PANCREAS AND END RESULTS.
51.2055 CLINICAL DIAGNOSIS AND THERAPY OF CANCER RELATED TO THE GENITAL AND REPRODUCTIVE SYSTEMS AND END RESULTS.
SEE ALSO: 51.23055 FOR HORMONE THERAPY OF SEX-RELATED CANCER.
51.20551 GENERAL.
51.20552 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF SEX-RELATED TISSUES IN FEMALES AND END RESULTS.
51.205521 GENERAL.
51.205522 CLINICAL DIAGNOSIS AND THERAPY OF OVARIAN CANCER, INCLUDING DYSGERMINOMA, AND END RESULTS.
51.205523 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE UTERUS, CERVIX, VAGINA, ENDOMETRIUM, AND PLACENTA, AND END RESULTS.
51.2055231 GENERAL.
51.2055232 DIAGNOSIS AND THERAPY OF CANCER OF THE UTERUS, INCLUDING CORPUS UTERI AND FUNDI.
51.2055233 DIAGNOSIS AND THERAPY OF CANCER OF THE CERVIX AND VAGINA.
51.20552331 GENERAL.
51.20552332 USE OF PAPANICOLAOU'S STAIN OR PAP SMEAR AND RELATED VAGINAL CYTOLOGY TO DETECT CERVICAL CANCER.
TRAINING OF TECHNICIANS FOR USING PAP SMEAR TECHNIQUES.
51.20552333 OTHER METHODS OF DETECTING VAGINAL AND CERVICAL CANCER.
51.20552334 THERAPY OF VAGINAL AND CERVICAL CANCER.
51.2055234 DIAGNOSIS AND THERAPY OF CANCER OF THE PLACENTA AND ENDOMETRIUM.
USE OF ENDOMETRIAL LAVAGE TO DIAGNOSE ENDOMETRIAL CANCER.

51.20552341 GENERAL. DIAGNOSIS AND THERAPY OF TROPHOBLASTIC CANCER.
51.20552342 DIAGNOSIS AND THERAPY OF CHORIOCARCINOMA.
51.20552343 DIAGNOSIS AND THERAPY OF MOLAR PREGNANCIES.
51.20552344 DIAGNOSIS AND THERAPY OF CHORIOADENOMA.
51.20552345 DIAGNOSIS AND THERAPY OF OTHER TYPES OF ENDOMETRIAL TROPHOBLASTIC DISEASES.
SEE ALSO: 51.205522 FOR TROPHOBLASTIC NEOPLASMS OF OVARY.
SEE ALSO: 51.205532 FOR TROPHOBLASTIC NEOPLASMS OF TESTIS.
51.20552346 DIAGNOSIS AND THERAPY OF OTHER TYPES OF ENDOMETRIAL CANCER.
51.205524 DIAGNOSIS AND THERAPY OF BREAST OR MAMMARY CANCER.
51.2055241 GENERAL. BREAST CANCER TASK FORCE AND ITS ACTIVITIES.
51.2055242 THERAPEUTIC METHODS FOR BREAST CANCER.
51.2055243 USE OF MAMMOGRAPHY (BREAST X-RAY) AND OTHER DIAGNOSTIC METHODS FOR DETECTION OF BREAST CANCER.
51.2055244 PROGNOSTIC METHODS USED TO PREDICT SURVIVAL OF PATIENTS WITH BREAST CANCER AND END RESULTS OF BREAST CANCER THERAPY.
SEE ALSO: 51.2305524 FOR HORMONE THERAPY OF BREAST CANCER AND THE BULBROOK DISCRIMINANT.
51.2055245 DETECTION AND CLINICAL ASPECTS OF BREAST CANCER METASTASES.
51.205525 DIAGNOSIS AND THERAPY OF CANCER OF THE FEMALE GENITALIA AND OTHER SEX-RELATED TISSUES NOT INCLUDED ABOVE.
51.20553 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF MALE REPRODUCTIVE AND SEX-RELATED TISSUES AND END RESULTS.
51.205531 GENERAL.
51.205532 DIAGNOSIS AND THERAPY OF TESTICULAR CANCER, INCLUDING TESTICULAR TROPHOBLASTIC TUMORS.
51.205533 DIAGNOSIS AND THERAPY OF CANCER OF THE PENIS AND SCROTUM.
51.205534 DIAGNOSIS AND THERAPY OF CANCER OF THE PROSTATE.
51.2056 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE ENDOCRINE GLANDS AND END RESULTS.
SEE ALSO: 51.20547 FOR DIAGNOSIS AND THERAPY OF PANCREATIC CANCER.
SEE ALSO: 51.2055 FOR DIAGNOSIS AND THERAPY OF OVARIAN AND TECTICULAR CANCER.
51.20561 GENERAL.
51.20562 DIAGNOSIS AND THERAPY OF CANCER OF THE PITUITARY GLAND (HYPOPHYSIS).
51.20563 DIAGNOSIS AND THERAPY OF CANCER OF THE THYROID GLAND.
51.20564 DIAGNOSIS AND THERAPY OF CANCER OF THE PARATHYROID GLAND.
51.20565 DIAGNOSIS AND THERAPY OF CANCER OF THE ADRENAL GLAND.
51.20566 DIAGNOSIS AND THERAPY OF CANCER OF OTHER ENDOCRINE GLANDS AND TISSUES.
51.206 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE BRAIN AND NERVOUS SYSTEM AND END RESULTS.
51.2061 GENERAL.
51.2062 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE NERVOUS SYSTTEM OTHER THAN THE BRAIN AND END RESULTS.
51.2065 CLINICAL DIAGNOSIS AND THERAPY OF BRAIN CANCER AND END RESULTS.
USE OF CARRIER MOLECULES WHICH LOCALIZE IN BRAIN TUMORS FOR CARRYING RADIOISOTOPES OR OTHER AGENTS TO THE BRAIN CANCER.
51.207 CLINICAL DIAGNOSIS AND THERAPY OF THE SENSE ORGANS AND END RESULTS.
SEE ALSO: 51.2092 FOR ALL INFORMATION ABOUT DIAGNOSIS AND THERAPY OF CANCER ASSOCIATED WITH THE EYE AND EAR AREAS OF THE FACE AND HEAD.
51.208 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF SKIN, CONNECTIVE, AND MINERALIZED TISSUES AND END RESULTS.
51.2082 CLINICAL DIAGNOSIS AND THERAPY OF CONNECTIVE TISSUE CANCERS SUCH AS FIBROMAS, FIBROSARCOMAS, AND FIBROMATOSES. (GENERAL).
51.2083 CLINICAL DIAGNOSIS AND THERAPY OF SKIN CANCER AND MELANOMAS AND END RESULTS.
51.20831 GENERAL.
51.20832 CLINICAL DIAGNOSIS AND THERAPY OF SKIN CANCERS OTHER THAN MELANOMAS.
51.20833 CLINICAL DIAGNOSIS AND THERAPY OF CUTANEOUS MELANOMAS.
SEE ALSO: 51.205422 FOR NON-CUTANEOUS MELANOMAS.
51.2084 CLINICAL DIAGNOSIS AND THERAPY OF BONE CANCER.
51.2085 CLINICAL DIAGNOSIS AND THERAPY OF LIPOMA AND OTHER CANCER OF FATTY TISSUES.
51.209 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF SPECIFIC BODY PARTS AND END RESULTS.
51.2091 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE ORAL CAVITY,THROAT, AND ADJACENT AREAS, AND END RESULTS.
51.20911 GENERAL.
51.20912 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE LIPS.
51.20913 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE TONGUE.

51.20914 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE LARYNX AND VOCAL CORDS.
51.20915 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE THROAT AND PHARYNX.
51.20916 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE JAW (MAXILLA AND MANDIBLE) AND NECK.
51.2092 CLINICAL DIAGNOSIS AND THERAPY OF CANCER IN THE AREA OF THE NOSE, EARS, SINUSES, AND OTHER CRANIAL CAVITIES.
51.20921 GENERAL.
51.20922 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE NOSE AND SINUSES.
51.20923 CLINICAL DIAGNOSIS AND THERAPY OF CANCER IN CAVITIES ASSOCIATED WITH THE EAR.
51.20924 CLINICAL DIAGNOSIS AND THERAPY OF TUMORS RELATED TO THE EYE AND EYE SOCKET.
51.2093 CLINICAL DIAGNOSIS AND THERAPY OF CANCER OF THE APPENDAGES AND END RESULTS.
51.2094 CLINICAL DIAGNOSIS, TREATMENT, AND COURSE OF METASTASES GROWING IN THE LOCATIONS LISTED BELOW.
51.209401 GENERAL.
51.209402 DIAGNOSIS AND THERAPY OF METASTASES GROWING IN THE LUNG.
51.209403 DIAGNOSIS AND THERAPY OF METASTASES IN LYMPH NODES. USE OF LYMPHADENOGRAPHY.
51.209404 DIAGNOSIS AND THERAPY OF METASTASES GROWING IN THE BONE.
51.209405 DIAGNOSIS AND THERAPY OF METASTASES GROWING IN THE LIVER.

51.21 CLINICAL ASPECTS OF CANCER DETECTION, DIAGNOSIS, CANCER PREVENTION, AND CANCER CONTROL.
SEE ALSO: 51.20 FOR CANCER DIAGNOSIS IN SPECIFIC ORGAN SYSTEMS.
SEE ALSO: 51.312 FOR DIAGNOSTIC STUDIES INVOLVING ANIMALS.
SEE ALSO: 51.4015 FOR PREMALIGNANT PATHOLOGY (GENERAL).
SEE ALSO: 51.2016 FOR PROGNOSTIC METHODS.
51.211 CANCER DETECTION, DIAGNOSIS, PREVENTION, AND CONTROL IN GENERAL.
REVIEWS OF DEVELOPMENT OF DIAGNOSTIC METHODS.
RELIABILITY AND ACCURACY OF DIAGNOSES.
51.2111 GENERAL.
51.2112 CANCER PREVENTION PROGRAMS AND METHODOLOGY (OTHER THAN ACTUAL SCREENING PROGRAMS).
DANGER SIGNALS OF CANCER.
SEE ALSO: 51.21804 FOR SPECIAL SYMPTOMS OF CANCER AND THEIR USE FOR DIAGNOSIS.
51.2113 CANCER SCREENING PROGRAMS (GENERAL).
SEE ALSO: 51.20552332 FOR USE OF PAPANICOLAOU'S STAIN OR PAPS SMEARS.
51.2114 TRAINING OF MANPOWER FOR CANCER DETECTION AND CANCER CONTROL PROGRAMS.
SEE ALSO: 51.20552332 FOR TRAINING OF CYTOTECHNICIANS IN THE USE OF PAPS SMEAR TECHNIQUES.
51.2115 FACTORS PREVENTING EARLY DIAGNOSIS OF CANCER.
SEE ALSO: 51.20112 FOR BEHAVIORAL, SOCIAL, AND PSYCHOLOGICAL ASPECTS OF CANCER WHICH MAY BE RELATED TO CANCER PREVENTION AND DIAGNOSIS.
51.212 DETECTION AND DIAGNOSIS OF CANCER IN SPECIFIC ORGAN SYSTEMS.
51.212253 DETECTION AND DIAGNOSIS OF LEUKEMIA.
51.212254 DETECTION AND DIAGNOSIS OF LYMPHOMAS.
51.2123 DETECTION AND DIAGNOSIS OF MUSCLE CANCER.
51.2124 DETECTION AND DIAGNOSIS OF KIDNEY CANCER.
51.21251 DETECTION AND DIAGNOSIS OF EXOCRINE GLAND CANCER.
51.21252 DETECTION AND DIAGNOSIS OF LUNG CANCER.
51.21253 DETECTION AND DIAGNOSIS OF LIVER CANCER.
51.21254 DETECTION AND DIAGNOSIS OF GASTROINTESTINAL CANCER.
51.21255 DETECTION AND DIAGNOSIS OF CANCER OF FEMALE REPRODUCTIVE SYSTEM.
51.21255BR DETECTION AND DIAGNOSIS OF BREAST CANCER.
51.21255OV DETECTION AND DIAGNOSIS OF OVARIAN CANCER.
51.21255UT DETECTION AND DIAGNOSIS OF UTERINE CANCER.
51.21256 DETECTION AND DIAGNOSIS OF CANCER OF MALE REPRODUCTIVE SYSTEM.
51.21256PR DETECTION AND DIAGNOSIS OF PROSTATE CANCER.
51.21257 DETECTION AND DIAGNOSIS OF CANCER IN OTHER ENDOCRINE SYSTEMS
51.2126 DETECTION AND DIAGNOSIS OF CANCER OF THE NERVOUS SYSTEM.
51.21265 DETECTION AND DIAGNOSIS OF BRAIN CANCER.
51.2127 DETECTION AND DIAGNOSIS OF CANCER OF THE SENSE ORGANS.
51.21282 DETECTION AND DIAGNOSIS OF CANCER OF SPECIFIC CONNECTIVE TISSUES.
51.21283 DETECTION AND DIAGNOSIS OF SKIN CANCER.
51.212833 DETECTION AND DIAGNOSIS OF MELANOMAS.
51.212842 DETECTION AND DIAGNOSIS OF BONE CANCER.
51.213 RADIOGRAPHIC METHODS OF CANCER DIAGNOSIS AND TUMOR LOCALIZATTION IN MAN AND ANIMALS.
SEE ALSO: 51.24 FOR USE OF RADIATION FOR CANCER THERAPY.

SEE ALSO: 51.20 FOR RADIOGRAPHIC METHODS USED TO DETECT SPECIFIC TYPES OF CANCER.
SEE ALSO: 51.2055243 FOR MAMMOGRAPHY.
51.2131 GENERAL.
51.2132 CLASSICAL USE OF X-RAY AND CINERADIOLOGY IN CANCER DIAGNOSIS AND RELATED METHODS AND EQUIPMENT.
51.2133 DIAGNOSTIC ANGIOGRAPHY INCLUDING VENOGRAPHY, LYMPHANGIOGRAPHY, LYMPHADENOGRAPHY, ARTERIOGRAPHY, HEPATOGRAPHY, AND RELATED TECHNIQUES FOR CANCER DIAGNOSIS.
51.2134 X-RAY TOMOGRAPHY AND RELATED METHODS AND EQUIPMENT FOR CANCER DIAGNOSIS.
51.2135 OTHER SPECIALIZED X-RAY TECHNIQUES.
51.2136 COMPUTER ANALYSIS OF X-RAY PICTURES AND OTHER AUTOMATED METHODS FOR DETECTING TUMORS ON ROENTGENOGRAMS.
SEE ALSO: 51.2144 FOR AUTOMATED ANALYSIS OF MICROSCOPIC IMAGES.
51.2137 CLINICAL DIAGNOSIS OF CANCER INVOLVING RADIOISOTOPES.
SEE ALSO: 51.23 FOR THERAPEUTIC USE OF ISOTOPES IN ANIMALS.
SEE ALSO: 51.244 FOR CLINICAL ISOTOPE THERAPY (GENERAL).
51.21371 GENERAL.
51.21372 METHODS AND EQUIPMENT USED IN DIAGNOSING TUMORS WITH ISOTOPES.
51.213721 GENERAL.
51.213722 ISOTOPE IMAGERY WITH POSITRON SCINTILLATION CAMERAS AND OTHER RADIONUCLEIDE IMAGING TECHNIQUES (SCINTIPHOTOGRAPHY).
51.213723 TOMOGRAPHIC RADIOISOTOPE SCANNING FOR TUMORS.
51.213724 USE OF MINIATURE GEIGER TUBES FOR TUMOR DIAGNOSIS.
51.21373 SPECIFIC ISOTOPES USED FOR CLINICAL CANCER DIAGNOSIS. (DIVIDE BY NUMBERS REPRESENTING ALPHABETIC POSITION OF ELEMENT ABBREVIATION).
51.2137300 GENERAL. USE OF SHORT-LIVED POSITRON EMITTING ISOTOPES FOR CANCER DIAGNOSIS.
51.2137308 USE OF AU-198 AND OTHER GOLD ISOTOPES FOR CANCER DIAGNOSIS.
51.2137322 USE OF CO-57 AND OTHER COBALT ISOTOPES FOR CANCER DIAGNOSIS.
51.2137329 USE OF F-18 AND OTHER FLUORINE ISOTOPES FOR CANCER DIAGNOSIS
51.2137330 USE OF FE-52 AND OTHER IRON ISOTOPES FOR CANCER DIAGNOSIS.
51.2137332 USE OF GA-68 AND OTHER GALLIUM ISOTOPES FOR CANCER DIAGNOSIS.
51.2137338 USE OF HG-203, HG-197, AND OTHER MERCURY ISOTOPES FOR CANCER DIAGNOSIS (SUCH AS SCANNING FOR BRAIN OR KIDNEY TUMORS).
51.2137340 USE OF I-131 AND OTHER IODINE ISOTOPES FOR CANCER DIAGNOSIS.
51.21373401 GENERAL.
51.21373402 USE OF IODINE ISOTOPES TO DIAGNOSE THYROID CANCER.
51.21373403 USE OF IODINE-LABELED ANTIBODIES WHICH LOCALIZE IN SPECIFIC TUMORS.
51.21373404 USE OF IODINE-LABELED ROSE BENGAL AND OTHER IODINE-LABELED AGENTS NOT INCLUDED ABOVE.
51.2137343 USE OF K-38 AND OTHER POTASSIUM ISOTOPES TO DIAGNOSE CANCER.
51.2137358 USE OF O-15 AND OTHER OXYGEN ISOTOPES TO DIAGNOSE CANCER.
51.2137360 USE OF P-32 AND OTHER PHOSPHORUS ISOTOPES TO DIAGNOSE CANCER.
51.2137378 USE OF SE-75 AND OTHER SELENIUM ISOTOPES TO DIAGNOSE CANCER IN PANCREAS, PARATHYROID, SPLEEN, AND OTHER TISSUES.
51.2137382 USE OF SR-87 AND OTHER STRONTIUM ISOTOPES TO DIAGNOSE CANCERIN BONE AND OTHER TISSUES.
51.2137385 USE OF TC-99 AND OTHER TECHNETIUM ISOTOPES TO DIAGNOSE CANCER.
51.21374 USE OF TUMOR-SPECIFIC OR ORGAN-SPECIFIC ISOTOPE CARRIERS TO DIAGNOSE CANCER.
SEE ALSO: 51.32325 FOR THERAPEUTIC USE OF CARRIERS IN ANIMALS.
SEE ALSO: 51.24133 FOR USE OF ISOTOPE-LABELED CARRIERS IN CLINICAL CANCER THERAPY.
51.2138 OTHER RADIOLOGIC METHODS USED TO DIAGNOSE CANCER.
51.21381 USE OF INFRA-RED RADIATION AND LIQUID CRYSTALS TO DIAGNOSE CANCER.
51.214 CYTOLOGICAL, HISTOLOGICAL, AND HISTOCHEMICAL METHODS OF CANCER DIAGNOSIS IN MAN AND ANIMALS.
SEE ALSO: 51.51 FOR TUMOR CYTOLOGY (GENERAL).
SEE ALSO: 51.2114 FOR TRAINING OF CYTOTECHNICIANS.
SEE ALSO: 51.2055233 FOR PAP SMEARS.
SEE ALSO: 51.202 TO 51.209 FOR STUDIES OF SPECIFIC TISSUES.
51.2141 GENERAL.
51.21415 DETECTION AND DIAGNOSIS OF CANCER BY ANALYSIS OF TUMOR CELLS CIRCULATING IN THE BLOOD AND OTHER BODY FLUIDS.
SEE ALSO: 51.7333 FOR DISTRIBUTION AND CIRCULATION OF TUMOR CELLS DURING METASTASIS.
51.2142 METHODS OF OBTAINING SAMPLES.
51.21421 GENERAL.

51.21422 COLLECTION OF CELLS BY MILLIPORE FILTRATIONS (FROM SPUTUM FOR EXAMPLE).
51.21423 CANCER BIOPSY TECHNIQUES IN GENERAL.
51.2143 FIXING, STAINING, AND RELATED PROCEDURES FOR EXFOLIATIVE CYTOLOGY.
ROMANOVSKY STAINING PROCEDURE.
51.2144 COMPUTER ANALYSIS AND OTHER AUTOMATED ANALYSIS OF SLIDES AND MICROSCOPIC IMAGES FOR CANCER DETECTION AND DIAGNOSIS.
SEE ALSO: 51.2136 FOR COMPUTER ANALYSIS OF X-RAY PICTURES.
51.2145 USE OF ELECTRON MICROSCOPY TO DETECT AND DIAGNOSE CANCER.
SEE ALSO: 51.514 FOR ULTRASTRUCTURE OF SPECIFIC TYPES OF CANCER.
51.2146 CHROMOSOME ANALYSIS AND KARYOTYPE STUDIES USED TO DETECT AND DIAGNOSE CANCER.
SEE ALSO: 51.512 FOR MOST INFORMATION ABOUT CANCER CHROMOSOMES.
51.2147 HISTOCHEMICAL ANALYSIS OF METABOLISM, ENZYME LEVELS, NUCLEIC ACID CONTENT, ETC, FOR DETECTION AND DIAGNOSIS OF CANCER.
SEE ALSO: 51.215 FOR OTHER TYPES OF BIOCHEMICAL METHODS FOR CANCER DETECTION AND DIAGNOSIS.
51.2148 SPECIFIC TYPES OF CYTOLOGICAL AND HISTOCHEMICAL ANALYSIS FOR DETECTION AND DIAGNOSIS OF CANCER.
51.214801 ANALYSIS OF BLOOD CELLS AS TEST FOR CANCER.
MALIGNANCY-ASSOCIATED CHANGES IN RED BLOOD CELLS.
51.214802 ANALYSIS OF CELLS OBTAINED BY BRONCHIAL ASPIRATION OR FROM SPUTUM.
51.214803 CANCER DIAGNOSIS BY ANALYSIS OF PLEURAL EXHUDATES.
51.214804 CANCER DIAGNOSIS BY ANALYSIS OF BONE MARROW FOR MALIGNANT CELLS.
51.215 BIOCHEMICAL AND HORMONAL ANALYSIS FOR DETECTION AND DIAGNOSIS OF CANCER IN MAN AND ANIMALS.
SEE ALSO: 51.6 FOR SPECIFIC ASPECTS OF CANCER BIOCHEMISTRY.
51.2150 GENERAL.
51.2151 CANCER DIAGNOSIS BY ANALYSIS OF NUCLEIC ACIDS AND RELATED COMPOUNDS.
51.2152 CANCER DIAGNOSIS BY ANALYSIS OF PROTEINS, AMINO ACIDS, GLYCOPROTEINS, AND RELATED AGENTS.
INCREASED C-REACTIVE PROTEIN USED TO DIAGNOSE CANCER.
51.2153 CANCER DIAGNOSIS BY ANALYSIS OF LIPIDS.
51.2154 CANCER DIAGNOSIS BY ANALYSIS OF CARBOHYDRATES.
51.2155 CANCER DIAGNOSIS BY ANALYSIS OF VITAMINS.
51.2156 CANCER DIAGNOSIS BY MEASUREMENT AND PROPERTIES OF ENZYMES.
SEE ALSO: 51.2147 FOR HISTOCHEMICAL METHODS OF ANALYSIS.
51.2157 CANCER DIAGNOSIS BASED ON BIOCHEMISTRY OF MINERALS.
51.2158 CANCER DIAGNOSIS BASED ON ANALYSIS OF HORMONE LEVELS IN BLOOD, URINE, AND OTHER TISSUES.
51.2159 OTHER METHODS OF CANCER DIAGNOSIS BASED ON BIOCHEMICAL ANALYSES.
51.216 IMMUNOLOGICAL AND SEROLOGICAL TESTS FOR CANCER AND TESTS INVOLVING ANTICANCER ANTIBODIES IN MAN AND ANIMALS.
51.21601 GENERAL.
51.21602 OPEN.
51.21603 CANCER TEST BASED ON DERMAL SENSITIVITY TO LUNG CANCER ANTIGENS IN CANCER PATIENTS.
51.21604 IMMUNE TESTS FOR UNUSUAL SERUM PROTEINS IN CANCER.
51.2160401 GENERAL.
51.2160402 CANCER TEST BASED ON PRESENCE OF EMBRYONYL SERUM ALPHA-GLOBULIN.
51.21605 CANCER TEST BASED ON CORRELATION OF POSITIVE HEMAGGLUTINATION WITH THE OCCURRENCE OF CANCER.
51.21606 CANCER TESTS BASED ON EFFECT OF CANCER SERA ON TISSURE CULTURE CELLS.
51.2160600 GENERAL.
51.2160601 CANCER TEST BASED ON REDUCTION OF MULTINUCLEATION IN CANCER CELLS EXPOSED TO CANCER SERUM IN VITRO.
51.21607 THE PROPOSED RAND CORPORATION (SERGIO DE CARVALLIO) TEST FOR CANCER ANTIGENS.
51.217 TECHNIQUES FOR DIRECT VISUALIZATION OF TUMORS IN MAN AND ANIMALS.
51.2171 GENERAL.
51.2172 ENDOSCOPY FOR VISUAL EXAMINATION OF TUMORS.
51.217201 GENERAL.
51.217202 SIGMOIDOSCOPY FOR TUMOR DETECTION.
51.2173 CAMERAS FOR VIEWING TUMORS IN INTERNAL CAVITIES.
51.217301 GENERAL.
51.217302 USE OF GASTROCAMERAS FOR VIEWING TUMORS.
51.2174 USE OF DYES, STAINS, AND FLUORESCENCE TO VISUALIZE TUMORS.
SEE ALSO: 51.21802 FOR USE OF LIQUID CHOLESTEROL ESTERS IN THERMOTOPOGRAPHY.
51.21741 GENERAL.
51.21742 USE OF FLUORESCENT PORPHYRINS TO VISUALIZE TUMORS.
ACCUMULATION OF HEMATOPORPHYRIN AND OTHER PORPHYRINS IN TUMORS.
USE OF TETRAPHENYLPORPHINE SULFONATES.

SEE ALSO: 51.6906 FOR PORPHYRIN BIOCHEMISTRY AND PHYSIOLOGY IN TUMORS.
51.21743 USE OF ACRIDINE DYES, TETRACYCLINES, QUINACRINE, ATABRINE, TOLUIDINE BLUE, AND OTHER DYES TO VISUALIZE MICROSCOPIC TUMORS.
SEE ALSO: 51.214 FOR USE OF DYES TO DIAGNOSE CANCER BY HISTOCHEMICAL METHODS.
51.218 OTHER DIAGNOSTIC METHODS USED OR TESTED FOR DETECTION AND DIAGNOSIS OF CANCER IN MAN AND ANIMALS.
SEE ALSO: 56.173 FOR CLINICAL USE OF ULTRASOUND IN GENERAL.
51.21801 USE OF ULTRASOUND TO DIAGNOSE TUMORS.
51.21802 USE OF THERMOGRAPHY TO DETECT TUMORS.
51.218021 GENERAL.
51.218022 USE OF THERMOTOPOGRAPHY WITH LIQUID CRYSTALS SUCH AS CHOLESTEROL ESTERS TO DETECT CANCER.
51.21803 USE OF ELECTRICAL CURRENT TO DETECT CANCER.
CHANGE IN ELECTRICAL RESISTANCE OF SKIN DUE TO DAMAGE TO THE SYMPATHETIC NERVE SYSTEM BY TUMORS.
51.21804 PRESENCE OF KERATOSES ON PALMS OF CANCER PATIENTS AND THEIR DIAGNOSTIC SIGNIFICANCE.
51.219 OTHER INFORMATION ABOUT CANCER DIAGNOSIS, CANCER DETECTION, AND CANCER PROGNOSIS.

51.22 CLINICAL CANCER CHEMOTHERAPY AND CLINICAL USE OF ANTICANCER AGENTS (INCLUDING NON-HORMONAL AGENTS ONLY).
SEE ALSO: 51.32 FOR PRE-CLINICAL ASPECTS OF CANCER CHEMOTHERAPY.
SEE ALSO: 51.23 FOR CLINICAL USE OF HORMONAL AND ANTIHORMONAL AGENTS.
SEE ALSO: 51.247 FOR AGENTS WHICH SENSITIZE CANCERS TO IRRADIATION.
SEE ALSO: 51.2015 FOR END RESULTS OF CANCER CHEMOTHERAPY (GENERAL).
51.22A139- A-139.
51.22A649- A-649.
51.22A8103 A-8103.
51.22A2096 A-20968.
51.22AB100 AB-100.
51.22AB103 AB-103.
51.22AB132 AB-132.
51.22ACETO ACETOPHENONE.
51.22ACRON ACRONYCIN.
51.22ACTH- ACTH.
51.22ACTIN ACTINOGAN.
51.22ACTIN ACTINOMYCIN D (DACTINOMYCIN, COSMEGEN, MERACTINOMYCIN).
51.22ACTIN ACTINOMYCIN P2.
51.22ADRIA ADRIAMYCIN.
51.22AE--- ALPHA-VINYL-AE ACETATE.
51.22ALANM ALANINE MUSTARD.
X 51.22AMETH AMETHOPTERIN: SEE METHOTREXATE.
51.22AMINO AMINOPTERIN.
51.22ARAC- ARA-C (CYTOSINE ARABINOSIDE, CYTARABINE, CYTOSAR, ARABINOSYLCYTOSINE).
51.22ARAFC ARA-FC (1-BETA-D-ARABINOFURANOSYL-5-FLUOROCYTOSINE).
51.22ASPAR ASPARAGINASE (EC2).
51.22AZACY 5-AZACYTIDINE.
51.22AZAGU 8-AZAGUANINE.
51.22AZIRI AZIRIDINES.
51.22AZAPI AZAPICLYNOYL HYDRAZINE.
51.22AZAPI AZAPICYL.
PICLYNOYL HYDRAZINE.
X 51.22AZARI AZARIBINE: SEE AZAURIDINE.
51.22AZASE AZASERINE.
X 51.22AZATH AZATHIOPRINE: SEE IMURAN.
51.22AZAUR 6-AZAURIDINE.
6-AZAURIDINE TRIACETATE (AZARIBINE).
51.22AZAXA 8-AZAXANTHINE.
51.22AZETE AZETEPA.
51.22AZOTO AZOTOMYCIN.
51.22BCNU- BCNU (1,3-BIS(2-CHLOROETHYL)-NITROSOUREA).
51.22BIC-- BIC (5-(3,3-BIS(2-CHLOROETHYL)-TRIAZENO) IMIDAZOLE-4-CARBOXAMIDE).
51.22BLEOM BLEOMYCIN.
51.22BONOM BONOMYCIN.
X 51.22BUSUL BUSULFAN: SEE MYLERAN.
X 51.22BUSUF BUSULFAN, DIHYDROXY: SEE MYLERAN, DIHYDROXY.
51.22CAMPT CAMPTOTHECIN AND CAMPTOTHECINATE.

51.22CARBA ACETYLINIC CARBAMATE.
51.22CARBA METHYLCARBAMATE.
51.22CARBE CARBESTROL.
51.22CARZO CARZOLAMIDE.
51.22CB134 CB-1348.
51.22CB136 CB-1364.
51.22CB150 CB-1506 (2-CHLOROETHYLMETHANE SULFONATE).
51.22CCNU- METHYL-CCNU.
51.22CHLOR CHLORAMPHENICOL.
51.22COLCH COLCHINCL, 4-ACETYL.
51.22COLCH COLCHINIC ACID, TRIMETHYL.
51.22CORTI CORTISONE.
X 51.22COSME COSMEGEN: SEE ACTINOMYCIN D.
51.22CYCLO CYCLOLEUCINE.
51.22CYCLO CYCLOPENTANE CARBOXYLIC ACID.
51.22CYCLO CYCLOPHOSPHAMIDE (CYTOXAN, ENDOXAN).
X 51.22CYTAR CYTARABINE: SEE ARA-C.
X 51.22CYTOS CYTOSAR: SEE ARA-C.
X 51.22CYTOS CYTOSINE ARABINOSIDE: SEE ARA-C.
51.22CYTOX CYTOXAL ALCOHOL.
X 51.22CYTOX CYTOXAN: SEE CYCLOPHOSPHAMIDE.
X 51.22DACTI DACTINOMYCIN: SEE ACTINOMYCIN D.
51.22DARAP DARAPRIM.
51.22DAUNO DAUNOMYCIN (DAUNORUBICIN, RUBIDOMICIN).
X 51.22DAUNO DAUNORUBICIN: SEE DAUNOMYCIN.
51.22DBD-- DBD (DIBROMODULCITOL).
51.22DBM-- DBM (DIBROMOMANNITOL, MYELOBROMOL).
51.22DCM-- DCM.
51.22DDD-- O,P-DDD (LYSODREN, MITOTANE).
X 51.22DELAT DELATESTRYL: SEE TESTOSTERONE ENANTHATE.
X 51.22DELTA DELTASONE: SEE PREDNISONE.
51.22DEMEC DEMECOLCINE.
DESMETHYLCOLCHICINE.
N-ACETYLCOLCHINOL.
TRIMETHYL COLCHINIC ACID.
51.22DIAZO 5-DIAZOURACIL.
X 51.22DIBRO DIBROMODULCITOL: SEE DBD.
X 51.22DIBRO DIBROMOMANNITOL: SEE DBM.
51.22DIC-- DIMETHYLAMINE IMIDAZOLE CARBOXAMIDE.
51.22DICHL DICHLOROMETHOTREXATE.
51.22DIETH DIETHYLSTILBESTROL.
51.22DIMET DIMETHANESULFONATE.
51.22DON-- DON (6-DIAZO-5-OXO-L-NORLEUCINE).
X 51.22DROLB DROLBAN: SEE DROMOSTANALONE.
51.22DROMO DROMOSTANALONE (DROLBAN).
DROMOSTANALONE PROPIONATE.
51.22DUAZO DUAZOMYCIN A.
X 51.22EC2-- EC-2: SEE ASPARAGINASE.
51.22ELDEM ELDERFIELD PYRIMIDINE MUSTARD.
51.22ELLIP ELLIPTICINE.
51.22EMETI EMETINE AND ITS SALTS.
51.22EMETI EMETINE, 2,3-DIHYDRO-DIHYDROCHLORIDE.
X 51.22ENDOX ENDOXAN: SEE CYCLOPHOSPHAMIDE.
51.22EPONA EPONATE.
51.22EPOYD EPODYL.
51.22ERYTH ERYTHRITOL AZIRIDINE.
51.22ESTRI ESTRIOL.
51.22ETHID ETHIDIUM CHLORIDE.
51.22ETHIN ETHINYL ESTRADIOL.
51.22ETHIO ETHIONINE.
51.22ETHOG ETHOGLUCID.
51.22FLUOR 2-FLUOROADENOSINE.
X 51.22FLUOR FLUOROCYTOSINE ARABINOSIDE: SEE ARA-FC.
51.22FLUOR FLUOROMETHALONE (OXYLONE).
51.22FLUOR 5-FLUOROOROTIC ACID.
51.22FLUOR 5-FLUOROURACIL (5-FU).
X 51.22FLUOR FLUOROURACIL DEOXYRIBOSIDE: SEE FUDR.
51.22FLUOX FLUOXYMESTERONE.
51.22FOLIC FOLIC ACID.
51.22FOWLE FOWLER'S SOLUTION.

51.22FU--- 5-FU: SEE 5-FLUOROURACIL.
51.22FUDR- FUDR (2'-DEOXY-5-FLUOROURACIL, FLUROURACIL DEOXYRIBOSIDE).
51.22GALAC GALACTOFLAVIN.
51.22GLUTI GLUTINOSIN.
51.22GUANA GUANAZOLE.
51.22HADAC HADACIDIN.
51.22HEXAM HEXAMETHYLMELAMINE AND ANALOGS (HMM, METHYL-HMM).
51.22HEXES HEXESTEROL.
X 51.22HMM-- HMM: SEE HEXAMETHYLMELAMINE.
51.22HN2-- HN2 (MECHLORETHAMINE, NITROGEN MUSTARD, MUSTARGEN).
MECHLORETHAMINE OXIDE.
51.22HPP-- 4-HPP.
X 51.22HYDRE HYDREA: SEE HYDROXYUREA.
51.22HYDRO HYDROCORTISONE.
51.22HYDRO HYDROXYSTILBAMIDINE.
51.22HYDRO HYDROXYUREA (HYDREA).
X 51.22IBENZ IBENZMETHYZIN: SEE MIH.
51.22IDOXU IDOXURIDINE.
51.22IMIDA IMIDAZOLE-4(5)-CARBOXAMIDE,5(4)-(3,3-DIMETHYL-1-TRIAZENO).
51.22IMIDA IMIDAZOLE CARBOXAMIDE, METHYL.
51.22IMIDA IMIDAZOLE CARBOXAMIDE MUSTARD.
51.22IMIDA IMIDAZOLE TEREPHTHALANILIDE.
51.22IMURA IMURAN (AZATHIOPRINE).
X 51.22IODOU IODOURACIL DEOXYRIBOSIDE: SEE IUDR.
51.22ISOPR ISOPROPYLIDINE.
51.22ITG-- ITG (2-AMINO-6-(1-METHYL-4-NITROIMIDAZAL-5-YL-THIO) PURINE).
51.22IUDR- 5-IUDR (IODOURACIL DEOXYRIBOSIDE).
51.22KANCH KANCHANOMYCIN.
X 51.22KREBI KREBIOZEN: SEE QUACK REMEDIES.
51.22LAPAC LAPACHOL.
X 51.22LEUKE LEUKERAN: SEE CHLORAMBUCIL.
X 51.22LYSOD LYSODREN: SEE DDD.
51.22MANNM MANNITOL MUSTARD.
51.22MANNO MANNOMUSTINE.
X 51.22MATUL MATULANE: SEE MIH.
X 51.22MECHL MECHLORETHAMINE: SEE HN2.
51.22MEGAG ME-GAG (METHYLGLYOXAL-BIS-GUANYLHYDRAZONE).
X 51.22MELPH MELPHALAN: SEE PAM.
X 51.22MERAC MERACTINOMYCIN: SEE ACTINOMYCIN D.
51.22MERCA 6-MERCAPTOPURINE (6-MP, PURINETHOL).
51.22MERCA MERCAPTOPURINE RIBOSIDE, 6-METHYL- (MMPR).
51.22MERCA MERCAPTOPURINE, 9-BUTYL-6-.
51.22MERCA MERCAPTOPURINE, 9-ETHYL-6-.
51.22MERCA 6-MERCAPTORIBOSIDE.
51.22METHO METHOTREXATE (MTX).
51.22METHY METHYLCARBAMATE.
51.22METHY METHYLHYDRAZINE.
51.22METHY METHYLMETHANE SULFONATE.
X 51.22METIC METICORTEN: SEE PREDNISONE.
51.22MIH-- MIH (NATULAN, IBENZMETHYZIN, METHYLHYDRAZINEASPARAGINASE,
PROCARBAZINE, MATULANE).
51.22MIRAC MIRACIL D.
51.22MITHR MITHRAMYCIN (MITHRACIN).
51.22MITOM MITOMYCIN.
MITOMYCIN C.
X 51.22MITOT MITOTANE: SEE DDD.
X 51.22MMPR- 6-MMPR: SEE 6-METHYLMERCAPTORIBOSIDE.
51.22MORPH MORPHALAN.
X 51.22MP--- 6-MP: SEE 6-MERCAPTOPURINE.
51.22MTX-- MTX (METHOTREXATE, USAN, AMETHOPTERIN).
METHOTREXATE DICHLORIDE.
X 51.22MUSTA MUSTARGEN: SEE HN2.
51.22MYCOR MYCORHODIN.
X 51.22MYELO MYELOBROMOL: SEE DBM.
51.22MYLER MYLERAN (BUSULFAN).
51.22MYLER MYLERAN, DIHYDROXY (DIHYDROXY BUSULFAN).
51.22NARAN NARANGOMYCIN.
51.22NARCO NARCOTINE.
X 51.22NATUL NATULAN: SEE MIH.
51.22NETRO NETROPSIN.

```
X    51.22NITRM NITROGEN MUSTARD:  SEE HN2.
     51.22NITRO NITROSOGUANIDINE.
     51.22NOGAL NOGALAMYCIN.
X    51.22ONCOV ONCOVIN:  SEE VCR.
X    51.22OXYLO OXYLONE:  SEE FLUOROMETHALONE.
     51.22OXYMA OXYMATE.
     51.22PA144 PA-144.
     51.22PACTA PACTAMYCIN.
     51.22PAM-- PAM (PHENYLALANINE MUSTARD, SARCOLYSIN, MELPHALAN).
                O-MELPHALAN.
                META-SARCOLYSIN.
                ORTHO-SARCOLYSIN.
X    51.22PARAC PARACORT:  SEE PREDNISONE.
     51.22PERTH PERTHANE.
     51.22PHENA PHENAZINIUM.
     51.22PHENE PHENESTERIN.
X    51.22PHENM PHENYLALANINE MUSTARD:  SEE PAM.
     51.22PHENO PHENOFORMIN.
     51.22PHOSM PHOSPHORAMIDE MUSTARD.
     51.22PIPER PIPERAZINE, 1,4-BIS-(3-BROMOPROPIONYL)-.
     51.22PLATI PLATINUM-II, CIS-DIAMINODICHLORO-.
     51.22PODOP PODOPHYLIC ACID.
     51.22PODOP PODOPHYLLOTOXIN.
     51.22POLYI POLY-IC.
     51.22PORFI PORFIROMYCIN.
     51.22PREDN PREDNISONE (DELTASONE, METICORTEN, PARACORT).
     51.22PREDN PREDNISOLONE.
     51.22PREGN 4-PREGNE-3,11,20-TRIONE, 6A-METHYL.
X    51.22PROCA PROCARBAZINE:  SEE MIH.
     51.22PROGE PROGESTERONE.
     51.22PSEUD PSEUDOTHIOUREA.
     51.22PURIN PURIN-6-YL-TRIMETHYLAMMONIUMCHLORIDE.
X    51.22PURIN PURINETHOL:  SEE 6-MERCAPTOPURINE.
     51.22PUROM PUROMYCIN DIHYDROCHLORIDE.
     51.22PYRAN PYRAN COPOLYMER.
     51.22PYRAZ PYRAZOLO(3,4-D) PYRIMIDINES.
     51.22QUINA QUINACRINE.
     51.22ROSEO ROSEOLIC ACID.
X    51.22RUBID RUBIDOMYCIN:  SEE DAUNOMYCIN.
     51.22S46-- S-46.
     51.22S73-- S-73.
     51.22S182- S-182.
     51.22SANGI SANGIVAMYCIN.
     51.22SARCI ALPHA-SARCIN.
X    51.22SARCO SARCOLYSIN:  SEE PAM.
     51.22SPARS SPARSOMYCIN.
     51.22STREP STREPTONIGRIN AND STREPTONIGRIN ESTERS (METHYL ESTERS).
     51.22STREP STREPTOVITACIN A.
     51.22STREP STREPTOZOTOCIN (ZEDALAN).
     51.22TAXOL TAXOL.
     51.22TEM-- TEM (TRIETHYLENEMELAMINE).
X    51.22TEPA- THIO-TEPA:  SEE TSPA.
     51.22TESTO TESTOLOLACTONE.
     51.22TESTO TESTOSTERONE ENANTHATE (DELATESTRYL).
     51.22TETRA TETRAMIN.
                ALPHA-VINYL-AE ACETATE.
                O-ACETYLTETRAMIN.
     51.22TETRA ALPHA-TETRANDRINE.
     51.22THALI THALICARPINE.
     51.22THALI THALIDOMIDE.
     51.22THIOC THIOCARZOLAMIDE.
     51.22THIOG 6-THIOGUANINE (TTG).
     51.22THIOG THIOGUANOSINE.
     51.22THIOG THIOGUANOSINE, BETA-DEOXY-.
     51.22THIOP THIOPHOSPHORAMIDE.
     51.22THIOQ THIOQUANOSINE.
     51.22TIC-- CHLORO-TIC.
     51.22TMCA- TMCA (TRIMETHYL COLCHICINE ACID METHYL ESTER D-TARTRATE).
     51.22TRENI TRENIMON.
     51.22TRIAZ TRIAZIQUONE.
```

X 51.22TRIET TRIETHYLENEMELAMINE: SEE TEM.
51.22TRIFL TRIFLUOROMETHYL-DEOXYURIDINE (F3TDR).
51.22TRYPM TRYPTOPHANE MUSTARD.
51.22TSPA- TSPA (THIO-TEPA, TRIETHYLENETHIOPHOSPHORAMIDE).
X 51.22TTG-- TTG: SEE 6-THIOGUANINE.
51.22TUBER TUBERCIDIN.
51.22URACM URACIL MUSTARD.
X 51.22USAN- USAN: SEE METHOTREXATE.
51.22VCR-- VCR (VINCRISTINE, ONCOVIN).
VINCRISTINE SULFATE.
51.22VELBA VELBAN.
51.22VINBL VINBLASTINE (VINBLASTINE SULFATE AND OTHER SALTS).
X 51.22VINCA VINCALEUKOBLASTINE: SEE VLB.
X 51.22VINCR VINCRISTINE: SEE VCR.
51.22VLB-- VLB (VINCALEUKOBLASTINE).
51.22WANDE WANDER DRUG.
X 51.22ZEDAL ZEDALAN: SEE STREPTOZOTOCIN.

51.220 CLINICAL TREATMENT OF SPECIFIC TYPES OF TUMORS WITH ANTICANCER AGENTS.
SEE ALSO: 51.221 FOR GENERAL INFORMATION ABOUT CLINICAL CANCER CHEMOTHERAPY WHICH WOULD USUALLY BE THE FIRST CATEGORY.

51.2201 GENERAL.
51.22011 SELECTION OF PATIENTS FOR CANCER CHEMOTHERAPY AND BASIS FOR SELECTION.
MATHEMATICAL MODELS AND DECISION THEORY FOR CHOOSING THE THERAPEUTIC METHOD.
SEE ALSO: 51.2016 FOR PROGNOSTIC METHODS USED TO PREDICT COURSE OF CANCER.
51.22012 METHODS FOR PREDICTING RESPONSE OF HUMAN TUMORS TO CANCER CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 51.2016 FOR PROGNOSTIC METHODS USED TO PREDICT CANCER COURSE.
51.220121 GENERAL.
51.220122 CORRELATION OF ANTICANCER TESTS IN ANIMALS WITH THE RESULTS OF USING ANTICANCER AGENTS IN MAN.
51.22013 SUCCESS OF CANCER CHEMOTHERAPY IN GENERAL.
NUMBER OF 5-YEAR SURVIVORS, CURES, AND OTHER RELATED STATISTICAL INFORMATION.
SEE ALSO: 51.2015 FOR MORE GENERAL ASPECTS OF END RESULTS OF CANCER THERAPY.
51.22014 COOPERATIVE GROUPS EVALUATING ANTICANCER AGENTS AND CANCER CHEMOTHERAPY.
SEE ALSO: 51.2018 FOR COOPERATIVE ANTICANCER EFFORTS IN GENERAL.
SEE ALSO: 51.22025315 FOR ACUTE LEUKEMIA TASK FORCE.
51.2201401 GENERAL.
51.2201402 CHILDRENS CANCER STUDY GROUP A.

51.2202 CHEMOTHERAPY OF CANCER IN CARDIOVASCULAR, RETICULOENDOTHELIAL, AND LYMPHATIC SYSTEMS.
SEE ALSO: 51.202 MORE GENERAL INFORMATION ABOUT DIAGNOSIS AND THERAPY OF THESE CANCERS.
51.22022 CHEMOTHERAPY OF CARDIAC CANCER.
51.22024 CHEMOTHERAPY OF VASCULAR AND ENDOTHELIAL CANCERS.
51.22025 CHEMOTHERAPY OF LEUKEMIAS AND LYMPHOMAS.
SEE ALSO: 51.22014 FOR COOPERATIVE CHEMOTHERAPY GROUPS.
SEE ALSO: 51.220255 FOR CHEMOTHERAPY OF LYMPHOMA.
51.22025AGL CHEMOTHERAPY OF ACUTE GRANULOCYTIC LEUKEMIA AND RELATED CONDDITIONS.
51.22025ALL CHEMOTHERAPY OF ACUTE LYMPHOCYTIC LEUKEMIA AND RELATED CONDITIONS.
51.22025ALO CHEMOTHERAPY OF OTHER TYPPES OF ACUTE LEUKEMIA.
51.22025ALT ACUTE LEUKEMIA TASK FORCE AND ITS ACTIVITIES.
51.22025CGL CHEMOTHERAPY OF CHRONIC GRANULOCYTIC LEUKEMIA AND RELATED CONDITIONS.
51.22025CLL CHEMOTHERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED CONDITIONS.
51.22025MIS CHEMOTHERAPY OF OTHER TYPES OF LEUKEMIA.
51.220251 GENERAL.
51.2202514 METHODS OF EVALUATING STATUS OF LEUKEMIC PATIENTS DURING CHEMOTHERAPY.
51.2202515 NUMBER OF LEUKEMIA AND LYMPHOMA PATIENTS TREATED WITH ANTICANCER AGENTS AND RESULTS OF THE CHEMOTHERAPY.
SEE ALSO: 51.2025 FOR END RESULTS OF ALL TYPES OF LEUKEMIA AND LYMPHOMA THERAPY.
51.220252 CLINICAL ASPECTS OF LEUKEMIA CHEMOTHERAPY IN GENERAL.
SEE ALSO: 51.222 FOR MORE GENERAL ASPECTS OF PATIENT MANAGEMENT AND CARE OF CANCER PATIENTS.

51.2202521 GENERAL.
51.2202522 SCHEDULING AND METHODS OF ADMINISTERING DOSES TO LEUKEMIA PATIENTS.
MODELS FOR DETERMINING DOSAGE SCHEDULES IN LEUKEMIA.
TIMING DRUG ADMINISTRATION TO MATCH CELL DIVISION TIME IN LEUKEMIA.
SEE ALSO: 51.2236 FOR MORE GENERAL ASPECTS OF DOSAGE LEVELS AND SCHEDULES IN CANCER CHEMOTHERAPY.
51.2202523 OTHER THERAPEUTIC PROCEDURES COMBINED WITH LEUKEMIA CHEMOTHERAPY.
SEE ALSO: 51.222 FOR PATIENT MANAGEMENT DURING CHEMOTHERAPY.
51.220252301 GENERAL.
51.220252302 THORACIC DUCT DRAINAGE TO REDUCE LYMPHOCYTE LEVELS BEFORE AND DURING LEUKEMIA CHEMOTHERAPY.
51.220252303 RADIATION COMBINED WITH CHEMOTHERAPY FOR TREATING LEUKEMIA.
51.2202524 CHEMOTHERAPY OF CHILDHOOD LEUKEMIA (GENERAL).
51.220253 OPEN
51.220254 SPECIFIC TYPES OF CHEMOTHERAPY USED TO TREAT LEUKEMIA.
SEE ALSO: 51.2202523 FOR CLINICAL PROCEDURES COMBINED WITH CHEMOTHERAPY.
SEE ALSO: 51.222 FOR PATIENT MANAGEMENT DURING CHEMOTHERAPY.
51.220254001 COMPARISON OF DIFFERENT TYPES OF CHEMOTHERAPY.
51.220254002 THE VAMP PROTOCOL INVOLVING VINCRISTINE, AMETHOPTERIN, MERCAPTOPURINE AND PREDNISONE.
51.220254003 THE POMP PROTOCOL INVOLVING THE SAME AGENTS AS VAMP (PREDNISONE, ONCOVIN, METHOTREXATE, AND MERCAPTOPURINE) BUT AT DIFFERENT DOSAGE LEVELS.
51.220254004 THE BIKE PROTOCOL (INDUCED REMISSION WITH VINCRISTINE AND PREDNISONE, FOLLOWED BY CYCLIC TREATMENT WITH MERCAPTOPURINE, METHOTREXATE, AND CYTOXAN).
51.220254005 COMBINATIONS OF CYCLOPHOSPHAMIDE, ONCOVIN, METHOTREXATE, AND 5-FLUOROURACIL.
51.220254006 THE ALCG-B6313 PROTOCOL OF ACUTE LEUKEMIA COOPERATIVE GROUP B.
51.220254007 THE PAP PROTOCOL (PREDNISONE, AMETHOPTERIN, AND 6-MP).
51.220254008 THE COMP PROTOCOL (CYCLOPHOSPHAMIDE, ONCOVIN, METHOTREXATE, AND 6-MP).
51.220254009 COMBINATIONS OF ACTINOMYCIN, CHLORAMBUCIL, AND METHOTREXATE.
51.220254010 COMBINATIONS OF PREDNISONE, VINCRISTINE, AND CYTOSINE ARABINOSIDE.
51.220254011 VINCRISTINE ALONE.
51.220254012 METHOTREXATE (AMETHOPTERIN) ALONE.
51.220254013 6-MERCAPTOPURINE ALONE.
51.220254014 PREDNISONE ALONE.
51.220254015 METHYL-GAG (METHY-GLYOXAL-BIS-GUANYLHYDRAZONE) ALONE.
51.220254016 CYCLOPHOSPHAMIDE ALONE.
51.220254017 METHOTREXATE AND 6-MERCAPTOPURINE (CCA-603).
51.220254018 METHOTREXATE PLUS PREDNISONE (CCA-607).
51.220254019 CYTOSINE ARABINOSIDE ALONE (CCA-701).
51.220254020 DAUNOMYCIN ALONE (CCA-602).
51.220254021 CYTOSINE ARABINOSIDE PLUS 6-MERCAPTOPURINE (CCA-802).
51.220254022 NITROGEN MUSTARD (HN2) PLUS ACTINOMYCIN D TO MAINTAIN REMISSIONS.
51.220255 CHEMOTHERAPY OF LYMPHOMA AND OTHER RETICULOENDOTHELIAL TUMORS.
51.2202551 GENERAL.
51.2202552 CHEMOTHERAPY OF SPECIFIC TYPES OF LYMPHOMAS AND RETICULOENDOTHELIAL TUMORS.
51.220255201 GENERAL.
51.220255202 LYMPHOMA TASK FORCE AND OTHER COOPERATIVE PROGRAMS.
51.220255203 CHEMOTHERAPY OF HODGKINS DISEASE.
51.220255204 CHEMOTHERAPY OF MULTIPLE MYELOMA, PLASMACYTIC MYELOMA, AND RELATED CONDITIONS.
MULTIPLE MYELOMA TASK FORCE ACTIVITIES AND RESULTS.
51.220255205 CHEMOTHERAPY OF LYMPHOSARCOMAS AND RELATED CONDITIONS.
51.220255206 CHEMOTHERAPY OF RETICULUM CELL SARCOMAS AND RELATED CONDITIONS.
51.220255207 CHEMOTHERAPY OF BURKITT LYMPHOMAS (AFRICAN LYMPHOMAS).
51.22026 CHEMOTHERAPY OF OTHER HEMATOPOIETIC AND HEMATOLOGIC CANCER.
51.2202601 GENERAL.
51.2202602 CHEMOTHERAPY OF POLYCYTHEMIA AND RELATED CONDITIONS.
51.2203 CHEMOTHERAPY OF MUSCLE CANCER.

51.2204 CHEMOTHERAPY OF CANCER OF KIDNEY, BLADDER, AND URINARY TRACT.
51.22041 GENERAL.
51.22042 CHEMOTHERAPY OF KIDNEY CANCER AND END RESULTS.
51.22043 CHEMOTHERAPY OF BLADDER CANCER, AND CANCER OF URETER AND URETHRA.
51.2205 CHEMOTHERAPY OF SPECIFIC INTERNAL ORGANS.
51.22051 GENERAL.
51.22052 CHEMOTHERAPY OF LUNG, BRONCHIAL, TRACHEAL, AND PULMONARY CANCER.
51.22053 CHEMOTHERAPY OF LIVER AND GALL BLADDER CANCER.
51.220531 CHEMOTHERAPY OF LIVER CANCER.
51.220532 CHEMOTHERAPY OF GALL BLADDER CANCER.
51.22054 CHEMOTHERAPY OF CANCER OF THE GASTROINTESTINAL TRACT, INCLUDING CARCINOID TUMORS AND NON-CUTANEOUS MELANOMAS.
51.220541 GENERAL.
51.220542 CHEMOTHERAPY OF SPECIFIC TYPES OF UNUSUAL GASTROINTESTINAL CANCER.
51.2205421 CHEMOTHERAPY OF CARCINOID TUMORS. USE OF SEROTONIN ANTAGONISTS.
51.2205422 CHEMOTHERAPY OF NON-CUTANEOUS MELANOMAS.
51.220543 CHEMOTHERAPY OF ESOPHAGEAL CANCER.
51.220544 CHEMOTHERAPY OF STOMACH CANCER.
51.220545 CHEMOTHERAPY OF INTESTINAL CANCER IN SMALL AND LARGE INTESTINE AND BOWEL.
51.220546 CHEMOTHERAPY OF CANCER OF THE COLON, RECTUM, AND ANAL CANAL.
51.220547 CHEMOTHERAPY OF CANCER OF THE PANCREAS.
51.22055 CHEMOTHERAPY (NON-HORMONAL) OF CANCER ASSOCIATED WITH REPRODUCTION, GONADS, AND SECONDARY SEX TISSUES.
SEE ALSO: 51.23055 FOR HORMONE THERAPY OF SEX-RELATED CANCER.
51.220551 GENERAL.
51.220552 NON-HORMONAL CHEMOTHERAPY OF REPRODUCTIVE AND SEX-RELATED TISSUES IN THE FEMALE.
51.2205521 GENERAL.
51.2205522 CHEMOTHERAPY OF OVARIAN CANCER.
51.2205523 CHEMOTHERAPY OF CANCER OF THE UTERUS, CERVIX, VAGINA, ENDOMETRIUM, AND PLACENTA.
51.22055231 GENERAL.
51.22055232 CHEMOTHERAPY OF THE CORPUS UTERI AND FUNDUS.
51.22055233 CHEMOTHERAPY OF THE CERVIX AND VAGINA.
51.22055234 CHEMOTHERAPY OF THE PLACENTA AND ENDOMETRIUM.
51.220552341 GENERAL.
51.220552342 CHEMOTHERAPY OF CHORIOCARCINOMA.
51.220552343 CHEMOTHERAPY OF MOLAR PREGNANCIES.
51.220552344 CHEMOTHERAPY OF CHORIOADENOMA.
51.220552345 CHEMOTHERAPY OF OTHER TYPES OF ENDOMETRIAL TROPHOBLASTIC DISEASES.
51.2205524 NON-HORMONAL ASPECTS OF BREAST CANCER CHEMOTHERAPY.
SEE ALSO: 51.2205534 FOR HORMONAL THERAPY OF BREAST CANCER.
51.2205525 CHEMOTHERAPY OF CANCER OF FEMALE GENITALIA AND OTHER SEX-RELATED TISSUES NOT INCLUDED ABOVE.
51.220553 CHEMOTHERAPY OF CANCER OF MALE REPRODUCTIVE AND SEX-RELATED TISSUES IN THE MALE.
51.2205531 GENERAL.
51.2205532 CHEMOTHERAPY OF TESTICULAR CANCER, INCLUDING TESTICULAR TROPHOBLASTIC TUMORS.
51.2205533 CHEMOTHERAPY OF CANCER OF THE PENIS AND SCROTUM.
51.2205534 CHEMOTHERAPY OF PROSTATE CANCER.
51.22056 NON-HORMONAL CHEMOTHERAPY OF ENDOCRINE GLAND CANCER.
SEE ALSO: 51.22055 FOR CHEMOTHERAPY OF OVARIAN AND TESTICULAR CANCER.
SEE ALSO: 51.23056 FOR HORMONAL THERAPY OF ENDOCRINE GLAND CANCER.
51.220561 GENERAL.
51.220562 CHEMOTHERAPY OF PITUITARY GLAND (HYPOPHYSEAL) CANCER.
51.220563 CHEMOTHERAPY OF THYROID GLAND CANCER.
51.220564 CHEMOTHERAPY OF PARATHYROID GLAND CANCER.
51.220565 CHEMOTHERAPY OF ADRENAL GLAND CANCER.
51.220566 CHEMOTHERAPY OF CANCER IN OTHER ENDOCRINE GLANDS AND TISSUES.
51.2206 CHEMOTHERAPY OF CANCER OF THE BRAIN AND NERVOUS SYSTEM.
51.22061 GENERAL.
51.22062 CHEMOTHERAPY OF CANCER OF THE NERVOUS SYSTEM OTHER THAN THE BRAIN.
51.22065 CHEMOTHERAPY OF BRAIN AND CEREBROSPINAL TUMORS.
51.220651 GENERAL.
51.220652 SPECIFIC TYPES OF PERFUSION AND OTHER SPECIAL METHODS OF ADMINISTERING ANTICANCER AGENTS.

51.220653 CHEMOTHERAPY OF GLIOBLASTOMA MULTIFORME.
51.2207 CHEMOTHERAPY OF CANCER ASSOCIATED WITH SENSE ORGANS.
SEE ALSO: 51.2092 FOR ALL INFORMATION ABOUT CHEMOTHERAPY OF CANCER ASSOCIATED WITH THE EYE AND EAR AREAS OF FACE AND HEAD.
51.2208 CHEMOTHERAPY OF SKIN, CONNECTIVE, AND MINERALIZED TISSUES.
51.22082 CHEMOTHERAPY OF VARIOUS CONNECTIVE TISSUE CANCERS SUCH AS FIBROMAS.
51.22083 CHEMOTHERAPY OF SKIN CANCER AND CUTANEOUS MELANOMAS.
51.220831 GENERAL.
51.220832 CHEMOTHERAPY OF SKIN CANCERS OTHER THAN MELANOMAS.
51.220833 CHEMOTHERAPY OF CUTANEOUS MELANOMAS.
SEE ALSO: 51.2205422 FOR CHEMOTHERAPY OF NON-CUTANEOUS MELANOMAS.
51.22084 CHEMOTHERAPY OF BONE CANCERS.
51.22085 CHEMOTHERAPY OF LYMPHOMA AND OTHER CANCER OF FATTY TISSUES.
51.2209 CHEMOTHERAPY OF CANCER OF SPECIFIC BODY PARTS.
51.22091 CHEMOTHERAPY OF CANCER OF THE ORAL CAVITY, THROAT, AND ADJACENT AREAS.
51.220911 GENERAL.
51.220912 CHEMOTHERAPY OF CANCER OF THE LIP.
51.220913 CHEMOTHERAPY OF CANCER OF THE TONGUE.
51.220914 CHEMOTHERAPY OF CANCER OF THE LARYNX AND VOCAL CORDS.
51.220915 CHEMOTHERAPY OF CANCER OF THE THROAT AND PHARYNX.
51.220916 CHEMOTHERAPY OF CANCER OF THE JAW AND NECK.
51.22092 CHEMOTHERAPY OF CANCER IN THE AREA OF THE NOSE, EAR, SINUSES, AND OTHER CRANIAL CAVITIES.
51.22093 CHEMOTHERAPY OF CANCER OF THE APPENDAGES AND END RESULTS.
51.22094 CHEMOTHERAPY OF METASTASES (GENERAL).
51.221 SELECTED GENERAL TOPICS RELATED TO CLINICAL CHEMOTHERAPY.
SEE ALSO: 51.2201 FOR OTHER GENERAL INFORMATION ON CANCER CHEMOTHERAPY.
51.2211 THEORETICAL CONSIDERATIONS OF GOALS, OBJECTIVES, AND RATIONALE OF CLINICAL CHEMOTHERAPY.
51.2212 HISTORICAL ASPECTS OF CLINICAL CHEMOTHERAPY.
USE OF POTASSIUM ARSENITE (FOWLER'S SOLUTION) (1870S).
USE OF COLEY'S TOXIN (1890S).
51.2213 UNPROVEN CANCER REMEDIES AND CANCER QUACKERY (LISTED BY TWO-DIGIT CODE FOR ALPHABET).
51.221300 GENERAL.
51.2213011 ALFALFA PRODUCTS USED FOR CANCER.
51.2213081 HOXEY TREATMENT.
51.2213111 KREBIOZEN.
51.2213121 LAETRILE.
51.2214 SUMMARIES LISTING COMPOUNDS TESTED CLINICALLY AND COMPARING RESULTS OF DIFFERENT AGENTS.
SEE ALSO: 51.224 THROUGH 51.227 FOR SPECIFIC COMPOUNDS.
51.222 PATIENT MANAGEMENT AND SUPPORTIVE CARE FOR PATIENTS DURING CHEMOTHERAPY.
SEE ALSO: 51.2011 FOR TREATMENT AND CARE OF CANCER PATIENTS IN GENERAL.
SEE ALSO: 51.223 FOR PHARMACOLOGICAL ASPECTS OF CANCER CHEMOTHERAPY.
SEE ALSO: 51.2202523 FOR THERAPEUTIC PROCEDURE COMBINED WITH CHEMOTHERAPY.
51.2221 GENERAL.
51.2222 PATIENT ISOLATION AND PATIENT STERILIZATION PROCEDURES.
USE OF LIFE ISLANDS AND REVERSE ISOLATION OR GERM-FREE ISOLATION.
SEE ALSO: 51.2223 FOR USE OF ANTIBIOTICS NOT ACCOMPANIED BY PATIENT ISOLATION PROCEDURES.
51.2223 USE OF ANTIBIOTICS TO REDUCE INFECTIONS DURING CANCER CHEMOTHERAPY.
SEE ALSO: 51.2222 FOR USE OF ANTIBIOTICS DURING PATIENT ISOLATION PROCEDURES.
51.22231 GENERAL.
51.22232 TYPES OF INFECTIONS THAT ACCOMPANY USE OF ANTICANCER AGENTS.
51.22233 VIRAL INFECTIONS DURING CANCER CHEMOTHERAPY AND THEIR TREATMENT.
51.22234 FUNGAL INFECTIONS DURING CANCER CHEMOTHERAPY AND THEIR TREATMENT.
51.22235 BACTERIAL INFECTIONS DURING CANCER CHEMOTHERAPY AND THEIR TREATMENT.
51.2224 BLOOD CELL REPLACEMENT PROCEDURES DURING CANCER CHEMOTHERAPY.
SEE ALSO: 48.3252 FOR LEUKOCYTE AND PLATELET TRANSFUSIONS (GENERAL).
SEE ALSO: 51.223225 FOR TOXIC EFFECTS OF ANTICANCER AGENTS ON HEMATOPOIETIC AND LYMPHATIC CELLS.
51.22241 GENERAL.
51.22242 WHITE BLOOD CELL OR LEUKOCYTE TRANSFUSIONS DURING CANCER CHEMOTHERAPY.
51.222421 GENERAL.
51.222422 GRANULOCYTE TRANSFUSIONS DURING CANCER CHEMOTHERAPY.
51.22243 PLATELET TRANSFUSIONS DURING CANCER CHEMOTHERAPY.
SEE ALSO: 53.2833 FOR PLATELET ISOLATION AND STORAGE.
SEE ALSO: 48.325225 FOR PLATELET TRANSFUSIONS (GENERAL).

51.2225 TISSUE TRANSPLANTATION USED DURING CANCER CHEMOTHERAPY.
51.22251 GENERAL.
51.22252 BONE MARROW TRANSPLANTATION TO PREVENT TOXICITY DURING CANCER CHEMOTHERAPY.
SEE ALSO: 53.232 FOR ISOLATION, STORAGE, AND TRANSFUSION OF GRANULOCYTES (GENERAL).
51.2226 SPLENECTOMY TO RAISE PLATELET, LEUKOCYTE, AND OTHER BLOOD CELL LEVELS DURING CANCER CHEMOTHERAPY.
51.223 CLINICAL PHARMACOLOGY RELATED TO CANCER CHEMOTHERAPY AND ANTICANCER AGENTS.
51.2231 GENERAL.
51.2232 CLINICAL TOXICOLOGY OF CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 55. FOR TOXICOLOGY (GENERAL).
SEE ALSO: 51.3235 FOR PRECLINICAL TOXICOLOGY OF ANTICANCER AGENTS.
51.22321 GENERAL.
51.223211 CYTOLOGICAL AND HISTOLOGICAL ALTERATIONS CAUSED IN PATIENTS BY ANTICANCER AGENTS.
51.2232111 GENERAL
51.2232112 EFFECT OF ANTICANCER AGENTS ON CHROMOSOMES IN HUMANS.
51.223212 CHEMICAL AGENTS USED TO REDUCE SYSTEMIC TOXIC EFFECT OF ANTICANCER AGENTS.
51.22321200 GENERAL.
51.22321201 SEROTONIN ANTAGONISTS (KB-95).
51.22321202 ANTIHISTAMINES (PYRIBENZAMINE).
51.22321203 ANDROGENS.
51.223213 DETERMINATION OF THERAPEUTIC INDEX ("MINIMUM-LOSS" APPROACH).
51.223214 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON IMMUNE STATUS OF PATIENTS.
SEE ALSO: 51.2232254 FOR EFFECT OF ANTICANCER AGENTS ON LYMPHOCYTE TRANSFORMATION IN HUMANS.
SEE ALSO: 48.43 FOR IMMUNOSUPPRESSIVE AGENTS.
51.22322 TOXIC EFFECTS OF ANTICANCER AGENTS ON LYMPHATIC, RETICULOENDOTHELIAL AND CARDIOVASCULAR SYSTEMS.
51.223222 TOXIC EFFECTS OF ANTICANCER AGENTS ON THE HEART.
51.223223 TOXIC EFFECTS OF ANTICANCER AGENTS ON THE CARDIOVASCULAR SYSTEM.
51.223225 TOXIC EFFECTS OF ANTICANCER AGENTS ON RETICULOENDOTHELIAL AND LYMPHATIC SYSTEMS.
SEE ALSO: 51.2224 FOR BLOOD CELL REPLACEMENT THERAPY TO REDUCE THESE EFFECTS.
51.2232251 GENERAL.
51.2232252 OCCURRENCE OF HEMORRHAGIC COMPLICATIONS.
51.2232253 OCCURRENCE AND CONTROL OF LEUKOCYTE (GRANULOCYTE) AND BONE MARROW DEPRESSION (MYELOSUPPRESSION).
51.2232254 EFFECT ON PROPERTIES OF LEUKOCYTES.
EFFECT ON MIGRATION OF "OROGRANULOCYTES" INTO THE ORAL CAVITY.
EFFECT ON LYMPHATIC TRANSFORMATION.
EFFECT ON LEUKEMIC BIOCHEMISTRY AND RESPIRATION.
EFFECT ON RETICULOENDOTHELIAL CELLS, ON IMMUNE STATUS OF PATIENT, AND ON PHAGOCYTOSIS.
51.223226 EFFECTS ON HEMATOPOIETIC SYSTEM AND ERYTHROPORESIS.
51.22323 EFFECT OF ANTICANCER AGENTS ON MUSCLE.
51.22324 EFFECT OF ANTICANCER AGENTS ON KIDNEY, BLADDER AND RELATED TISSUES.
51.22325 EFFECT OF ANTICANCER AGENTS ON SELECTED INTERNAL ORGANS.
51.223251 EFFECT OF ANTICANCER AGENTS ON EXOCRINE GLANDS.
51.223252 EFFECT OF ANTICANCER AGENTS ON LUNG AND RESPIRATION.
51.223253 EFFECT OF ANTICANCER AGENTS ON LIVER.
51.223254 EFFECT OF ANTICANCER AGENTS ON THE GASTROINTESTINAL TRACT AND DIGESTIVE SYSTEM.
51.223255 EFFECT OF ANTICANCER AGENTS ON GENITAL AND REPRODUCTIVE TISSUES OF GONADS.
51.223256 EFFECT OF ANTICANCER AGENTS ON OTHER ENDOCRINE GLANDS.
51.22326 EFFECT OF ANTICANCER AGENTS ON THE NERVOUS SYSTEM AND BRAIN.
51.22327 EFFECT OF ANTICANCER AGENTS ON THE SENSE ORGANS.
51.22328 EFFECT OF ANTICANCER AGENTS ON CONNECTIVE AND MINERALIZED TISSUES AND SKIN.
51.223282 EFFECT ON CONNECTIVE TISSUE AND CONNECTIVE TISSUE STRUCTURES.
51.223283 EFFECT ON SKIN.
51.223284 EFFECT ON BONES AND MINERALIZED TISSUES.
SEE ALSO: 51.223225 FOR EFFECT ON BONE MARROW.
51.2235 METHODS OF ADMINISTERING CANCER CHEMOTHERAPEUTIC AGENTS.
51.22351 GENERAL.
51.22352 REGIONAL INFUSIONS AND PERFUSIONS.

51.223521 GENERAL. TYPES OF PUMPS (PORTABLE PUMPS).
51.223522 FOR CANCER OF CARDIOVASCULAR, LYMPHATIC, AND RETICULOENDOTHELIAL SYSTEMS.
51.223523 FOR MUSCLE CANCERS.
51.223524 FOR KIDNEY, BLADDER, AND URINARY TRACT CANCER.
51.2235252 FOR LUNG CANCER.
51.2235253 FOR LIVER CANCER. HEPATIC ARTERY INFUSION (WITH HEPATIC OUTFLOW BLOCK).
51.2235254 FOR GASTROINTESTINAL CANCER.
51.2235255 FOR CANCER OF REPRODUCTIVE SYSTEM.
51.2235256 OTHER ENDOCRINE SYSTEM TUMORS.
51.223526 FOR CANCER OF BRAIN AND NERVOUS SYSTEM.
51.2235272 FOR CANCER OF THE EYE.
51.2235282 FOR CANCER OF CONNECTIVE TISSUE STRUCTURES.
51.2235283 FOR SKIN CANCER.
51.2235284 FOR BONE CANCER.
51.223529 FOR CANCER IN APPENDAGES OR SPECIFIC BODY PARTS NOT INCLUDED ABOVE.
51.22353 TOPICAL APPLICATION.
SEE ALSO: 51.22083 FOR USE OF OINTMENTS FOR SKIN CANCER.
51.2236 STUDIES RELATED TO DOSAGE AND MEANS OF ADMINISTRATION.
51.22361 GENERAL.
51.22362 DOSE SIZE AND NUMBER OF DOSES.
51.22363 TYPE OF DOSE (ROUTE OF ADMINISTRATION - PERFUSION AND INFUSIONS AND OTHER REGIONAL CHEMOTHERAPY METHODS (INTRALUMINAL CHEMOTHERAPY).
51.22364 INTERVAL BETWEEN DOSES AND PERIODIC APPLICATION; CORRELATION OF DOSE RATE WITH CELL DIVISION TIME.
51.22365 DOSAGE ROUTES.
51.223651 GENERAL.
51.223652 ORAL.
51.223653 PARENT.
51.223654 PERFUSION.
51.2237 OTHER PHARMACOLOGICAL STUDIES OF ANTICANCER AGENTS AND MECHANISM OF ACTION (GENERAL).
51.22371 CLINICAL ASPECTS OF DEVELOPMENT OF RESISTANCE TO ANTICANCER AGENTS.
51.22372 DISTRIBUTION OF ANTICANCER AGENTS IN BODY FLUIDS AND TISSUES. FACTORS AFFECTING THIS DISTRIBUTION.
51.22373 METABOLIC STUDIES ON ANTICANCER AGENTS (GENERAL).
51.224 CLINICAL USE OF ALKYLATING AGENTS.
SEE ALSO: 51.4283 FOR CARCINOGENIC ACTIVITY OF THESE AGENTS.
51.2241 GENERAL.
51.2242 CLINICAL USE OF NITROGEN MUSTARDS (ARRANGED ALPHABETICALLY).
51.224200 GENERAL.
51.2242011 A-8103 (N,N'-BIS-(3-BROMOPROPIONYL) PIPIPERAZINE.
51.2242012 ALKERAN.
SEE ALSO: 51.2242131
51.2242021 BCNU (1,3-BIS-(2-CHLOROETHYL)-1-(NITROSOUREA).
51.2242031 CHLORAMBUCIL (LEUKERAN).
51.2242041 DIPINE (TETRAETHYLENIMIDE-N,N-PIPERAZINE-DIPHOSPHORIC ACID.
51.2242131 MELPHALAN (L-PHENYLALANINE MUSTARD, L-SARCOLYSIN, PAM , ALKERAN).
51.2242132 MANNOMUSTINE.
51.2242133 MECHLORETHAMINE (MUSTARGEN, HN2, "NITROGEN MUSTARD").
51.2242134 MECHLORETHAMINE OXIDE.
SEE ALSO: 51.2242131 FOR SHEALA MUSTARD, PAM, SARCOLYSIN.
51.2242135 MANNITOL DERIVATIVES.
51.224213501 DEGRANOL.
51.224213502 BROMDEGRANOL.
51.224213503 DIBROMOMANNITOL.
51.224213504 MYELOBROMOL.
51.224213505 MANNITOLBUSULFAN (MANNOGRANOL).
51.224213506 TETRAMEZYL MANNITOL (R52).
51.2242191 S-73 (ESKERASE SUSCEPTABLE, WATER SOLUBLE NITROGEN MUSTARD USED TO DEPRESS BONE MARROW).
51.2242201 TRYPTOPHANE MUSTARD (NSC 62403).
51.2242211 URACIL MUSTARD.
51.2243 CLINICAL USE OF PHOSPHORUS-CONTAINING ALKYLATING AGENTS (ARRANGED ALPHABETICALLY).
51.2243001 GENERAL.
51.2243011 AZOTEPA.
51.2243031 CYCLOPHOSPHAMIDE (CYTOXAN, ENDOXAN) AND RELATED COMPOUNDS - PHOSPHORODIAMIDIC ACIDS (ONF 59).

51.2243201 TRIETHYLENE-PHOSPHORAMIDE (TEPA).
51.2243202 THIOTEPA (TRIETHYLENE-THIOPHOSPHORAMIDE).
51.2244 CLINICAL USE OF ETHYLENEIMINE (AZIRIDINE OR EPIMINE) ALKYLATING AGENTS.
SEE ALSO: 51.2243 FOR EPIMINE AGENTS CONTAINING PHOSPHORUS.
51.2244201 TRIETHYLENE-MELAMINE (TEM).
51.2244202 TRIETHYLENE-IMINOBENZOQUINONE (TRENIMON).
51.2244203 HEXAMETHYLMELAMINE.
51.2245 SULFONIC ACID ESTERS.
51.2245021 BUSULFAN (DIMETHANE-SULFONYLOXYBUTANE, MYELERAN).
51.2246 SULFUR MUSTARDS.
51.2246191 S-182.
51.2247 ALKYLATING EPOXIDES.
51.22470501 EPODYL (AY 62013); ETHOGLUCID TRIETHYLENEGLYCOL DIGLYCIDYL ETHER.
51.225 CLINICAL USE OF ANTIMETABOLITES.
51.2251 GENERAL. CLINICAL USE OF ANTIMETABOLITES.
51.2252 CLINICAL USE OF NUCLEIC ACID ANALOGS.
SEE ALSO: 11.8 FOR OTHER INFORMATION ABOUT THESE COMPOUNDS.
SEE ALSO: 51.2242211 FOR URACIL MUSTARD.
51.22520101 8-AZAGUANINE.
51.22520102 AZAURACIL.
51.22520201 5-BROMO-5-FLUORO-6-METHOXY-DIHYDRO-2'-DEOXYURIDINE.
51.22520301 CYTOSINE ARABINOSIDE (ARA C).
51.22521302 6-METHYLMERCAPTOPURINE RIBOSIDE.
51.22520401 DEOXYURIDINE.
51.22520601 5-FLUORO-2-DEOXYURIDINE.
51.22520602 5-FLUOROURACIL.
51.22520901 IODODEOXYURIDINE (IODOXURIDINE).
51.22521301 6-MERCAPTOPURINE (6-MP, PURINETHOL).
51.22521302 6-METHYL-MERCAPTOPURINE RIBOSIDE.
51.22522001 6-THIOGUANINE.
51.22522002 TRI-O-ACETYL-6-AZAURIDINE.
51.2253 CLINICAL USE OF OTHER AGENTS WHICH INHIBIT NUCLEIC ACID BIOSYNTHESIS.
51.22531 GENERAL.
51.22532 CLINICAL USE OF ANTIFOLICS (FOLIC ACID ANTAGONISTS).
51.225321 GENERAL.
51.225322 AMINOPTERIN.
51.225323 METHOTREXATE (AMETHOPTERIN).
51.225324 DICHLOROMETHOTREXATE.
51.22533 CLINICAL USE OF GLUTAMINE ANTAGONISTS (INHIBIT PURINE BIOSYNTHESIS).
51.225331 GENERAL.
51.225332 AZASERINE.
51.225333 DON (6-DIAZO-5-OXO-NORLEUCINE).
51.2254 CLINICAL USE OF OTHER ANTIMETABOLITES.
51.22541 CLINICAL USE OF ANTIMETABOLITES OF AMINO ACIDS (GENERAL).
SEE ALSO: 51.22533 FOR USE OF GLUTAMINE ANALOGS (DON, AZASERINE).
51.22542 CLINICAL USE OF ANTIMETABOLITES OF VITAMINS.
SEE ALSO: 51.22532 FOR CLINICAL USE OF ANTIFOLICS.
SEE ALSO: 51.2834 FOR EFFECT OF VITAMIN-DEFICIENT DIETS.
51.225421 GENERAL.
51.225422 USE OF GALACTOFLAVIN AND OTHER RIBOFLAVIN ANALOGS (U-2112).
51.225423 USE OF ANTIPDXN COMPOUNDS.
51.225424 USE OF ANTI-NIACIN AGENTS (SKLEROVITOL).
51.22543 ANTIMETABOLITES AND ANALOGS OF SUGARS.
51.226 CLINICAL USE OF OTHER SYNTHETIC ORGANIC COMPOUNDS AND INORGANIC COMPOUNDS.
51.2260101 AB-132.
51.2260102 ADL-45.
51.2260103 6-AMINO CHRYSENE (CHRYSENEX).
51.2260201 BAYER #39.
51.2260401 O,P'-DDD.
51.2260402 DIHYDRO E. 73.
51.2260403 DIETHYL-DITHIO-CARBAMATE.
51.2260404 OZTHIZONE.
51.2260801 HYDROXYUREA (HYDREA).
51.2261301 METHYL-GAG (METHYLGLYOXAL BIS (GUANYLHYDRAZONE)) (CH3G).
51.2261302 MIH (NSC 77213) (1-METHYL-2-P-(ISOPROPYL-CARBAMOYL-BENZYL)-HYDRAZINE HYDROCHLORIDE) OR (N-ISOPROPYL-ALPHA-(2-METHYL-HYDRAZINO)-P-TOLUAMIDE OR PROCARBAZINE OR MH OR NATULAN.
SEE ALSO: 51.2202548 FOR REMISSIONS OF HODGKINS DISEASE BY MIH.
SEE ALSO: 51.4607 FOR CARCINOGENICITY OF MIH.
SEE ALSO: 55.56131 FOR TERATOGENIC EFFECT OF MIH.

51.2261303 3-METHYLCHOLANTHRENE.
51.2261304 METHYL-METHANESULFONATE (NSC 50256).
51.2261305 MBBA, BETA-4-METHOXYBENZOYL-BETA-BROMACRYLIC ACID, MEBRYL.
51.2261501 OXYLONE.
51.2261601 PHENAZINIUM (NSC 33414).
51.2261602 O-PHENYLENE DIAMINE.
51.2262001 THIOCARZOLAMIDE.
51.2262101 URETHANE.
51.2263 CLINICAL USE OF INORGANIC SUBSTANCES.
51.2263061 USE OF SODIUM FLUORIDE FOR BONE CANCER.
51.2263081 HYDROGEN PEROXIDE AND HYPERBARIC OXYGEN.
SEE ALSO: 51.2473 FOR HYPERBARIC OXYGEN IN RADIATION THERAPY.
51.227 CLINICAL USE OF CANCER CHEMOTHERAPEUTIC AGENTS FROM NATURAL SOURCES.
51.2271 CLINICAL USE OF ALKALOIDS AND OTHER PLANT EXTRACTIVES (ARRANGED IN ALPHABETICAL ORDER).
51.227100 GENERAL.
51.22710301 COLCHICINE AND DERIVATIVES (TRIMETHYL COLCHICINIC ACID).
SEE ALSO: 51.2271041 FOR DEMECOLCINE (CLOSELY RELATED TO COLCHICINE).
51.22710401 DEMECOLCINE (SANTAVY'S SUBSTANCE; COLCEMID) FROM COLCHICUM.
SEE ALSO: 51.2271031 FOR COLCHICINE.
51.22711201 LAPACHOL.
51.22711601 PODOPHYLLIN ('PRORESID') AND RELATED SUBSTANCES.
51.227116011 GENERAL.
51.227116012 PODOPHYLLOTOXIN (NSC 24818).
51.227116013 ALPHA-PELTATIN (NSC 24817).
51.227116014 CHEMICALLY MODIFIED DERIVATIVES.
51.2271160141 GENERAL.
51.2271160142 SPI-77.
51.2271160143 SPG-827.
51.22711602 PHENANTHRIDINIUM COMPOUNDS (ISOMETAMIDIUM (IMDM)).
51.22711701 QUINACRINE (ATABRINE).
51.2271221 VINCA ALKALOIDS.
51.22712211 GENERAL.
51.22712212 VINBLASTINE (VELBAN OR VINCALEUCOBLASTINE) (VLB, VBR).
51.22712213 VINCRISTINE (ONCOVIN) (VCR) (LEMOCRISTINE).
51.22712214 VINGLYCINATE (VGL).
51.2272 CLINICAL USE OF ANTIBIOTICS AND FERMENTATION BROTHS.
51.227200 GENERAL.
51.22720101 ACTINOMYCIN D (DACTINOMYCIN).
51.22720102 AZOTOMYCIN.
51.22720103 A-649.
51.22720104 ACTINOGAN.
51.22720401 DUAZOMYCIN A.
51.22720402 DAUNOMYCIN.
51.22721101 KANAMYCIN.
51.22721301 MITOMYCIN C.
51.22721302 MITHRAMYCIN.
51.22721601 PORFIROMYCIN.
51.22721901 SARKOMYCIN.
51.22721902 STREPTONIGRIN.
51.22721904 STEPTOMYCES ANTIBOTICUS EXTRACT.
51.22721905 SANGIVAMYCIN.
51.2273 CLINICAL USE OF ENZYMES AND OTHER MICROBIAL SUBSTANCES (OR MICROBES THEMSELVES).
SEE ALSO: 51.275 FOR CLINICAL USE OF INTERFERON-PRODUCING VIRUSES.
SEE ALSO: 51.284 FOR USE OF CLOSTRIDAL AND OTHER ONCOLYTIC BACTERIA.
51.2273011 ASPARAGINASE.
51.2274 CLINICAL USE OF PRODUCTS FROM ANIMAL SOURCES.
SEE ALSO: 51.2213111 FOR KREBIOZEN.
51.227401 CLINICAL TRIALS USING ALTERED TUMOR DNA.
51.227402 CLINICAL USE OF GUINEA PIG SERUM.
51.227403 CLINICAL USE OF PROTAMINE AND PROTAMINE DERIVATIVES (PROLATHON).
51.227404 POLYPEPTIDE H11 FROM NORMAL HUMAN URINE.
51.228 CLINICAL COMBINATION CHEMOTHERAPY.
USE OF MULTIPLE CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES) SIMULTANEOUSLY OR SEQUENTIALLY.
SEE ALSO: 51.26 FOR OTHER TYPES OF COMBINATION THERAPY.
SEE ALSO: 51.220255 FOR COMBINATION CHEMOTHERAPY USED AGAINST LEUKEMIA (POMP, VAMP, BIKE, ALCG-86313, ETC.).

51.2281 GENERAL.
51.22815 AGENTS THAT INCREASE OR ENHANCE THE EFFECT OF CHEMOTHERAPEUTIC AGENTS AND RELATED STUDIES OF SYNERGISM OF ANTICANCER AND OTHER TYPES OF DRUGS.
51.2282 COMBINATION THERAPY INVOLVING TWO CHEMOTHERAPEUTIC AGENTS.
51.2283 COMBINATION THERAPY INVOLVING THREE CHEMOTHERAPEUTIC AGENTS.
PAP TREATMENT (PREDNISONE, AMETHOPTERIN, AND 6-MERCAPTOPURINE).
51.2284 COMBINATION THERAPY INVOLVING FOUR ANTICANCER AGENTS.
51.229 CLINICAL USE OF UNIDENTIFIED COMPOUNDS.
51.2290801 "HTS" (A YUGOSLAV DRUG).

51.23 CLINICAL USE OF HORMONES AND HORMONE-RELATED THERAPY.
51.230 USE OF HORMONES OR HORMONE-RELATED THERAPY FOR CANCER OF SPECIFIC TYPES OF TUMORS (SUB-DIVIDE LIKE CLASS 51.5).
51.2301 GENERAL.
51.23022 FOR CANCER OF THE CARDIOVASCULAR SYSTEM.
51.23025 FOR TUMORS OF LYMPHATIC, LYMPHOID, AND RETICULOENDOTHELIAL SYSTEMS.
USE OF HORMONES OR HORMONE-RELATED THERAPY FOR TREATING LEUKEMIAS AND LYMPHOMAS.
51.2303 FOR TUMORS OF MUSCLE TISSUE.
51.2304 FOR TUMORS OF KIDNEY, BLADDER, AND URINARY TRACT.
51.23051 FOR CANCER OF THE EXOCRINE GLANDS.
51.23052 FOR LUNG CANCER.
51.23053 FOR CANCER OF THE LIVER AND GALL BLADDER.
51.23054 FOR CANCER OF THE GASTROINTESTINAL TRACT (ESOPHAGUS THROUGH RECTUM).
51.23055 FOR CANCER OF THE REPRODUCTIVE ORGANS AND RELATED TISSUES.
51.230551 GENERAL.
51.230552 FOR CANCER OF THE FEMALE GONADS AND ACCESSORY SEX TISSUES.
51.2305521 GENERAL.
51.2305522 FOR OVARIAN CANCER.
51.2305523 FOR CANCER OF THE UTERUS, CERVIX, ENDOMETRIUM, AND PLACENTA.
EFFECT OF OVARIECTOMY (HYSTERECTOMY) IN THE TREATMENT OF UTERINE CANCER.
VALUE OF PROGESTERONE FOR TREATING UTERINE CANCER.
ADJUVANT UTERINE CANCER CHEMOTHERAPY PROJECT.
51.23055231 GENERAL.
51.23055232 UTERUS.
51.23055233 CERVIX AND VAGINA.
51.23055234 ENDOMETRIUM.
51.2305524 FOR CANCER OF THE BREAST.
51.23055241 GENERAL; METHODS USED TO DETERMINE TYPE OF HORMONAL TREATMENT.
51.23055242 COOPERATIVE STUDY OF HORMONE THERAPY FOR BREAST CANCER.
51.23055243 EFFECT OF HYPOPHYSECTOMY OR ADRENALECTOMY ON THE REMISSION OF BREAST CANCER.
51.23055244 USE OF ANDROGENS; USE OF DELTA¹ TESTOLOLACTONE.
51.23055245 USE OF CORTICOIDS.
51.23055246 USE OF PROGESTERONE.
51.23055247 CASTRATION.
51.230553 FOR CANCER OF THE TESTIS AND ACCESSORY MALE SEX TISSUES.
51.2305531 GENERAL.
51.2305532 FOR TESTICULAR CANCER.
51.2305533 FOR CANCER OF THE PENIS AND SCROTUM.
51.2305534 FOR CANCER OF THE PROSTATE.
USE OF PROGESTERONE AND ITS DERIVATIVE (DELALUTAN) FOR PROSTATE CANCER.
USE OF CASTRATION AND ESTROGEN FOR PROSTATE CANCER.
USE OF CHLORMADINONE FOR PROSTATE CANCER.
USE OF CYPROTERONE FOR PROSTATE CANCER.
USE OF TESTOSTERONE FOR PROSTATE CANCER.
51.23056 FOR CANCER OF OTHER ENDOCRINE TISSUES.
51.230562 FOR CANCER OF THE PITUITARY.
51.230563 FOR CANCER OF THYROID.
51.230564 FOR CANCER OF THE PARATHYROID.
51.230565 FOR CANCER OF THE ADRENAL.
51.2306 FOR CANCER OF THE BRAIN AND NERVOUS SYSTEM.
51.23072 FOR CANCER OF THE EYE.
51.23082 FOR CANCER OF CONNECTIVE TISSUE STRUCTURES (JOINTS, ETC).
51.23083 FOR SKIN CANCER AND MELANOMAS.
51.23084 FOR CANCER OF THE BONE (EXCLUDING BONE MARROW).
51.23091 FOR CANCER OF HEAD AND NECK.

51.231 SELECTED TOPICS ON USE OF HORMONES AND HORMONE-RELATED THERAPY.
51.2311 COOPERATIVE STUDIES OF HORMONE THERAPY.
SEE ALSO: 51.23055242 FOR COOPERATIVE STUDY OF HORMONE THERAPY FOR BREAST CANCER.
51.232 CLINICAL CANCER THERAPY INVOLVING DESTRUCTION OR INHIBITION OF ENDOCRINE GLANDS.
51.2321 GENERAL.
51.2322 USE OF HYPOPHYSECTOMY.
USE OF SURGERY OR Y90.
SEE ALSO: 51.23055242 FOR EFFECT ON BREAST CANCER REMISSION.
51.2323 USE OF THYRODECTOMY.
51.2324 USE OF PARATHYRODECTOMY.
51.2325 USE OF ADRENALECTOMY OR MEDICAL ADRENALECTOMY (METOPIRONE) OR CORTICOID ANTAGONISTS.
SEE ALSO: 51.23055242 FOR EFFECT ON BREAST CANCER REMISSION.
51.23262 USE OF OVARIECTOMY (HYSTERECTOMY) OR ESTROGEN ANTAGONISTS.
USE OF OVARIAN IRRADIATION.
SEE ALSO: 51.2305523 FOR USE IN TREATING UTERINE CANCER.
51.23263 USE OF CASTRATION IN THE MALE OR ANDROGEN ANTAGONISTS.
51.233 CLINICAL USE OF PROGESTERONE AND OTHER PROGESTATIONAL AGENTS FOR CANCER THERAPY.
USE OF CHLORMADINONE AND CYPROTERONE.
USE OF NSC 17256E (A PROGESTECTIONAL STEROID).
USE OF 17-ALPHA-HYDROXYPROGESTERONE AND ITS ESTERS (DELALUTIN OR PROVERA).
USE OF THESE COMPOUNDS IN THE "ADJUVANT UTERINE CANCER CHEMOTHERAPY" PROJECT.
51.234 CLINICAL USE OF ESTROGENS FOR CANCER THERAPY.
USE OF ANTITHYROID AGENTS (METHIMAZOLE) TO SENSITIZE TISSUES TO ESTROGEN.
USE OF HEXESTROL (DIHYDRO-DIETHYLSTIBESTROL).
SEE ALSO: 51.63422 FOR ESTROGEN METABOLISM IN HUMANS WITH CANCER.
51.235 CLINICAL USE OF ANDROGENS FOR CANCER THERAPY.
USE OF DELTA^{1}-TESTOLOLACTONE.
USE OF TESTOSTERONE.
USE OF BROMOSTANOLONE PROPIONATE (DROLBAN).
51.236 CLINICAL USE OF CORTICOIDS ON ACTH FOR CANCER THERAPY.
USE OF PREDNISONE.
USE OF OXYLONE (FLUOROMETHOLONE) (21-DESOXY-9-ALPHA-FLUORO-6-ALPHA-METHYLPREDNISONE.
51.237 CLINICAL USE OF OTHER HORMONES AND RELATED PROCEDURES.
51.23701 CLINICAL USE OF PINEAL EXTRACTS AND PINEAL.
51.23702 USE OF PARATHYROID HORMONE.
51.238 USE OF SYNTHETIC STEROIDS AND HORMONES.
51.2381301 METHYLPREGNENETRIONE (NSC 17256).

51.24 CLINICAL USE OF RADIATION IN CANCER THERAPY.
51.240 EFFECT OF AND USE OF CLINICAL RADIATION ON TUMORS OF SPECIFIC ORGANS.
51.2401 GENERAL.
51.24011 OPEN.
51.2402 CLINICAL RADIATION THERAPY FOR CANCER OF THE CARDIOVASCULAR AND RETICULOENDOTHELIAL AND LYMPHATIC SYSTEM.
51.24021 GENERAL.
51.24022 HEART TUMORS.
51.24023 OPEN.
51.24024 BLOOD VESSEL TUMORS.
51.24025 CLINICAL RADIATION THERAPY FOR LEUKEMIAS, LYMPHOMAS, AND OTHER CANCER OF THE LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS.
USE OF EXTRACORPOREAL IRRADIATION THERAPY FOR MUSCLE CANCER.
USE OF RADIATION TO CURE HODGKINS DISEASE.
SEE ALSO: 48.4332 FOR EXTRACORPOREAL IRRADIATION TO INDUCE IMMUNE TOLERANCE.
51.240257 TREATMENT OF METASTASES IN LYMPH NODES.
51.2403 CLINICAL RADIATION THERAPY FOR MUSCLE CANCER.
51.2404 CLINICAL RADIATION THERAPY FOR CANCER OF THE KIDNEY AND URINARY SYSTEM.
51.24041 GENERAL.
51.24042 CLINICAL RADIATION THERAPY FOR KIDNEY CANCER.
51.24043 CLINICAL RADIATION THERAPY FOR CANCER OF THE BLADDER, URETER, URETHRA AND RELATED TISSUES.
51.2405 CLINICAL RADIATION THERAPY FOR CANCER OF SELECTED INTERNAL ORGANS.
51.24050 GENERAL.
RADIATION THERAPY FOR VISCERAL, AND PERITONEAL CANCER, AND FOR CANCER OF INTERNAL ORGANS IN GENERAL.

51.24051 CLINICAL RADIATION OF EXOCRINE GLAND CANCER.
51.24052 CLINICAL RADIATION OF LUNG CANCER.
51.24053 CLINICAL RADIATION OF LIVER CANCER.
51.24054 CLINICAL RADIATION OF GASTROINTESTINAL CANCER.
51.240541 GENERAL.
51.240542 OPEN.
51.240543 CLINICAL RADIATION OF ESOPHAGEAL CANCER.
51.240544 CLINICAL RADIATION OF STOMACH CANCER.
51.240545 CLINICAL RADIATION OF INTESTINAL CANCER AND CARCINOID DISEASE.
51.240546 CLINICAL RADIATION OF CANCER OF THE COLON AND RECTUM.
51.240547 CLINICAL RADIATION OF CANCER OF THE PANCREAS.
51.24055 CLINICAL RADIATION OF CANCERS OF THE REPRODUCTIVE ORGANS AND RELATED TISSUES.
51.540551 GENERAL.
51.240552 CLINICAL RADIATION OF CANCERS OF THE FEMALE GONADS AND ACCESSORY SEX TISSUES.
51.2405521 GENERAL.
51.2405522 CLINICAL RADIATION OF OVARIAN CANCER.
51.2405523 CLINICAL RADIATION OF CANCER OF THE UTERUS, CERVIX, VAGINA, ENDOMETRIUM AND PLACENTA.
51.24055231 GENERAL.
51.24055232 CANCER OF THE CORPUS UTERI AND FUNDUS.
51.24055233 CANCER OF THE CERVIX AND VAGINA.
GOOD RESPONSE TO RADIOTHERAPY OF CERVICAL CANCER AMONG WOMEN WITH BLOOD TYPE O (AS COMPARED TO OTHER BLOOD GROUPS).
51.24055234 CANCER OF THE PLACENTA AND ENDOMETRIUM.
TROPHOBLASTIC DISEASES.
TROPHOBLAST-CHORIOCARCINOMA.
CHORIOADENOMA AND CHORIOADENOMA DESTRUENS.
CHORIOCARCINOMA.
MOLAR PREGNANCIES.
51.2405524 CANCER OF THE BREAST. MAMMARY CANCER.
51.240553 CLINICAL RADIATION THERAPY FOR CANCER OF THE MALE GONADS AND ACCESSORY SEX TISSUES.
51.2405531 GENERAL.
51.2405532 TESTICULAR CANCER.
51.2405533 CANCER OF THE PENIS AND SCROTUM.
51.2405534 CANCER OF THE PROSTATE.
51.24056 CLINICAL RADIATION THERAPY FOR CANCER AND OTHER ENDOCRINE GL
51.24056 CLINICAL RADIATION THERAPY FOR CANCER OF OTHER ENDOCRINE GLANDS.
51.240561 GENERAL.
51.240562 RADIOTHERAPY OF PITUITARY CANCER.
51.240563 RADIOTHERAPY OF THYROID CANCER.
51.240564 RADIOTHERAPY OF PARATHYROID CANCER.
51.240565 RADIOTHERAPY OF ADRENAL CANCER.
51.240566 OPEN.
51.240567 RADIOTHERAPY OF PANCREATIC CANCER.
51.240568 RADIOTHERAPY OF NEUROENDOCRINE CANCER.
51.2406 CLINICAL RADIATION OF TUMORS OF THE NERVOUS SYSTEM AND BRAIN.
51.24062 CLINICAL RADIATION THERAPY FOR CANCER OF THE NERVOUS SYSTEM OTHER THAN THE BRAIN.
51.24065 CLINICAL RADIATION THERAPY FOR BRAIN CANCER.
51.2407 CLINICAL RADIATION THERAPY FOR CANCER OF THE SENSE ORGANS.
51.24072 CLINICAL RADIATION THERAPY FOR CANCER OF THE EYE (RETINOBLASTOMA).
51.2408 CLINICAL RADIATION THERAPY FOR CANCER OF CONNECTIVE TISSUE, MINERALIZED TISSUES, AND SKIN.
51.24081 GENERAL.
51.240811 OPEN.
51.240812 CLINICAL RADIATION THERAPY OF SARCOMAS.
51.24082 CLINICAL RADIATION THERAPY FOR CANCER OF CONNECTIVE TISSUE STRUCTURES.
51.24083 CLINICAL RADIATION THERAPY FOR SKIN CANCER AND MELANOMAS.
51.24084 CLINICAL RADIATION THERAPY FOR BONE CANCER (EXCLUDING BONE MARROW).
51.24085 CLINICAL RADIATION OF THERAPY FOR CANCER OF FATTY TISSUES.
51.2409 CLINICAL RADIATION THERAPY FOR CANCER IN SPECIFIC PARTS OF THE BODY.
51.24091 CLINICAL RADIATION THERAPY FOR CANCER IN THE ORAL CAVITY AND JAW AND RELATED AREAS.
51.24092 CLINICAL RADIATION THERAPY FOR CANCER OF THE FACE, NOSE, SINUSES, HEAD CAVITIES, TONSILS AND THROAT.
51.241 SELECTED BROAD TOPICS.
51.2411 OPEN.

51.2412 RADIOTHERAPY CENTERS.
51.2413 RADIOSENSITIVITY OF HUMAN CANCER (CLINICAL ASPECTS).
SEE ALSO: 51.34 FOR EFFECT OF IRRADIATION OF CELL BIOCHEMISTRY AND PHYSIOLOGY AND VIABILITY.
SEE ALSO: 51.34 FOR PRE-CLINICAL ASPECTS OF RADIOSENSITIVITY.
51.2414 COMPARISON OF THE THERAPEUTIC EFFECTIVENESS OF DIFFERENT TYPES OF IRRADIATION (CLINICAL ASPECTS).
51.2415 EFFECTS OF RADIATION ON SPECIFIC STRUCTURES.
51.241501 EFFECT ON CHROMOSOMES.
51.241525 EFFECT ON LEUKOCYTES AND LYMPH TISSUES AND RETICULARENDOTHELIAL TISSUES IN GENERAL.
51.2415545 EFFECT ON COLON AND RECTUM.
51.2415523 EFFECT ON VAGINA AND UTERUS AND CERVIX.
51.242 CLINICAL STUDIES OF RADIATION DOSAGE IN CANCER THERAPY.
51.2421 GENERAL.
51.2422 ISODOSE CURVES AND WEIGHING FACTORS FOR TUMORS.
USE OF COMPUTERS TO DETERMINE TUMOR DOSAGE.
51.243 USE OF X-RAY FOR CANCER THERAPY (GENERAL).
SEE ALSO: 51.243 FOR USE OF X-RAY FOR CANCER DIAGNOSIS.
SEE ALSO: 51.240 FOR X-RAY THERAPY FOR SPECIFIC TYPES OF CANCER.
51.244 CLINICAL USE OF ISOTOPES AND ISOTOPE-CARRIERS FOR CANCER THERAPY (TWO-DIGIT NUMBER AFTER THE HYPHEN IS ALPHABETICAL POSITION OF CHEMICAL SYMBOL).
SEE ALSO: 51.2137 FOR USE OF ISOTOPES IN CANCER DIAGNOSIS.
SEE ALSO: 51.2425 FOR MEASUREMENT OF ISOTOPE DOSAGE.
SEE ALSO: 51.2472 FOR NEUTRON CAPTURE TECHNIQUES.
51.24400 GENERAL.
51.244001 METHODS OF POSITIONING ISOTOPE SOURCES IN TUMORS AND BODY CAVITIES.
51.244002 USE OF SHORT-LIVED POSITRON EMITTERS (GENERAL).
51.244003 USE OF CAVIER MOLECULES TO TRANSPLANT ISOTOPES TO SPECIFIC LOCATION IN BODY.
51.24408 USE OF RADIOACTIVE GOLD (AU-198).
51.24414 BR-82.
51.24422 USE OF COBALT-60.
51.24424 USE OF CESIUM-137.
51.24429 USE OF F-18.
51.24435 H3 - TRITIUM; USE OF TRITIATED 2-METHYL-1,4-NAPTHOQUINOL DIPHOSPHATE.
51.2444401 I-131 AND LIPIODOL-I131 AND H3 LABELLED ANTIBODIES IN HUMAN FIBRINOGEN.
51.244601 USE OF P-32.
51.24469 USE OF RADIUM FOR CANCER CHEMOTHERAPY.
51.24473 CLINICAL USE OF HYDROGEN PEROXIDE.
51.24474 USE OF VASODILATORS TO INCREASE BLOOD FLOW AND OXYGEN.
51.24482 USE OF STRONTIUM-90.
51.24483 USE OF TANTALUM-82.
51.24495 USE OF YTTRIUM-90 AND Y90 MICROSPHERES.
51.245 CLINICAL USE OF RADIATION FROM PARTICLE ACCELERATORS.
51.2451 GENERAL.
51.2452 CLINICAL USE OF ELECTRON BEAMS FOR CANCER THERAPY.
51.2453 CLINICAL USE OF NEUTRON BEAMS FOR CANCER THERAPY.
SEE ALSO: 51.24722 FOR NEUTRON CAPTURE TECHNIQUES.
51.2454 PHOTON BEAMS.
51.246 CLINICAL USE OF LASER IRRADIATION.
SEE ALSO: 35.91 FOR EFFECT OF LASER IRRADIATION ON BIOLOGICAL MATERIAL (GENERAL).
SEE ALSO: 56.1771 FOR CLINICAL USES OF LASERS (GENERAL).
51.247 CLINICAL USE OF AGENTS WHICH SENSITIZE CANCER TO RADIATION.
51.2471 GENERAL.
51.2472 CLINICAL USE OF NEUTRON-CAPTURE TECHNIQUES.
51.24721 GENERAL.
51.24722 CLINICAL USE OF BORON COMPOUNDS FOR BRAIN TUMORS.
51.2473 CLINICAL USE OF INCREASED OXYGEN TENSION.
51.24731 GENERAL.
51.24732 HYBAROXIC RADIATION THERAPY AND SIDE EFFECTS OF THIS TREATMENT (LARYNGEAL NECROSIS).
51.2474 CLINICAL USE OF DRUGS WHICH SENSITIZE CANCER TO IRRADIATION AND POTENTIATE RADIATION EFFECTS. RADIOTHERAPY ADJUVANTS.
51.24741 GENERAL.
51.24742 USE OF HALOGENATED PYRIMIDINES.
51.24743 USE OF OTHER CHEMOTHERAPEUTIC AGENTS.
51.24744 USE OF ENZYMES (CHYMOTRYPSIN).

51.24745 OTHER AGENTS.
51.2474501 2-METHYL-1,4-NAPTHOQUINOL DIPHOSPHATE.
51.2475 USE OF IMMUNOTHERAPY AS ADJUVANT TO RADIOTHERAPY.
51.248 AGENTS (CYTOPROTECTANTS) AND TREATMENTS WHICH PREVENT RADIATION DAMAGE DURING RADIATION THERAPY OF CANCER.
51.24801 GENERAL.
51.24802 USE OF ADRENAL CORTICAL STEROIDS OR ACTH AS PROTECTIVE AGENTS DURING RADIATION THERAPY OF CANCER.
51.24803 USE OF SH COMPOUNDS.
51.24804 USE OF HYPOXIA TO PROTECT NORMAL TISSUES.
USE OF TOURNIQUETS.
USE OF VASOCONSTRICTORS (PROTECTION FROM RADIATION-INDUCED NEPHRITIS BY INFUSING EPINEPHRINE IN RENAL ARTERY).

51.25 SURGICAL REMOVAL OF CANCER FROM HUMAN PATIENTS.
SEE ALSO: 51.232 FOR REMOVAL OF NON-CANCEROUS ENDOCRINE GLANDS (TO MODIFY THE HORMONAL ENVIRONMENT).
SEE ALSO: 56.161 FOR GENERAL INFORMATION ABOUT SURGICAL TECHNIQUES AND RELATED PROCEDURE. USE OF ANTIBIOTICS.
51.251 GENERAL.
51.2511 OPEN.
51.2512 METHODS USED TO PREVENT CANCER METASTASES AT THE TIME OF SURGERY.
51.2513 USE OF CRYOSURGERY TO REMOVE CANCEROUS TISSUES.
51.2514 CARE OF PATIENTS BEFORE, DURING AND AFTER CANCER SURGERY ANDRELATED STUDIES (BODY FLUIDS DURING SURGERY).
51.252 SURGERY RELATED TO CANCER OF THE LYMPHATIC, CARDIOVASCULAR AND RETICULOENDOTHELIAL SYSTEMS.
51.2521 GENERAL.
51.2522 SURGERY RELATED TO HEART CANCER.
51.2523 OPEN.
51.2524 SURGERY RELATED TO BLOOD VESSEL CANCER.
51.2525 SURGERY RELATED TO LEUKEMIAS, LYMPHOMAS, AND OTHER CANCER OF THE RETICULOENDOTHELIAL AND LYMPHATIC TISSUES.
51.253 SURGERY RELATED TO MUSCLE CANCER.
51.254 SURGERY RELATED TO CANCER OF THE URINARY SYSTEM.
51.2541 GENERAL.
51.2542 SURGERY RELATED TO KIDNEY CANCER (NEPHRECTOMY).
51.2543 SURGERY RELATED TO BLADDER CANCER AND CANCER OF THE URETER AND URETHRA AND RELATED TISSUES OF THE URINARY SYSTEM.
51.255 SURGERY RELATED TO CANCER OF SELECTED INTERNAL ORGANS.
51.2550 GENERAL (VISCERAL AND PERITONEAL CANCER).
51.25501 OPEN.
51.25502 MULTIVISCERAL PELVIC SURGERY OR RESECTION (PELVIC EXENTERATION).
51.2551 SURGERY RELATED TO EXOCRINE GLAND CANCER.
51.25511 GENERAL.
51.25512 SURGICAL REMOVAL OF SALIVARY GLAND CANCER.
51.2552 SURGERY RELATED TO LUNG CANCER AND CANCER OF RELATED TISSUES OF THE PULMONARY SYSTEM (TRACHEA, BRONCHI).
51.2553 SURGERY RELATED TO LIVER CANCER.
51.2554 SURGERY RELATED TO CANCER OF THE GASTROINTESTINAL TRACT.
51.25541 GENERAL.
51.25542 OPEN.
51.25543 MALNUTRITION SYNDROME FOLLOWING ESOPHOGECTOMY.
51.25543 SURGERY RELATED TO ESOPHAGEAL CANCER.
51.25544 SURGERY RELATED TO STOMACH CANCER.
51.25545 SURGERY RELATED TO INTESTINAL CANCER AND COLON.
51.25546 SURGERY RELATED TO CANCER OF THE RECTUM AND ANAL CANAL OR COLON RECTAL AREA IN GENERAL.
51.25547 SURGERY RELATED TO CANCER OF THE PANCREAS.
51.2555 SURGERY RELATED TO CANCER OF THE GENITAL AND REPRODUCTIVE SYSTEMS.
51.25551 GENERAL.
51.25552 SURGERY RELATED TO CANCER OF THE FEMALE GONADS AND ACCESSORY SEX TISSUE.
51.255521 GENERAL.
51.255522 SURGERY RELATED TO OVARIAN CANCER.
51.255523 SURGERY RELATED TO CANCER OF THE UTERUS, CERVIX, VAGINA, ENDOMETRIUM AND PLACENTA.
51.2555231 GENERAL.
51.2555232 SURGERY RELATED TO CANCER OF THE CORPUS UTERI AND FUNDUS.
51.2555233 SURGERY RELATED TO CANCER OF THE CERVIX AND VAGINA.
USE OF PALLIATIVE URINARY DIVERSION.
WERTHEIM'S OPERATION FOR VAGINAL CANCER.

51.2555234 SURGERY RELATED TO CANCER OF THE PLACENTA AND ENDOMETRIUM.
TROPHOBLASTIC DISEASES.
TROPHOBLAST-CHORIOCARCINOMA.
CHORIOADENOMA AND CHORIOADENOMA DESTRUENS.
CHORIOCARCINOMA.
MOLAR PREGNANCIES.
51.255524 SURGERY RELATED TO CANCER OF THE BREAST TUMORS (MASTECTOMY).
51.255524 THE HALSTEAD OPERATION (HALSTEAD'S SUTURE).
51.255525 SURGERY RELATED TO CANCER OF THE EXTERNAL GENITALIA AND OTHER SEX-RELATED TISSUES.
51.25553 SURGERY RELATED TO CANCER OF THE MALE GONADS AND ACCESSORY SEX TISSUES.
51.255531 GENERAL.
51.255532 SURGERY RELATED TO TESTICULAR CANCER.
51.255533 SURGERY RELATED TO CANCER OF THE PENIS AND SCROTUM.
51.255534 SURGERY RELATED TO CANCER OF THE PROSTATE.
51.25561 GENERAL.
51.25563 THYROID.
51.25564 PARATHYROID.
51.25565 ADRENAL.
SEE ALSO: 51.2555.
51.25568 NEUROENDOCRINE.
51.256 SURGERY RELATED TO CANCER OF THE BRAIN AND NERVOUS SYSTEM.
51.2561 GENERAL.
51.2562 SURGERY RELATED TO CANCER OF THE NERVOUS SYSTEM OTHER THAN BRAIN.
51.2565 SURGERY RELATED TO BRAIN TUMORS.
51.257 SURGERY RELATED TO CANCER OF THE SENSE ORGANS.
51.2571 GENERAL.
51.2572 SURGERY FOR CANCER RELATED TO THE EYE AND VISION.
51.258 SURGERY FOR CANCER OF CONNECTIVE TISSUES AND RELATED AND MINERALIZED TISSUES.
51.2581 GENERAL.
51.2582 SURGERY RELATED TO CANCER OF CONNECTIVE TISSUE STRUCTURES (JOINTS).
51.2583 SURGERY RELATED TO SKIN CANCER.
51.25831 GENERAL.
51.25832 SKIN.
51.25833 MELANOMAS.
51.2584 SURGERY RELATED TO BONE CANCER.
51.259 SURGERY RELATED TO CANCER OF SPECIFIC PARTS OF THE BODY.
51.2591 SURGERY RELATED TO CANCER OF THE ORAL CAVITY AND ADJACENT AREAS.
SURGICAL REMOVAL OF TUMORS OF THE JAW AND NECK, LIPS, TONGUE, MOUTH, THROAT, PHARYNX, LARYNX.
SURGICAL REMOVAL OF TUMORS OF THE LIPS, TONGUE, MOUTH, THROAT, PHARYNX, LARYNX.
51.2592 SURGERY RELATED TO CANCER IN OTHER AREAS OF THE HEAD AND NECK REGION.
REMOVAL OF TUMORS OF THE PARANASAL SINUS AREA (TUMORS ORIGINATING IN THE MAXILLARY ANTRUM, ETHMOID, NASAL ETHMOID, NASAL SEPTUM, CANTHUS, ORBIT OR TURBINATE).
51.2593 SURGERY RELATED TO CANCER OF THE APPENDAGES.

51.26 CLINICAL USE OF COMBINATION THERAPY (ADJUNCT OR ADJUVANT THERAPY).
USE OF CHEMOTHERAPEUTIC AGENTS AND/OR RADIATION AND/OR SURGERY AND/OR HORMONES.
SEE ALSO: 51.27 FOR USE OF IMMUNOTHERAPY COMBINED WITH ANY OTHER THERAPY.
SEE ALSO: 51.228 FOR COMBINATION CHEMOTHERAPY (INCLUDING HORMONES).
51.261 GENERAL.
51.262 COMBINATIONS OF RADIATION AND SURGERY.
51.263 COMBINATIONS OF CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES) AND SURGERY.
51.264 COMBINATIONS OF RADIATION AND CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES).
ACTINOMYCIN D AND IRRADIATION.
51.265 COMBINATIONS OF RADIATION, SURGERY, AND CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES).

51.27 CLINICAL IMMUNOTHERAPY.
USE OF ANTIBODIES AND OTHER IMMUNOLOGICAL PROPHYLAXIS TO INHIBIT TUMOR GROWTH.
SEE ALSO: 51.2013 FOR ETHICAL ASPECTS OF INJECTING OR TRANSPLANTING CANCER IN HUMANS.
SEE ALSO: 51.74112 FOR GENERAL ASPECTS OF TUMOR IMMUNITY IN HUMANS.
SEE ALSO: 51.216 FOR USE OF IMMUNE METHODS TO DETECT CANCER.
51.271 GENERAL.
51.272 CLINICAL USE OF ANTIBODIES AGAINST TUMORS (USED ALONE OR COMBINED WITH OTHER METHODS). **31**
USE OF PRIMATE ANTIBODIES (USE OF BABOON ANTI-PROSTATE ANTIBODIES).
USE OF ANTI-HUMAN ANTIBODIES (OBTAINED BY INJECTING CANCER CELLS INTO HUMANS).
BJORKLAND ANTI-HELA VACCINE.

SEE ALSO: 51.744 FOR ANTIBODIES AGAINST TUMORS (GENERAL) AND THEIR EFFECT ON TUMORS.

51.273 CLINICAL USE OF ANTIGENS AND CANCER VACCINES (INACTIVATED CELLS OR CELL PRODUCTS; WITH OR WITHOUT ADJUVANT).
INJECTION OF MODIFIED CELLS OR EXTRACTS OF CANCER CELLS.
INJECTION OF CANCER CELL ANTIGENS OR NUCLEIC ACIDS.

51.274 TRANSPLANTATION OF INTACT CANCER CELLS OR TISSUES IN HUMANS (AS POTENTIAL THERAPEUTIC PROCEDURE).
"CROSSOVER TRANSPLANTS".

51.275 CLINICAL USE OF VIRUSES (WHICH MAY PRODUCE HIGH INTERFERON).
USE OF VIRUS INFECTIONS TO TREAT LEUKEMIA.

51.28 NOVEL METHODS OF CLINICAL THERAPY NOT LISTED ELSEWHERE.
SEE ALSO: 51.2025 FOR CELL REPLACEMENT THERAPY IN LEUKEMIA.
SEE ALSO: 51.246 FOR USE OF LASER IRRADIATION.

51.281 CLINICAL THERAPY INVOLVING PHYSICAL FORCES.
51.2811 USE OF MAGNETIC FIELDS FOR CLINICAL CANCER THERAPY.

51.282 USE OF SELECTIVE HEATING, COAGULATION TECHNIQUES, AND USE OFCOOLING.
51.2821 GENERAL.
51.2822 EFFECT OF RAISING OR LOWERING BODY OR TUMOR TEMPERATURE ON COURSE OF CANCER.
51.2823 DESTRUCTION OF LYMPH NODE METASTASES BY HYSTERESIS HEATING (FLUCTUATING MAGNETIC FIELDS) AFTER INJECTING IRON PARTICLES.

51.283 USE OF SPECIAL DIETS.
SEE ALSO: 51.4012 FOR RELATION OF DIET TO CANCER ETIOLOGY.
51.2831 GENERAL.
USE OF VITAMIN-DEFICIENT DIETS IN GENERAL.
SEE ALSO: 51.22542 FOR USE OF ANTIMETABOLITES OF VITAMINS.
51.2832 USE OF LOW TRYPTOPHANE DIET TO TREAT CARCINOID DISEASE.
51.2833 TREATMENT OF MELANOMA BY DIETS LOW IN TYROSINE AND PHENYLALANINE.

51.284 USE OF ONCOLYTIC BACTERIA.
USE OF CLOSTRIDIA.
SEE ALSO: 51.327303 FOR USE IN MAN.

51.3 PRE-CLINICAL ASPECTS OF CANCER DIAGNOSIS AND THERAPY.
INCLUDES EFFECTS OF ALL TYPES OF EXOGENOUS AGENTS ON NON-HUMAN CANCER IN VIVO AND IN VITRO.
SEE ALSO: 51.73 FOR EFFECTS OF ENDOGENOUS AGENTS ON TUMORS.
SEE ALSO: 51.74 FOR TUMOR IMMUNOLOGY (GENERAL).

51.31 SELECTED GENERAL TOPICS.
51.311 GENERAL.
51.312 METHODS FOR DIAGNOSING CANCER IN ANIMALS.
51.3121 GENERAL.
51.3122 RADIOGRAPHIC METHODS.
51.3123 CYTOLOGICAL METHODS (INCLUDING CHROMOSOME STUDIES).
51.3124 BIOCHEMICAL METHODS.
51.3125 IMMUNOLOGICAL AND SEROLOGICAL METHODS.
51.3126 USE OF DEVICES FOR DIRECT VISUALIZATION OF INTERNAL TUMORS.
51.3127 UNUSUAL METHODS WITH DIAGNOSTIC POTENTIAL (EXPERIMENT WITH LAB ANIMALS).
51.31271 VISUALIZATION OF TUMORS BY ULTRASOUND IN ANIMALS.
51.31272 USE OF THERMOGRAPHY IN EXPERIMENTAL ANIMALS.

51.313 VERY GENERAL ASPECTS OF THE EFFECT OF ANTICANCER AGENTS ON ANIMAL TUMORS IN VIVO AND ON TUMOR CELLS IN VITRO AND ON NORMAL TISSUE.
MODELS OF MECHANISM OF CHEMOTHERAPEUTIC AGENT ACTION.
SEE ALSO: 51.32 FOR EFFECT OF CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 51.33 FOR EFFECT OF HORMONES AND ENDOCRINE-RELATED THERAPY.
SEE ALSO: 51.34 FOR EFFECT OF RADIATION.
51.3131 GENERAL.
51.3132 MECHANISM OF TUMOR REGRESSION AND DISAPPEARANCE FROM CANCER THERAPEUTIC AGENTS.
51.3133 SENSITIVE AND RESISTANT TUMOR CELL LINES STUDIED IN VIVO ANDEMPLOYMENT OF PROTECTION BY CHEMOTHERAPEUTIC AGENTS.

51.314 PRE-CLINICAL STUDIES OF WAYS TO PREVENT DAMAGE TO NORMAL TISSUES DURING CANCER THERAPY (STUDIED IN ANIMALS OR IN IN VITRO SYSTEMS).
SEE ALSO: 51.323 FOR USE OF THESE METHODS DURING CANCER CHEMOTHERAPY.
51.3141 GENERAL.
51.3142 PREVENTION OF DAMAGE TO BONE MARROW AND RETICULO-ENDOTHELIAL SYSTEM.
51.3143 USE OF GENERALIZED HYPOTHERMIA, WITH LOCAL HEATING OF TUMORS DURING ANTICANCER THERAPY.

51.3144 USE OF CHEMICAL AGENTS OR SUBSTANCES TO PREVENT DAMAGE TO NORMAL TISSUES.
51.31441 GENERAL.
51.31442 USE OF A "RESPIRATION-STIMULATING FACTOR" FROM YEAST AND ANIMAL TISSUES.
51.31443 USE OF VITAMIN OR DIETARY ALTERATIONS.

51.32 PRE-CLINICAL ASPECTS OF CANCER CHEMOTHERAPY IN ANIMALS OR IN VITRO.
51.32-593A 593-A.
51.32ABIES ABIES CONCOLOR EXTRACT.
51.32AB100 AB-100.
51.32AB103 AB-103.
51.32AB132 AB-132.
51.32ACENA ACENAPTHALENES.
AZAPYRACENES.
X 51.32ACERN ACER NEGUNDO SAPONIN: SEE ACERONIN.
51.32ACERO ACERONIN (ACER NEGUNDO SAPONIN).
51.32ACETO ACETOPHENONE.
X 51.32ACETO ACETOXY-ACTIDIONE: SEE E-37.
51.32ACETY 1-ACETYL-2-PICOLINOYLHYDRAZINE.
51.32ACRON ACRONYCINE (ACRONYCIN).
51.32ACTH- ACTH.
51.32ACTID50 ACTIDIONE (A CYCLOHEXIMIDE).
51.32ACTIN ACTINOBOLIN.
51.32ACTIN ACTINOGAN.
51.32ACTIN00 ACTINOMYCINS AS A CLASS.
51.32ACTIN ACTINOMYCIN D (DACTINOMYCIN, COSMEGEN, MERACTINOMYCIN).
51.32ACTIN ACTINOMYCIN P2.
51.32ACTIN60 OTHER SPECIFIC ACTINOMYCINS.
51.32ADENO ADENOSINE-N-OXIDE.
X 51.32ADL4S ADL-4S: SEE NAMS.
51.32ADRIA ADRIAMYCIN.
51.32AE--- ALPHA-VINYL-AE ACETATE.
51.32AGAVE AGAVE AMERICANA EXTRACTS.
51.32AGAVE AGAVE SCHOTTI EXTRACTS.
51.32AGN14 AGN-1414 (N-ETHYL-N-BETA-CHLOROETHYL-5-BROMO-3-BENZOTHIENYLMETHYLAMINE HYDROCHLORIDE).
51.32ALANG ALANGIUM SALVIIFOLIUM EXTRACT.
51.32ALANM ALANINE MUSTARD.
X 51.32ALKAL ALKALOID C: SEE HARRINGTONINE.
X 51.32ALKIR ALKIROM: SEE IOB-82.
51.32ALLOM ALLOMYRINA DICHOTOMUS FRACTIONS (FROM A BEETLE).
51.32ALLOP ALLOPURINOL.
51.32ALNIS ALNISTUS ARBORESCENS EXTRACT.
51.32ALNUS ALNUS OREGONA EXTRACT.
X 51.32AMETH AMETHOPTERIN: SEE METHOTREXATE.
51.32AMICE AMICETIN.
51.32AMINO 8-AMINOADENOSINE.
51.32AMINO AMINOCYCLOPENTANE CARBOXYLIC ACID.
51.32AMINO AMINOPTERIN.
51.32ANILI ANILINE MUSTARD (N,N-BIS(2-CHLOROETHYL)-ANILINE).
51.32ANTHR ANTHRAMYCIN.
51.32APOCA APOCANNOSIDE.
51.32ARAA- ARA-A.
X 51.32ARABI ARABINOSYL CYTOSINE: SEE ARA-C.
51.32ARAC- ARA-C (CYTOSINE ARABINOSIDE, CYTARABINE, CYTOSAR, ARABINOSYL CYTOSINE.
51.32ARAMP ARA-6-MP.
CYTOSINE ARABINOSIDE HYDROCHLORIDE.
51.32ARAFC ARA-FC (1-BETA-D-ARABINOFURANOSYL-5-FLUOROCYTOSINE).
51.32ARIST ARISTOLOCHIC ACID.
51.32ASPAR ASPARAGINASE FROM VARIOUS SOURCES.
AGOUTI ASPARAGINASE.
ASPARAGINASE EC2.
GUINEA PIG ASPARAGINASE.
X 51.32ATPU- ATPU: SEE BITU.
51.32AZACY 5-AZACYTIDINE.
51.32AZAGU 8-AZAGUANINE.
51.32AZAIN 8-AZAINOSINE.
51.32AZALE 4,1-AZALEUCINE.
51.32AZIRI AZIRIDINES.
1,6-AZIRIDINE STEROIDAL ALKYLATING AGENTS.

51.32AZAPI AZAPICLYNOYL HYDRAZINE.
51.32AZAPI AZAPICYL.
PICLYNOYL HYDRAZINE.
X 51.32AZARI AZARIBINE: SEE AZAURIDINE.
51.32AZASE AZASERINE.
X 51.32AZATH AZATHIOPRINE: SEE IMURAN.
51.32AZAUR 6-AZAURIDINE.
6-AZAURIDINE TRIACETATE (AZARIBINE).
51.32AZAXA 8-AZAXANTHINE.
51.32AZETE AZETEPA.
51.32AZOTO AZOTOMYCIN.
51.32A139- A-139.
51.32A649- A-649.
51.32A6413 A-6413.
51.32A6492 ANTIBIOTIC A-649-22.
51.32A8103 A-8103.
51.32A2096 A-20968.
51.32BAGAS BAGASSE EXTRACTS.
51.32BCAPA BCAPAA (P-BIS(2-CHLOROETHYL)AMINOPHENYLACETIC ACID ESTERS).
51.32BCNU- BCNU (1,3-BIS(2-CHLOROETHYL)-NITROSOUREA).
51.32BEGON BEGONIA TUBERHYBRIDA EXTRACT.
51.32BENZO BENZOQUINONE.
51.32BERBE BERBERINE.
51.32BERMU BERMUDA SPONGE EXTRACT.
51.32BERSA BERSALDEGENIN.
BERSALDEGENIN 1,3,5-ORTHOACETATE.
51.32BETUL BETULIN.
51.32BFC1- BFC1.
51.32BFC2- BFC2.
51.32BIC-- BIC (5-(3,3-BIS(2-CHLOROETHYL)-TRIAZENO) IMIDAZOLE-4-CARBOXAMIDE, AND ITS ANALOGS.
51.32BITU- BITU (ATPU, PSEUDOUREA, 9,10-(BIS-ISOTHIOUREIDOMETHYL)ANTHRACENE).
51.32BLAST BLASTICIDIN S.
51.32BLEOM BLEOMYCIN.
51.32BLEOM50 BLEOMYCIN A.
51.32BONOM BONOMYCIN.
X 51.32BRIST BRISTOL C-274: SEE MYCORHODIN.
51.32BRYON ALPHA-BRYONIA ALBA L. EXTRACTS.
51.32BURSE ALPHA-BURSERA MICROPHYLLA EXTRACTS; SEE ALSO BURSERAN.
51.32BURSE BURSERA FAGAROIDES EXTRACT.
51.32BURSE BURSERAN.
X 51.32BUSUL BUSULFAN: SEE MYLERAN.
BUSUFAN, DIHYDROXY.
51.32CAESA CAESALPINIA GILLEISII EXTRACTS.
51.32CALOT CALOTROPIN.
51.32CAMPT CAMPTOTHECIN.
CAMPTOTHECINATE, SODIUM.
CAMPTOTHECIN ANALOGS (HYDROXYCAMPTOTHECIN, METHOXYCAMPTOTHECIN, CAMPTOTHECIN LACTONE).
51.32CANAL CANALINE.
51.32CANAV CANAVANINE.
51.32CARBA ACETYLINIC CARBAMATE.
51.32CARBA METHYLCARBAMATE.
51.32CARBA 5-CARBAMYL-L-CYSTEINE.
51.32CARBA CARBAZILQUINONE (CBQ).
51.32CARBE CARBENICILLIN.
51.32CARBE CARBESTROL.
51.32CARRA CARRAGEENIN, SULFATED.
51.32CARZO CARZOLAMIDE.
51.32CATOP CATOPSILIA CROALE CRAMER EXTRACTS (FROM A BUTTERFLY).
51.32CB154 CB-154 (ERGOCORNINE, 2-BROMO-ALPHA-ERGOCRYPTINE).
51.32CB134 CB-1348.
51.32CB136 CB-1364.
51.32CB150 CB-1506 (2-CHLOROETHYLMETHANE SULFONATE).
51.32CB185 CB-1850.
X 51.32CBQ-- CBQ: SEE CARBAZILQUINONE.
51.32CCNU- CCNU (1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA).
METHYL-CCNU.
ISOPHOSPHAMIDE (A CCNU DERIVATIVE).
51.32CENTR CENTRAZENE.

```
X    51.32CEPHA CEPHALOTAXINE:  SEE HARRINGTONINE.
     51.32CESAL CESALIN.
     51.32CFNU- CFNU (3-CYCLOHEXYL-1,1-(2-FLUROETHYL)-1-NITROSOUREA.
     51.32CHLOR CHLORAMBUCIL.
     51.32CHLOR CHLORAMPHENICOL.
     51.32CHLOR N,N-BIS(2-CHLOROETHYL)-ANILINE.
     51.32CHLOR CHLOROQUINE.
     51.32CHLOR CHLORPROMAZINE (CPZ).
     51.32CHOND CHONDROITIN SULFATE.
     51.32CHROM CHROMOMYCIN A2, A3, A4.
     51.32CISSA CISSAMPAREINE.
     51.32COBRA COBRA VENOM.
     51.32COLUB COLUBRINA (COLUBRINA TEXENSIS) EXTRACTS.
     51.32CONCA CONCANAVALIN A (CON-A).
     51.32CONVA CONVALLARIA EXTRACTS.
     51.32CORTI CORTISONE.
X    51.32COSME COSMEGEN:  SEE ACTINOMYCIN D.
     51.32COUMA COUMARINS.
                PENCEDANIN.
X    51.32CPZ-- CPZ:  SEE CHLORPROMAZINE.
     51.32CRINA CRINAMINE.
     51.32CROTE CROTEPOXIDE.
     51.32CRYPT CRYPTOWOLLINE.
     51.32CUCUR CUCURBITACINS (O, P, Q).
     51.32CYMAR CYMARIN.
         51.32CYCLOOO CYCLOHEXIMIDES, AS A GROUP.
                      SEE ALSO ACTIDIONE, STREPTOVITACIN A, AND E-73.
     51.32CYCLO CYCLOLEUCINE.
     51.32CYCLO CYCLOPENTANE CARBOXYLIC ACID.
     51.32CYCLO CYCLOPHOSPHAMIDE (CYTOXAN, ENDOXAN).
     51.32CYSTE L-CYSTEINE, S-TRITYL-, AND ITS ANALOGS.
X    51.32CYTAR CYTARABINE:  SEE ARA-C.
X    51.32CYTOS CYTOSAR:  SEE ARA-C.
X    51.32CYTOS CYTOSINE ARABINOSIDE:  SEE ARA-C.
     51.32CYTOX CYTOXAL ALCOHOL.
X    51.32CYTOX CYTOXAN:  SEE CYCLOPHOSPHAMIDE.
     51.32C3506 C-35,062.
     51.32C3710 C-37,10.
     51.32DAAP- DAAP (DIALLYL-BETA-AZIRIDINOPROPIONAMIDE).
X    51.32DACTI DACTINOMYCIN:  SEE ACTINOMYCIN D.
     51.32DAMOS DAMOS (3-DIETHYLAMIDA-2-BIS(CHLOROETHYL)AMINO-O-METHYL-DL-
                  THYROSINUM).
     51.32DARAP DARAPRIM.
X    51.32DAU-- DAU:  SEE DIALLYLUREA.
     51.32DAUNO DAUNOMYCIN (DAUNORUBICIN, RUBIDOMICIN).
         51.32DAUNOSO DAUNOMYCIN (RUBIDOMYCIN) AND RUBOMYCIN C.
X    51.32DAUNO DAUNORUBICIN:  SEE DAUNOMYCIN.
     51.32DBD-- DBD (DIBROMODULCITOL).
     51.32DBM-- DBM (DIBROMOMANNITOL, MYELOBROMOL).
                1,6-DIBROMO-1,6-DIDEOXY-D-MANNITOL.
     51.32DCM-- DCM.
     51.32DDD-- O,P-DDD (LYSODREN, MITOTANE).
     51.32DDUG- DDUG (4,4'-DIACETYLDIPHENYLUREA-BIS(GUANYLHYDRAZONE)).
         51.32DEAZASO DEAZADENINE - SEE TUBERCIDIN.
     51.32DECOY DECOYININE (DEHYDRO-PSICOFURANINE).
     51.32DEGRA DEGRANOL.
     51.32DEHYD DEHYDROBIOTIN.
     51.32DEHYD DEHYDROEPIANDROSTERONE MUSTARD.
         51.32DEHYDSO DEHYDRO-PSICOFURANINE - SEE DECOYININE.
X    51.32DELAT DELATESTRYL:  SEE TESTOSTERONE ENANTHATE.
X    51.32DELTA DELTASONE:  SEE PREDNISONE.
     51.32DEMEC DEMECOLCINE.
     51.32DESME DESMETHYLCOLCHICINE.
                N-ACETYLCOLCHINOL.
                TRIMETHYL COLCHINIC ACID.
         51.32DEMETSO DEMETRIC ACID.
     51.32DEMET 11-DEMETHYL-ELLIPTICINE.
     51.32DEOXY 2'-DEOXYADENOSINE, 8-AMINO.
     51.32DEOXY 3-DEOXYADENOSINE; 3'-DEOXYADENOSINE.
X    51.32DEOXY DEOXYURIDINE-6-3H:  SEE UDR.
```

51.32DIALL 1,3-DIALLYLUREA (DAU).
51.32DIAMI DIAMINOPURINE.
51.32DIAMI 2,4-DIAMINOQUINAZOLINES.
"4-AMINO-5,8-DEAZAPTEROYLASPARTATE" (N-(P-(((2,4-DIAMINO-6-QUINAZOLINYL)METHYL)AMINO)BENZOYL-L)ASPARTIC ACID).
51.32DIAMI 4,6-DIAMINOTRIAZINES.
51.32DIAZO DIAZOACETYLAMINOACETIC ACID HYDRAZIDE.
51.32DIAZO 1,2-BIS DIAZOACETYLETHANE.
51.32DIAZO 5-DIAZOURACIL.
X 51.32DIBRO DIBROMODULCITOL: SEE DBD.
X 51.32DIBRO DIBROMOMANNITOL: SEE DBM.
51.32DIC-- DIMETHYLAMINE IMIDAZOLE CARBOXAMIDE.
51.32DICHL DICHLOROALLYL LAWSONE, SODIUM SALT.
51.32DICHL DICHLOROMETHOTREXATE.
51.32DIETH DIETHYLSTILBESTROL.
51.32DIGLY DIGLYCOLALDEHYDE, ALPHA-(HYDROXYMETHYL)-ALPHA'-(6-HYDROXY-9H-PURIN-9-YL).
51.32DIMET DIMETHANESULFONATE.
51.32DIMET P-DIMETHYLAMINOAZABENZENE.
51.32DIMET DIMETHYLSULFOXIDE.
51.32DIMID DIMIDIUM.
51.32DIPHE DIPHENYLHYDANTOIN.
51.32DIPIN DIPINE (TETRAETHYLENIMIDE-N,N-PIPERAZINE DIPHOSPHORIC ACID).
51.32DITHI DITHIZONE.
X 51.32DIVEE DIVEEMA: SEE MALEIC ANHYDRIDE POLYMERS.
51.32DMAA- DMAA (9-(P-DIMETHYLAMINO-ANILINO)-ACRIDINE).
51.32DNA-- DNA FROM VARIOUS SOURCES.
51.32DNASE DNASE.
51.32DON-- DON (6-DIAZO-5-OXO-L-NORLEUCINE).
51.32DONV- DONV (DIAZO OXO NORVALINE).
51.32DOP-- DOP (4-DESOXYPYRIDOXINE).
X 51.32DROLB DROLBAN: SEE DROMOSTANALONE.
51.32DROMO DROMOSTANALONE (DROLBAN).
DROMOSTANALONE PROPIONATE.
51.32DUAZO DUAZOMYCIN A.
51.32D54-- D54 (4,6-DIAMINO-1-(3,4-DICHLOROPHENYL-1,2-DIHYDRO-2,2-DIMETHYL-5-TRIAZINE).
51.32D168- D168-HYDROCHLORIDE.
51.32ECBAL ECBALLIUM ELLATURIUM EXTRACT.
51.32EC2-- EC-2 (ASPARAGINASE).
51.32EDODE EDODESAN (BETA-1,4 AND 1,6 GLUCAN).
51.32ELATE ELATERICIN A.
51.32ELDEM ELDERFIELD PYRIMIDINE MUSTARD.
51.32ELEPH ELEPHANTIN.
51.32ELEPH ELEPHANTOPIN.
51.32ELLIP ELLIPTICINE.
51.32EMETI EMETINE.
EMETINE HYDROCHLORIDE.
EMETINE DIHYDROCHLORIDE.
51.32EMETI EMETINE, 2,3-DIHYDRODIHYDROCHLORIDE.
X 51.32ENDOX ENDOXAN: SEE CYCLOPHOSPHAMIDE.
X 51.32EPIMI EPIMINE: SEE AZIRIDINE.
51.32EPONA EPONATE.
51.32EPOYD EPODYL.
51.32ERWIN ERWINIA CARATOVORA L-ASPARAGINASE.
51.32ERYTH ERYTHRITOL AZIRIDINE.
51.32ESTRI ESTRIOL.
51.32ETD9- ETD 9.
51.32ETHID ETHIDIUM BROMIDE.
51.32ETHID ETHIDIUM CHLORIDE.
51.32ETHIN ETHINYL ESTRADIOL.
51.32ETHIO ETHIONINE.
51.32ETHOG ETHOGLUCID.
X 51.32ETHYL ETHYLENEIMINE: SEE AZIRIDINE.
51.32EUPAC EUPACHLORIN (EUPACHLORIN ACETATE).
51.32EUPAC EUPACHLOROXIN.
51.32EUPAR EUPAROTIN (EUPAROTIN ACETATE).
51.32EUPAT EUPATIN.
51.32EUPAT EUPATORETIN.
51.32EUPAT EUPATORIUM ROTUNDIFOLIUM EXTRACTS.

51.32EUPAT EUPATOROXIN AND ANALOGS (10-EPI-EUPATOROXIN).
51.32EUPAT EUPATUNDIN.
51.32E37-- E-37 (ACETOXY-ACTIDIONE), A CYCLOHEXIMIDE.
51.32FIGAR FIGAROIC ACID.
51.32FLUOR 2-FLUOROADENOSINE.
51.32FLUOR 8-FLUOROADENOSINE.
51.32FLUOR FLUOROMETHALONE (OXYLONE).
51.32FLUOR 5-FLUOROOROTIC ACID.
51.32FLUOR CIS-4-FLUORO-L-PROLINE.
51.32FLUOR 5-FLUOROURACIL (5-FU).
X 51.32FLUOR FLUOROURACIL DEOXYRIBOSIDE: SEE FUDR.
51.32FLUOX FLUOXYMESTERONE.
51.32FOLIC FOLIC ACID.
51.32FOWLE FOWLER'S SOLUTION.
X 51.32FREEF FREE FATTY ACIDS: SEE FFA.
51.32FU--- 5-FU: SEE 5-FLUOROURACIL.
51.32FUCOS L-FUCOSE.
51.32FUDR- FUDR (2'-DEOXY-5-FLUOROURACIL, FLUROURACIL DEOXYRIBOSIDE).
51.32FUMAG FUMAGILLIN.
51.32GAILL GAILLARDIN.
51.32GALAC GALACTOFLAVIN.
51.32GALAC D-GALACTOSAMINE.
51.32GALLI GALLIUM SALTS.
51.32GENTA GENTAMYCIN.
51.32GLAUC GLAUCARUBOLONE.
51.32GLUTA GLUTAMINASE.
51.32GLUTI GLUTINOSIN.
51.32GLUTA GAMMA-GLUTAMYLHYDRAZIDE.
51.32GLYCE GLYCERALDEHYDE.
51.32GLYCI GLYCINE, N-(DIAZOACETYL)-, HYDRAZIDE.
N-(DIAZOACETYL)ETHYLGLYCINE.
N-(DIAZOACETYL)GLYCINE AMIDE.
51.32GOUGE GOUGERATIN.
51.32GUANA GUANAZOLE.
51.32GUTIE GUTIERREZIA SAROTHRAE EXTRACTS.
51.32G253- G-253.
51.32HADAC HADACIDIN.
51.32HARRI HARRINGTONINE (ALKALOID C, CEPHALOTAXINE) AND RELATED COMPOUNDS (ISOHARRINGTONINE, HOMOHARRINGTONINE).
51.32HEDAM HEDAMYCIN.
51.32HELEN HELENALIN, HELENALINE.
51.32HELLE HELLEBRIGENIN-3-ACETATE.
HELLEBRIGENIN-3,5-DIACETATE.
51.32HEXAC HEXACHLOROPLATINATE.
CIS AND TRANS DIAMINO TYPES.
51.32HEXAM HEXAMETHYLMELAMINE AND ANALOGS (HMM, METHYL-HMM).
51.32HEXES HEXESTEROL.
X 51.32HMM-- HMM: SEE HEXAMETHYLMELAMINE.
51.32HN2-- HN2 (MECHLORETHAMINE, NITROGEN MUSTARD, MUSTARGEN).
MECHLORETHAMINE OXIDE.
51.32HOLOC HOLOCANTHONE.
X 51.32HOMOH HOMOHARRINGTONINE: SEE HARRINGTONINE.
51.32HPP-- 4-HPP.
X 51.32HYDRE HYDREA: SEE HYDROXYUREA.
51.32HYDRO N-HYDROXYADENOSINE.
51.32HYDRO HYDROXYLYSINE.
51.32HYDRO HYDROXYSTILBAMIDINE.
51.32HYDRO50 HYDROXY-ACTIDIONE: USE STREPTOVITACIN A.
51.32HYDRO HYDROXYUREA (HYDREA).
X 51.32IBENZ IBENZMETHYZIN: SEE MIH.
51.32IDOXU IDOXURIDINE.
51.32IFOSF IFOSFAMIDE.
51.32ILLUD ILLUDINS (LAMPTEROL) (FROM MUSHROOMS).
51.32IMDM- IMDM (ISOMETAMIDIUM).
51.32IMIDA IMIDAZOLE-4(5)-CARBOXAMIDE,5(4)-(3,3-DIMETHYL-1-TRIAZENO).
51.32IMIDA IMIDAZOLE CARBOXAMIDE, METHYL.
51.32IMIDA IMIDAZOLE CARBOXAMIDE MUSTARD.
51.32IMIDA IMIDAZOLE TEREPHTHALANILIDE.
51.32IMURA IMURAN (AZATHIOPRINE).
51.32INCL- INDIUM CHLORIDE.

51.32INDEN INDENE, 1-(4-N,N-DIMETHYLAMINOBENZYLIDENE).
51.32INNO3 INDIUM NITRATE.
51.32INOSI INOSINE DIALDEHYDE.
51.32INSO4 INDIUM SULFATE.
51.32INTER INTERFERON FROM VARIOUS EXOGENOUS SOURCES.
51.32IO882 IOB-82 (ALKIROM).
51.32IODOG 8-IODOGUANOSINE.
X 51.32IODOU IODOURACIL DEOXYRIBOSIDE: SEE IUDR.
51.32ISOPR ISOPROPYLIDINE.
51.32IQ1-- IQ1 (1-FORMYLISOQUINOLINE THIOSEMICARBAZONE).
X 51.32ISOHA ISOHARRINGTONINE: SEE HARRINGTONINE.
51.32ISONI ISONICOTINIC HYDROXAMIC ACID.
51.32ISOPR ISOPROPYL METHANE SULFATE.
51.32ITG-- ITG (2-AMINO-6-(1-METHYL-4-NITROIMIDAZAL-5-YL-THIO) PURINE).
51.32IUDR- 5-IUDR (IODOURACIL DEOXYRIBOSIDE).
51.32IXIAS IXIAS PYRENE INSIGNIS BUTLER EXTRACTS (FROM A BUTTERFLY).
51.32IYOMY IYOMYLIN.
51.32JATRO JATROPHONE.
51.32JUGLO JUGLONE.
51.32KANAM KANAMYCIN.
51.32KANCH KANCHANOMYCIN.
X 51.32KREBI KREBIOZEN: SEE QUACK REMEDIES.
51.32KETHO KETHOXAL.
51.32KTS-- KTS (2-KETO-3-ETHYOXYBUTYRALDEHYDE-BIS(THIOSEMICARBAZONE)).
COPPER(II)KTS.
51.32KUNDR KUNDRYMYCIN.
51.32LAPAC LAPACHOL.
X 51.32LAMPT LAMPTEROL: SEE ILLUDINS.
51.32LENTI LENTINAN (BETA-1,3-LINEAR GLUCAN).
X 51.32LEUKE LEUKERAN: SEE CHLORAMBUCIL.
X 51.32LEURO LEUROSINE: SEE VINLEUROSINE.
51.32LIATR LIATRIS CHAPMANII EXTRACT.
51.32LITHO LITHOSPERMUM ERYTHRORHIZON EXTRACT.
51.32LUNAS LUNASINE.
51.32LUPEO LUPEOL.
51.32LYCOR LYCORINE.
X 51.32LYSOD LYSODREN: SEE DDD.
51.32LYSOL LYSOLECITHIN.
51.32MALEA MALEAMIC ACID DERIVATIVES.
51.32MALEA11 METHYL-N-CARBAMYLMALEAMATE.
51.32MALEA12 BETA-HYDROXYETHYL-N-CARBAMYL-MALEAMATE.
51.32MALEI MALEIC ANHYDRIDE COPOLYMERS (WITH
DIVINYLCYCLOPENTANEMETHYLENESILANE, DIVINYL SULFONE, AND DIVINYL
ETHER).
SEE ALSO PYRAN COPOLYMER.
51.32MALEI11 DIVEEMA (DIVINYLETHER ETHYLENE MALEIC ANHYDRIDE COPOLYMER).
51.32MALEU MALEURIC ACID DERIVATIVES.
51.32MALEU11 ALLYL MALEURATE.
51.32MALEU12 2-CHLOROETHYLMALEURATE.
51.32MALEU13 ISOPROPYLMALEURATE.
51.32MALEU14 ETHYLENE BIS(MALEURATE).
51.32MALEU15 PROPARGYL MALEURATE.
51.32MANNM MANNITOL MUSTARD.
51.32MANNO MANNOMUSTINE.
X 51.32MATUL MATULANE: SEE MIH.
51.32MCBOA MCBOA (2-MERCAPTO-5-(P-CHLOROETHYL)-OROTIC ALDEHYDE.
51.32MCM-- MCM (METHYL-N-CARBAMYL MALEAMATE).
51.32MCNU- MCNU (1-MONO-(2-CHLOROETHYL)-1-NITROSOUREA; MONODERIVATIVE OF
BCNU).
51.32MELAN MELANITIS LEDA DETERMINATA BUTLER FRACTIONS (A BUTTERFLY).
X 51.32MECHL MECHLORETHAMINE: SEE HN2.
51.32MEGAG ME-GAG (METHYLGLYOXAL-BIS-GUANYLHYDRAZONE).
X 51.32MELPH MELPHALAN: SEE PAM.
X 51.32MERAC MERACTINOMYCIN: SEE ACTINOMYCIN D.
51.32MERCA 6-MERCAPTOPURINE (6-MP, PURINETHOL).
51.32MERCA MERCAPTOPURINE RIBOSIDE, 6-METHYL- (MMPR).
51.32MERCA MERCAPTOPURINE, 9-BUTYL-6-.
51.32MERCA MERCAPTOPURINE, 9-ETHYL-6-.
51.32METAM METAMIDINUM.
51.32METHI METHIONINE SULFOXIMINE.

51.32METHO METHOTREXATE (MTX).
51.32METHO 5-METHOXYCANTHIN-6-ONE.
51.32METHO 8-METHOXYGUANOSINE.
51.32METHY O-METHYLARMEPAVINE.
51.32METHY METHYLCARBAMATE.
51.32METHY METHYLHYDRAZINE.
51.32METHY METHYLMETHANE SULFONATE.
51.32METHY 1-METHYLNITROSOUREA.
51.32METHY 4-METHYLTHIOCANTHIN-6-ONE.
X 51.32METIC METICORTEN: SEE PREDNISONE.
51.32MIH-- MIH (NATULAN, IBENZMETHYZIN, METHYLHYDRAZINEASPARAGINASE, PROCARBAZINE, MATULANE).
51.32MIRAB MIRABILIS MULTIFLORA EXTRACTS.
51.32MIRAC MIRACIL D.
51.32MITHR MITHRAMYCIN (MITHRACIN).
51.32MITOC MITOCHROMIN.
51.32MITOM MITOMALCIN.
51.32MITOM MITOMYCIN A, B, C.
MITOMYCIN C.
METHYL-MITOMYCIN C: USE PORFIROMYCIN.
X 51.32MITOT MITOTANE: SEE DDD.
X 51.32MMPR- 6-MMPR: SEE 6-METHYLMERCAPTORIBOSIDE.
51.32MORPH MORPHALAN.
X 51.32MP--- 6-MP: SEE 6-MERCAPTOPURINE.
51.32MPA-- MPA (P-N-MORPHOLINOPHENYLACETIC ACID).
51.32MPE-- MPE (ETHYL-P-N-MORPHOLINOACETATE).
51.32MTX-- MTX (METHOTREXATE, USAN, AMETHOPTERIN).
METHOTREXATE DICHLORIDE.
51.32MUCON MUCONOMYCIN (VERRUCARIN A).
X 51.32MUSTA MUSTARGEN: SEE HN2.
51.32MYCH050 MYCHORHODIN (BRISTOL C-274).
51.32MYCOP MYCOPHENOLIC ACID.
51.32MYCOR MYCORHODIN.
X 51.32MYELO MYELOBROMOL: SEE DBM.
51.32MYELO MYELOPEROXIDASE.
51.32MYLER MYLERAN (BUSULFAN).
51.32MYLER MYLERAN, DIHYDROXY.
51.32MYRSI MYRSINE AFRICANA SAPONIN.
51.32NAMS- NAMS (N,N-BIS(2-METHANESULFONOXYETHYL)P-NITROSOANILINE; ADL-50, ASC-79423).
51.32NARAN NARANGOMYCIN.
51.32NARCI NARCICLASINE.
51.32NARCO NARCOTINE.
X 51.32NATUL NATULAN: SEE MIH.
51.32NEOCA NEOCARZINOSTATIN.
51.32NEOCA50 NEOCARZINOSTATIN.
51.32NERII NERIIFOLIN.
51.32NETRO50 NETROPSIN (SINANOMYCIN, CONGOCIDINE).
51.32NICOT NICOTINAMIDE, 6-AMINO- (6-AN).
51.32NICOT NICOTINIC HYDROXAMIC ACID.
51.32NITID NITIDINE CHLORIDE.
X 51.32NITRM NITROGEN MUSTARD: SEE HN2.
51.32NITRO NITROSOGUANIDINE.
1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA.
1-1'-(TRANS-1,2-CYCLOHEXYLENE)BIS(3-(I-CHLOROETHYL)-3-NITROSOUREA).
1-1'-P-PHENYLENE BIS-(3-(2-CHLOROETHYL)-3-NITROSOUREA).
51.32NOGAL50 NOGALAMYCIN (A QUINONE ANTIBIOTIC) (NSC 70845) (UPJOHN U-15167).
51.320BAME OBAMEGINE.
51.320HSB- OHSB (HYDROXYSTILBAMIDINE).
51.320LIVO OLIVOMYCIN A, B, C, D.
51.320MF59 OMF-59 (N,N-BIS(2-CHLOROETHYL)PHOSPHORODIAMIDIC ACID).
X 51.320NCOV ONCOVIN: SEE VCR.
51.320RPHE ORPHEOMYCIN.
51.320STEO OSTEOMELES SCHWERINAE EXTRACTS.
51.320XIMI OXIMINOACETIC ACID.
X 51.320XYLO OXYLONE: SEE FLUOROMETHALONE.
51.320XYMA OXYMATE.
51.320XYNI OXYNITIDINE.

51.32PACTA PACTAMYCIN.
51.32PAM-- PAM (PHENYLALANINE MUSTARD, SARCOLYSIN, MELPHALAN).
O-MELPHALAN.
META-SARCOLYSIN.
ORTHO-SARCOLYSIN.
51.32PANTA PANTANGA SUCCINATA (A GRASSHOPPER) EXTRACT.
51.32PAOLI PAOLINS (MOLLUSC EXTRACTS).
51.32PD--- PALLADIUM COMPLEXES OF 6-MP.
X 51.32PARAC PARACORT: SEE PREDNISONE.
51.32PA144 PA-144.
51.32PELTA PELTATIN (ALPHA AND BETA).
X 51.32PENCE PENCEDANIN: SEE COUMARINS.
51.32PENIC D-PENICILLAMINE.
51.32PEPTI PEPTINOGAN.
51.32PERAT PERATHIEPINE.
51.32PERTH PERTHANE.
51.32PHELL PHELLODENDRON AMURENSE EXTRACT.
51.32PHENA PHENACID.
51.32PHENA PHENACID, DIHYDROXY-, AND RELATED ESTERS (DHPA AND DHPE).
51.32PHENA PHENAZINIUM.
51.32PHENE PHENESTER.
51.32PHENE PHENESTERIN.
51.32PHENE PHENESTRADIOL (PED) AND MONOPHENESTRADIOL.
X 51.32PHENM PHENYLALANINE MUSTARD: SEE PAM.
51.32PHENO PHENOFORMIN.
51.32PHLEO PHLEOMYCIN.
51.32PHOSM PHOSPHORAMIDE MUSTARD.
51.32PHOSP PHOSPHORYL CHOLINE (GLYCERYL PHOSPHORYL CHOLINE).
51.32PICOL PICOLINALDEHYDE, 5-HYDROXY-, THIOSEMICARBAZONE.
51.32PIERI PIERIS RAPAE CRUAVORA EXTRACTS (FROM A BUTTERFLY).
51.32PILOC PILOCEREINE.
51.32PIPER PIPERAZINE, 1,4-BIS-(3-BROMOPROPIONYL)-.
51.32PLATI PLATINUM COMPLEXES OF 6-MP.
51.32PLATI PLATINUM, 2-CIS-DIAMINOTETRACHLORO.
51.32PLATI PLATINUM, 2-CIS-DIAMINODICHLORO-.
51.32PLEXA PLEXAURA HOMOMALLA EXTRACT.
51.32PODOP PODOPHYLIC ACID.
51.32PODOP PODOPHYLLOTOXIN.
51.32PODOP PODOPHYLLOTOXIN BENZYLIDENE GLUCOSIDE AND ITS ANALOGS
(EPIPODOPHYLLOTOXIN BENZYLIDENE GLUCOSIDE).
51.32POLYA POLYAMINES.
SPERMINEOXIDASE.
51.32POLYE POLYETHYLENEIMINE.
51.32POLYI POLYINOSINIC-POLYCYTIDYLIC ACID.
POLY-IC.
51.32POLYO POLYOXINS.
51.32POLYV POLYVINYLAMINE.
51.32PORFI50 PORFIROMYCIN (METHLY DERIVATIVE OF MITOMYCIN C).
51.32PPORO P. POROSA EXTRACT.
51.32PREDN PREDNISONE (DELTASONE, METICORTEN, PARACORT).
51.32PREDN PREDNISOLONE.
51.32PREGN 4-PREGNE-3,11,20-TRIONE, 6A-METHYL.
51.32PRION PRIONERIS THESTYLIS DBLDY. FRACTIONS (FROM A BUTTERFLY).
X 51.32PROCA PROCARBAZINE: SEE MIH.
51.32PROGE PROGESTERONE.
51.32PROMI PROMINE.
51.32PROTO PROTOANEMONIN.
X 51.32PSEUD PSEUDOUREA: SEE BITU.
51.32PSEUD PSEUDOTHIOUREA.
51.32PSICO PSICOFURANINE.
SEE ALSO: DECOYININE (DEHYDRO-PSICOFURANINE).
51.32PSILO PSILOTACHYIN.
51.32PURIN PURIN-6-YL-TRIMETHYLAMMONIUMCHLORIDE.
X 51.32PURIN PURINETHOL: SEE 6-MERCAPTOPURINE.
51.32PUROM50 PUROMYCIN.
51.32PUROM PUROMYCIN DIHYDROCHLORIDE.
51.32PYRAN PYRAN COPOLYMER (SEE ALSO DIVEEMA).
SEE ALSO MALEIC ANHYDRIDE COPOLYMERS.
51.32PYRAZ PYRAZINE, 2-METHYL-3-(P-TOLYLOXY)-.
51.32PYRAZ PYRAZOLO(3,4-D) PYRIMIDINES (4-AMINO-PYRAZOLO(3,4-D) PYRIMIDINE).

51.32P81-- P81-HYDROCHLORIDE.
51.32QUAHA QUAHAUG EXTRACT.
51.32QUINA QUINACRINE.
51.32QUINA QUINASPAR (N-(O-(((2,4-DIAMINO-6-
QUINAZOLINYL)METHYL)AMINO)BENZOYL)-L-ASPARTIC ACID).
51.32RETIN RETINE.
51.32RNA-- RNA, NATURAL.
51.32RNA-- RNA, SYNTHETIC (DOUBLE STRANDED).
51.32RNASE RNASE; THE 'Z' PROTEIN (FROM BEEF PANCREAS).
51.32ROSEO ROSEOLIC ACID.
51.32ROUS-50 ROUS FOCUS INHIBITOR.
X 51.32RUBID RUBIDOMYCIN: SEE DAUNOMYCIN.
51.32RUMEX RUMEX HYMENOSEPALUS EXTRACTS.
51.32R52-- R-52 (1,2,5,6-TETRA-O-METHYLSULFONYL-D-MANNITOL).
51.32SANGI SANGIVAMYCIN.
51.32SANGU SANGUISORBA OFFICINALIS EXTRACT.
51.32SARAM SARAMYCETIN.
51.32SARCI ALPHA-SARCIN.
X 51.32SARCO SARCOLYSIN: SEE PAM.
51.32SAVIN SAVIN (FROM JUNIPERIS SABINA).
51.32SEASQ SEA SQUIRT EXTRACT.
51.32SIMAR SIMAROUBA GLAUCA EXTRACT.
51.32SITOS BETA-SITOSTEROL.
SITOSTEROL SUCCINATE.
51.32SOLAM BETA-SOLAMARINE.
51.32SOLAP SOLAPALMITENE.
51.32SOLAP SOLAPALMITENINE.
51.32SOLAP SOLAPARTINE.
51.32SOLAS SOLASADINE.
51.32SPARS SPARSOMYCIN.
51.32SPERM SPERMINE.
51.32SP38- SP38 TETRAHYDROCHLORIDE (N,N'-BIS(3-AMINOPROPYL)NONANE-1,9-DIAMINE
TETRAHYDROCHLORIDE).
51.32SSHIM S. SHIMOFUSAENIS EXTRACTS A, B, C.
51.32STATO STATOLON.
51.32STREP STREPTOGAN.
51.32STREP80 STREPTONIGRIN AND ITS DERIVATIVES.
STREPTONIGRIN ESTERS (METHYL ESTERS).
51.32STREP STREPTOVITACIN A.
51.32STREP50 STREPTOVITACIN (HYDROXY-ACTIDIONE), A CYCLOHEXIMIDE.
51.32STREP60 STREPTOZOTOCIN (ZEDALAN) AND ITS COFACTOR (U-15, 774).
DIABETOGENIC ACTIVITY OF STREPTOZOTOCIN AND REVERSAL BY
NICOTINAMIDE.
51.32S46-- S-46.
51.32S73-- S-73.
51.32S182- S-182.
51.32S191- S-191.
51.32S339- S-339.
51.32TABAS TABASHIR.
51.32TAXOD TAXODIUM DISTICHUM EXTRACTS.
51.32TAXOD TAXODIONE.
51.32TAXOD TAXODONE.
51.32TAXOL TAXOL.
51.32TAXON TAXONE.
51.32TAXUS TAXUS BREVIFOLIA EXTRACTS (TAXOL).
51.32TEM-- TEM (TRIETHYLENEMELAMINE).
51.32TENUA TENUAZONIC ACID AND ITS ANALOGS.
X 51.32TEPA- THIO-TEPA: SEE TSPA.
51.32TESTO TESTOLOLACTONE.
51.32TESTO TESTOSTERONE ENANTHATE (DELATESTRYL).
X 51.32TETRA TETRACHLORODIAMINOPLATINATE: SEE PLATINUM, 2-CIS-
DIAMINOTETRACHLORO.
51.32TETRA TETRAHYDROHOMOFOLIC ACID.
51.32TETRA TETRAHYDROURIDINE.
51.32TETRA TETRAMEZYL-MANNITOL R52.
51.32TETRA TETRAMIN.
ALPHA-VINYL-AE ACETATE.
O-ACETYLTETRAMIN.
51.32TETRA ALPHA-TETRANDRINE.
51.32TETRO TETRONIC ACID.

51.32TGDR- TGDR (ALPHA AND BETA DEOXYTHIOGUANOSINES).
51.32THALF THALFOETIDINE.
51.32THALI THALICARPINE.
51.32THALI THALICTRUM ROGUSUM EXTRACT.
51.32THALI THALIDASINE.
51.32THALI THALIDOMIDE.
51.32THIOC THIOCARZOLAMIDE.
51.32THIOG 6-THIOGUANINE (TTG) AND ITS ANALOGS (9-ETHYL-6-TTG).
51.32THIOG THIOGUANINE ARABINOSIDE.
51.32THIOG THIOGUANOSINE.
THIOGUANOSINE, BETA-DEOXY-.
51.32THIOP THIOPHOSPHORAMIDE.
51.32THIOQ THIOQUANOSINE.
51.32THIOS THIOSEMICARBAZONES, ALPHA-N-HETEROCYCLIC.
51.32THREI THREITOL, 1,4-DIMETHANESULFONATE.
X 51.32THYMI THYMIDINE-2 14-C: SEE TDR.
51.32TIC-- CHLORO-TIC.
51.32TIGON TIGONENIN.
51.32TILOR TILORONE HYDROCHLORIDE.
51.32TLCL- THALLIUM CHLORIDE.
51.32TLNO3 THALLIUM NITRATE.
51.32TLSO4 THALLIUM SULFATE.
51.32TMCA- TMCA (TRIMETHYL COLCHICINE ACID METHYL ESTER D-TARTRATE).
51.32TPMA- TPMA (P-N-THIOMORPHOLINOPHENYLACETIC ACID).
51.32TRENI TRENIMON.
51.32TRIAZ TRIAZIQUONE.
51.32TRICH TRICHOSANTHES KIRILONII EXTRACT.
X 51.32TRIET TRIETHYLENEMELAMINE: SEE TEM.
51.32TRIFL TRIFLUORLEUCINE.
51.32TRIFL TRIFLUOROMETHYL-DEOXYURIDINE (F3TDR).
51.32TRIPA TRIPARANOL.
51.32TRITY TRITYLTHIO-L-ALANINE.
51.32TRYPM TRYPTOPHANE MUSTARD.
51.32TSPA- TSPA (THIO-TEPA, TRIETHYLENETHIOPHOSPHORAMIDE).
X 51.32TTG-- TTG: SEE 6-THIOGUANINE.
51.32TUBER50 TUBERCIDIN (7-DEAZADENINE).
51.32TYLOC TYLOCREBRINE.
51.32UDR-- UDR (DEOXYURIDINE-6-3H).
51.32URACM URACIL MUSTARD.
51.32URETH BIS-(AZIRIDINO)-PHOSPHORYL URETHANES.
X 51.32USAN- USAN: SEE METHOTREXATE.
51.32USNIC USNIC ACID.
51.32U149450 U-14941 - SEE 51.337212 (LISTED AS A STEROID).
51.32U2112 U-2112 (6,7-DIMETHYL-9-(2'-ACETOXYETHYL)-ISOALLOXAZINE).
51.32VCR-- VCR (VINCRISTINE, ONCOVIN).
VINCRISTINE SULFATE.
51.32VELBA VELBAN.
51.32VERNO VERNODALIN.
51.32VERNO VERNOMYGDIN.
51.32VERNO VERNOLEPIN.
X 51.32VERRU VERRUCARIN A: SEE MUCONOMYCIN.
51.32VGL-- VGL (VINGLYCINATE SULFATE).
51.32VINBL VINBLASTINE (VINBLASTINE SULFATE AND OTHER SALTS).
51.32VINBL VINBLASTINE ANALOGS (DHVLB, DIHYDROVINBLASTINE).
X 51.32VINCA VINCALEUKOBLASTINE: SEE VLB.
X 51.32VINCR VINCRISTINE: SEE VCR.
X 51.32VINGL VINGLYCINATE SULFATE: SEE VGL.
51.32VINLE VINLEUROSINE (LEUROSINE).
51.32VLB-- VLB (VINCALEUKOBLASTINE).
51.32VM26- VM 26.
51.32WANDE WANDER DRUG.
51.32WITHA WITHACNISTIN.
51.32WITHA WITHAFERIN A.
51.32XYLA- XYL-A.
51.32YEAST YEAST MANNAN.
51.32YOMAS FRACTIONS OF YOMA SABINA VASUKI DOHERTY (A BUTTERFLY).
X 51.32ZEDAL ZEDALAN: SEE STREPTOZOTOCIN.
X 51.32ZPROT "Z" PROTEIN: SEE RNASE.
51.32ZEARA ZEARALENONE.
51.32ZITOS ZITOSTOP.

51.320 PRECLINICAL CHEMOTHERAPY OF SPECIFIC TYPES OF TUMORS IN ANIMALS.
SEE ALSO: 51.3235 FOR TOXIC EFFECTS OF CHEMOTHERAPEUTIC AGENTS ON NORMAL TISSUES.
51.3201 GENERAL.
51.3202 PRE-CLINICAL CHEMOTHERAPY OF CANCER OF HEART, CARDIOVASCULAR, RETICULO-ENDOTHELIAL, AND LYMPHATIC SYSTEMS.
51.32025 PRE-CLINICAL CHEMOTHERAPY OF LEUKEMIA AND LYMPHOMA IN AMIMALS AND LEUKEMIC CELLS IN VITRO.
EFFECT OF CHEMOTHERAPEUTIC AGENTS ON GROWTH KINETICS OF LEUKEMIC CELLS.
SEE ALSO: 51.3224 FOR SCREENING METHODS INVOLVING VARIOUS TYPES OF LEUKEMIC CELLS.
51.320251 GENERAL.
51.320252 IN VITRO LEUKEMIA.
51.320253 USE OF L-120 MICROSOME LEUKEMIA TO DETERMINE OPTIMUM CHEMOTHERAPY TECHNIQUE .
51.320261 GENERAL.
51.320262 IN VITRO TESTS.
51.320263 IN VIVO TESTS.
51.320264 SPLEEN.
51.320265 BONE MARROW.
51.3203 PRE-CLINICAL CHEMOTHERAPY OF MUSCLE TUMORS.
51.3204 PRE-CLINICAL CHEMOTHERAPY OF KIDNEY AND BLADDER TUMORS.
51.32052 PRE-CLINICAL CHEMOTHERAPY OF LUNG TUMORS.
51.32053 PRE-CLINICAL CHEMOTHERAPY OF LIVER TUMORS.
51.32054 PRE-CLINICAL CHEMOTHERAPY OF GASTROINTESTINAL TRACT TUMORS.
51.32055 PRECLINICAL CHEMOTHERAPY OF TUMORS OF THE REPRODUCTIVE TRACT AND REPRODUCTIVE ORGANS.
51.320551 GENERAL.
51.320552 FEMALES.
51.3205521 GENERAL.
51.3205522 OVARIAN CANCER.
51.3205524 BREAST CANCER.
51.320553 MALES.
51.3205532 TESTICULAR TUMORS AND TESTICULAR TERATOMA.
51.3205534 PROSTATE.
51.320554 TERATOMAS IN GENERAL.
SEE ALSO: 51.320554 FOR TERATOMAS IN GENERAL.
51.32056 PRE-CLINICAL CHEMOTHERAPY OF ENDOCRINE-RELATED TUMORS.
51.320561 GENERAL.
51.320563 THYROID.
51.320564 PARATHYROID.
51.320565 ADRENAL.
51.3206 PRE-CLINICAL CHEMOTHERAPY OF TUMORS OF THE BRAIN AND NERVOUS SYSTEM.
51.32072 PRE-CLINICAL CHEMOTHERAPY OF TUMORS RELATED TO THE EYE.
51.32083 PRE-CLINICAL CHEMOTHERAPY OF SKIN CANCER AND MELANOMAS.
51.32084 PRE-CLINICAL CHEMOTHERAPY OF BONE CANCER (EXCLUDING LEUKEMIAS, LYMPHOMAS AND RETICULO-ENDOTHELIAL CANCER).
51.321 SELECTED GENERAL TOPICS RELATED TO PRE-CLINICAL CANCER CHEMOTHERAPY.
GENERAL PROPERTIES OF CANCER CHEMOTHERAPEUTIC AGENTS.
51.3211 OPEN.
51.3212 THEORETICAL APPROACHES TO CANCER CHEMOTHERAPY.
DIFFERENCES IN ENZYME LEVELS BETWEEN NORMAL AND CANCER CELLS, AND EXPLOITATION OF THESE DIFFERENCES IN CHEMOTHERAPY.
51.322 SYNTHESIS AND PRE-CLINICAL TESTING OF POTENTIAL CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 51.324 THROUGH 51.329 FOR SPECIFIC ACTIVE AGENTS.
51.3221 GENERAL.
51.3222 SYNTHESIS OF POTENTIAL CANCER CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 51.33 FOR SYNTHESIS OF STEROID ANALOGS.
SEE ALSO: 54.12 FOR SYNTHESIS OF COMPOUNDS WITH POTENTIAL PHARMACOLOGICAL ACTIVITY (GENERAL ASPECTS).
SEE ALSO: 51.327 FOR COMPOUNDS OBTAINED FROM NATURAL SOURCES.
SEE ALSO: 51.3224 FOR SCREENING PROCEDURES USED TO MEASURE ANTICANCER ACTIVITY.
51.32221 GENERAL.
51.322211 PROGRAMS FOR SYNTHESIZING MULTIPLE CLASSES OF COMPOUNDS.
51.322212 RATIONALE INVOLVED IN DESIGNING COMPOUNDS TO BE SYNTHESIZED AND STRUCTURE - ACTIVITY CONSIDERATIONS.
51.32222 SYNTHESIS OF ALIPHATIC COMPOUNDS.
51.32223 SYNTHESIS OF AROMATIC COMPOUNDS.
51.32224 SYNTHESIS OF ALICYCLIC COMPOUNDS.

51.32225 SYNTHESIS OF ANALOGS OF NATURAL PRODUCTS.
51.322250 GENERAL.
51.322251 SYNTHESIS OF NUCLEIC ACID ANALOGS.
51.322252 SYNTHESIS OF AMINO ACID AND POLYPEPTIDE ANALOGS.
51.322253 SYNTHESIS OF LIPID AND STEROID ANALOGS.
51.322254 SYNTHESIS OF CARBOHYDRATE ANALOGS.
51.322255 SYNTHESIS OF ALKALOID ANALOGS.
51.322256 SYNTHESIS OF TERPENE ANALOGS.
51.32226 SYNTHESIS OF HETEROCYCLIC COMPOUNDS.
51.32227 SYNTHESIS OF ORGANOMETALLICS (INCLUDING PHOSPHORUS AND BORON COMPOUNDS).
SEE ALSO: 51.3222904 FOR SYNTHESIS OF METAL COMPLEXES AND CHELATES.
51.32228 SYNTHESIS OF ALKYLATING AGENTS.
51.32229 SYNTHESIS OF OTHER SPECIFIC CLASSES OF POTENTIAL ANTICANCER COMPOUNDS.
51.3222901 SYNTHESIS OF FLUOROCARBONS.
51.3222902 SYNTHESIS OF POLYMERS.
51.3222903 SYNTHESIS OF SPIRO COMPOUNDS.
51.3222904 SYNTHESIS OF METAL COMPLEXES, CHELATES AND CHELATING AGENTS.
SEE ALSO: 51.32227 FOR SYNTHESIS OF ORGANOMETALLIC COMPOUNDS.
51.3223 PRE-CLINICAL SCREENING PROGRAM OF THE CANCER CHEMOTHERAPY NATIONAL SERVICE CENTER (CCNSC).
51.32231 HISTORY OF CCNSC .
NUMBER AND TYPE OF COMPOUNDS TESTED AND RELATED STATISTICS.
CLINICALLY USEFUL COMPOUNDS IDENTIFIED BY CCNSC PROGRAM.
51.3224 METHODS USED FOR SCREENING POTENTIAL ANTICANCER AGENTS.
SEE ALSO: 51.3235 FOR EFFECT OF CHEMOTHERAPEUTIC AGENTS ON NORMAL TISSUES.
SEE ALSO: 51.32345 FOR EFFECT OF CHEMOTHERAPEUTIC AGENTS ON BIOCHEMICHEMICAL COMPOSITION AND METABOLISM OF CANCEROUS AND NORMAL SYSTEMS.
SEE ALSO: 51.320 FOR EFFECTS OF VARIOUS CHEMOTHERAPEUTIC AGENTS ON SPECIFIC TYPES OF CANCER CELLS.
SEE ALSO: 51.3314 FOR SCREENS OF HORMONAL AGENTS AND CHEMOTHERAPEUTIC AGENT EFFECTS ON ENDOCRINE AND RELATED TUMORS.
51.32241 GENERAL.
51.322412 PHILOSOPHY BEHIND CHOICE OF METHODS.
51.32242 METHODS USED AND PROPOSED NEW METHODS.
51.3224200 GENERAL.
51.3224201 USE OF TUMORS GROWING ON GRIDS IMPLANTED ON CHORIO-ALLANTOIC MEMBRANES OF CHICK EMBRYOS.
51.3224202 SCREENS EMPLOYING TUMORS GROWING IN PERFUSION SYSTEMS (PERFUSION OF ISOLATED ORGANS).
51.3224203 EXPLANT CULTURE METHODS.
51.32243 SCREENS INVOLVING MOUSE TUMORS IN VIVO.
51.32243001 GENERAL.
51.32243011 ADENOCARCINOMA 755.
51.32243012 ADENOCARCINOMA 1025.
51.32243031 CLOUDMAN MELANOMA S-91.
51.32243061 FRIEND VIRUS LEUKEMIA.
51.32243081 HEPATOMA 129.
51.32243121 LEWIS LUNG CARCINOMA.
51.32243122 LYMPHOID LEUKEMIA L1210 (IN VIVO).
51.32243123 LYMPHOSARCOMA P-1798.
51.32243124 LGH LEUKEMIA (CAUSES TRANSPLANTABLE LEUKEMIA IN FISCHER/344 RATS).
51.32243131 MAMMARY TUMORS (PRIMARY) IN C3H AND C3HO MICE.
51.32243151 OSTEOGENIC SARCOMA HE-10734.
51.32243161 PLASMA CELL TUMORS IN MICE (LPC-1; LCF-1).
51.32243191 SARCOMA 180.
51.32244 SCREENS INVOLVING RAT TUMOR IN VIVO.
51.32244041 DUNNING LEUKEMIA (ASCITES).
51.32244041 DUNNING LEUKEMIA (SOLID).
51.32244121 LYMPHOMA 8.
51.32244131 MURPHY-STURM LYMPHOSARCOMA.
51.32244231 WALKER 256 (SUBCUTANEOUS).
51.32244232 WALKER 256 (INTRAMUSCULAR).
51.3224501 SCREENS INVOLVING HAMSTER TUMORS.
51.32245011 HAMSTER ADENOCARCINOMA OF SMALL BOWEL.
51.32245012 HAMSTER ADENOCARCINOMA OF ENDOMETRIUM.
51.32245013 HAMSTER ADENOCARCINOMA OF DUODENUM.
51.32245014 HAMSTER MYOSARCOMA.
51.3224502 SCREENS INVOLVING INTRACEREBRAL TRANSPLANTED TUMORS.

51.32246 SCREENS INVOLVING TRANSPLANTED HUMAN TUMORS (IN HETEROLOGOUS HOSTS).
51.3224601 HUMAN (BLADDER) CANCER TRANSPLANTED INTO HAMSTER CHEEK POUCHES. H.AD. NO. 1, AND GW-39.
51.3224602 HAD-1 IN EMBRYONATED EGGS.
51.32247 SCREENS INVOLVING CULTURED CELLS AND TISSUE CULTURE.
51.32247051 EPIDERMOID CARCINOMA (HUMAN) OF THE NASOPHARYNX IN KB CELLS.
51.32247121 L1210 (IN VITRO).
SEE ALSO: 51.32242122 FOR L1210 IN VIVO.
51.32247141 NORMAL TISSUES CULTURES OF NORMAL TISSUES USED TO SCREEN FOR TOXICITY.
51.32248 SCREENS FOR ANTICANCER ACTIVITY EFFECT OF AGENTS ON MICROBIAL SYSTEMS.
51.3224801 GENERAL.
51.3224802 INHIBITION OF ROUS FOCI (ROUS FOCI INHIBITION TEST).
51.3224803 INDUCTION OF LYSOGENIC BACTERIA (ILB) BY ANTICANCER AGENTS.
51.3225 LIST OF COMPOUNDS TESTED AND THEIR ACTIVITY (OR LACK OF ACTIVITY).
51.323 EXPERIMENTAL THERAPEUTICS - RELATED PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES OF CANCER CHEMOTHERAPEUTIC AGENTS IN ANIMALS AND IN VITRO.
SEE ALSO: 51.314 FOR METHODS OF PREVENTING TOXICITY (IF GENERALLY APPLICABLE TO ALL TYPES OF ANTICANCER THERAPY).
SEE ALSO: 51.220122 FOR CORRELATION OF FINDINGS IN ANIMALS WITH EFFECTS ON HUMAN TUMORS.
SEE ALSO: 51.2201 FOR SELECTION OF PATIENTS AND CHOICE OF CHEMOTHERAPEUTIC AGENTS (PREDICTING RESPONSE).
51.3231 GENERAL.
51.32312 CORRELATION OF FINDINGS IN VITRO WITH EFFECT ON HUMAN TUMORS.
51.3232 STUDIES OF ADMINISTRATION OF CANCER CHEMOTHERAPEUTIC AGENTS TO ANIMALS.
SEE ALSO: 51.32304 FOR EFFECT OF CHEMOTHERAPEUTIC AGENTS ON CELLS.
51.32321 GENERAL.
51.32322 REGIONAL PERFUSION AND INFUSION TECHNIQUES IN ANIMALS.
INTRAARTERIAL AND INTRALYMPHATIC INFUSIONS AND METHODS USED TO STANDARDIZE PHARMACOLOGY OF ANTICANCER AGENTS.
USE OF ORGAN PERFUSION METHODS.
51.32323 OPTIMUM DOSAGE METHODS STUDIED IN VIVO; DOSE SIZE, INTERVAL BETWEEN DOSES, AND LENGTH OF TREATMENT TO DOSE RESPONSE CORRELATIONS AND RELATED MODELS; CELL KILL KINETICS.
51.32324 USE OF IN VITRO METHODS TO DETERMINE DOSE AND METHOD OF ADMINISTRATION.
51.32325 USE OF CARRIERS WHICH LOCALIZE AGENTS IN THE TUMOR.
SEE ALSO: 51.21374 FOR USE OF TUMOR-SPECIFIC ISOTOPE CARRIERS USED IN TUMOR DIAGNOSIS.
51.323252 USE OF ANTIBODIES OR ANTIGENS TO CARRY CHEMOTHERAPEUTIC AGENTS TO THE TUMOR (IMMUNOCHEMOTHERAPY).
51.323253 USE OF CHEMOTHERAPEUTIC AGENTS LINKED TO PROTEINS AND OTHER COMPOUNDS TAKEN UP BY PINOCYTOTIC TUMOR CELLS OR WHICH PENETRATE TUMOR CELLS.
51.32326 USE OF ADJUVANTS TO INCREASE ANTICANCER EFFECT OR TO REDUCE TOXIC REACTIONS IN VIVO; CYTOPROTECTANTS.
51.3232601 GENERAL.
51.3232602 USE OF ANTICOAGULANTS DURING CHEMOTHERAPY TO REDUCE METASTASIS.
51.3232603 USE OF HYPOXIA TO INCREASE EFFECT OF CHEMOTHERAPEUTIC AGENTS ON TUMORS.
51.3232604 PROTECTION AGAINST BONE MARROW DEPRESSION AND LEUCOPENIA.
USE OF CHEMICAL AGENTS (CATECHOL AMINES, SEROTONIN ANTAGONISTS, ANTIHISTAMINES).
51.3232605 USE OF SUCH REAGENTS.
51.3232606 EFFECT OF HORMONES ON ACTIVITY OF ANTICANCER AGENTS.
51.32327 USE OF COMBINATION CHEMOTHERAPY (CHEMOTHERAPY OF TWO OR MORE AGENTS.
51.32328 ALTERATION OF PHYSICAL ENVIRONMENT DURING CANCER CHEMOTHERAPY IN ANIMALS.
51.323281 GENERAL.
51.323282 USE OF HYPOTHERMIA AND HYPERTHERMIA DURING CHEMOTHERAPY.
51.3233 PHARMACOLOGY OF CANCER CHEMOTHERAPEUTIC AGENTS.
SEE ALSO: 51.313 FOR EFFECT OF THESE AGENTS ON TUMOR CELLS.
SEE ALSO: 51.324002 FOR MECHANISM OF ACTION OF ALKYLATING AGENTS (GENERAL).
SEE ALSO: 51.325 THROUGH 51.329 FOR MECHANISM OF ACTION OF OTHER SPECIFIC AGENTS.
51.32331 GENERAL.
51.32332 DEVELOPMENT OF RESISTANCE TO CANCER CHEMOTHERAPEUTIC AGENTS.
MECHANISM OF DRUG RESISTANCE (GENERAL).
KINETICS OF DEVELOPMENT OF RESISTANCE.
SENSITIVE AND RESISTANT TUMOR STRAINS.
RELATION OF RESISTANCE TO ABILITY TO METABOLIZE THE AGENTS.
RELATION OF RESISTANCE TO EFFECT OF THE AGENTS ON NUCLEIC ACIDS OR PROTEINS.

STUDIES ON DRUG RESISTANT CELL LINES.
COLLATERAL SENSITIVITY.
LOSS OF DRUG PERMEABILITY (REDUCED PERMEABILITY).
LOSS OF KINASES AS A MECHANISM OF DRUG RESISTANCE.
SEE ALSO: 51.324004 FOR RESISTANCE TO ALKYLATING AGENTS.
SEE ALSO: 51.34025 FOR COMBINING SENSITIVITY TO REDUCTION IN CELLS OFTHE BIOCHEMICAL DRUG RESISTANCE (LACK OF CROSSREACTION BY CHEMOTHERAPEUTIC AGENTS AND REDUCTION).

51.32333 UPTAKE, ABSORPTION,TRANSPORT AND TISSUE OR SERUM LEVELS AND DISTRIBUTION AND EXCRETION OF CHEMOTHERAPEUTIC AGENTS (GENERAL) AND FACTORS THAT AFFECT THIS.
TRANSPORT BY PLASMA PROTEINS.
SEE ALSO: 51.32325 FOR USE OF CAMERAS.

51.32334 IN VIVO METABOLISM OF CHEMOTHERAPEUTIC AGENTS (GENERAL) AND FACTORS AFFECTING THIS IN VIVO.

51.32335 IN VITRO METABOLISM OF CHEMOTHERAPEUTIC AGENTS AND FACTORS AFFECTING THIS.

51.3234 MECHANISM OF ACTION OF CANCER CHEMOTHERAPEUTIC AGENTS (GENERAL).
SEE ALSO: 51.3235 FOR ADVERSE EFFECTS OF THESE AGENTS ON SPECIFIC TISSUES.

51.32341 GENERAL.
51.323411 OPEN.
51.323412 STUDIES OF CHEMOTHERAPEUTIC AGENTS AND THEIR EFFECT ON TISSUE CULTURE CELLS IN VITRO (GENERAL ASPECTS).
51.3234124 ON LEUCOCYTES.

51.32342 STRUCTURE-ACTIVITY RELATIONS AND RELATED STUDIES OF ANTI-TUMOR ACTIVITY (SYNERGISTS).
51.3234201 GENERAL; CORRELATION OF STRUCTURE OR PHYSICAL PROPERTIES WITH ANTICANCER ACTIVITY (GENERAL).
51.3234202 CORRELATION OF ANTICANCER ACTIVITY WITH ANTICARCINOGENIC ACTIVITY.
51.3234203 CORRELATION OF ANTICANCER ACTVITY WITH ABILITY TO BIND METALS.
51.3234204 CORRELATION OF ANTICANCER ACTIVITY WITH ABILITY TO BIND TO LIPIDS OR PROTEINS OR OTHER CELL CONSTITUENTS.
51.3234205 CORRELATION OF ANTICANCER ACTIVITY WITH METABOLISM BY CANCER CELLS AND INHIBITION OF SPECIFIC ENZYMES IN THESE CELLS.
51.3234206 SYNERGISM OF CHEMOTHERAPEUTIC AGENTS AND SYNERGISTIC AGENTS.
SEE ALSO: 51.3240401 FOR POTENTIATION OF DDUG BY DHSB.

51.32343 EFFECT OF CANCER CHEMOTHERAPEUTIC AGENTS ON CYTOLOGY, MORPHOLOGY, AND HISTOLOGY OF NORMAL OR TUMOR CELLS (IN VIVO OR IN VITRO).
SEE ALSO: 51.32344 FOR OTHER CYTOTOXIC EFFECTS AND CYTOTOXICITY IN GENERAL.
SEE ALSO: 51.51 FOR TUMOR CYTOLOGY (GENERAL).

51.323431 GENERAL.
51.3234311 UPTAKE AND INTRACELLULAR DISTRIBUTION OF ANTICANCER AGENTS.

51.323432 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON CHROMOSOMES.
CHROMOSOMAL CHANGES DURING CHEMOTHERAPY.
EFFECTS OF CHEMOTHERAPEUTIC AGENTS ON CHROMOSOMES IN VITRO.
SEE ALSO: 51.512 FOR CHROMOSOME ABNORMALITIES IN CANCER PATIENTS.

51.323433 OTHER EFFECTS OF CHEMOTHERAPEUTIC AGENTS ON CELL NUCLEI.

51.323434 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON THE CYTOPLASM AND SUB-CELLULAR PARTICLES IN CYTOPLASM.
51.3234341 GENERAL.
51.3234342 EFFECT ON MITOCHONDRIA.
51.3234343 EFFECT ON RIBOSOMES, POLYRIBOSOMES, AND MICROSOMES.
51.3234344 EFFECT OF LYSOSOMES AND THEIR ROLES IN PRODUCING TUMOR REGRESSION DURING CHEMOTHERAPY.
51.3234345 EFFECT ON OTHER PARTICULATE FRACTIONS.
51.3234346 EFFECT ON SOLUBLE FRACTION AND CELL SAP OR SUPERNATANT.
51.3234347 EFFECT ON CELL MEMBRANES.
SEE ALSO: 51.3254 FOR EFFECT OF METHOTREXATE ON TUMOR CELL MEMBRANES.

51.32344 EFFECT OF CANCER CHEMOTHERAPEUTIC AGENTS ON CELL GROWTH, DIVISION, DIFFERENTIATION, AND "VIABILITY".
51.323441 GENERAL.
51.323442 CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS IN GENERAL.
51.323443 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON RATE OF GROWTH, CELL DIVISION, AND DIFFERENTIATION IN VIVO.
EFFECT OF CHEMOTHERAPEUTIC AGENTS ON " TAKE" OF INJECTED CELLS.
EFFECT OF TUMOR LOCATION ON ACTION OF ANTICANCER AGENTS.
SEE ALSO: 43.363 FOR ANTIMITOTIC AGENTS IN GENERAL.

51.3234434 IN VITRO MECHANISMS BY WHICH CHEMOTHERAPEUTIC AGENTS CAUSE TUMOR REGRESSION.
ROLE OF ENZYMES AND PROTEIN BREAKDOWN IN TUMOR REGRESSION.
SEE ALSO: 51.3234344 FOR ROLE OF LYSOSOMAL ENZYMES.
51.323444 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON RATE OF CELL DIVISION AND CELL "VIABILITY" AND "TRANSPLANTABILITY" IN VITRO.
SEE ALSO: 43.363 FOR ANTIMITOTIC AGENTS (GENERAL) AND THEIR ACTIVITY.
51.32345 EFFECT OF CANCER CHEMOTHERAPEUTIC AGENTS ON THE CHEMICAL CONSTITUTION, METABOLISM, AND BIOCHEMISTRY OF CELLS.
SEE ALSO: 51.6 FOR METABOLISM AND BIOCHEMISTRY OF CANCER CELLS AND TISSUES.
51.323450 GENERAL.
51.323451 EFFECT ON NUCLEIC ACID CONTENT, METABOLISM, AND BIOSYNTHESIS.
EFFECT ON PURINE AND PYRIMIDINE, NUCLEOSIDE, AND NUCLEOTIDE BIOCHEMISTRY.
51.323452 EFFECT ON PROTEINS, AMINO ACIDS, AND ENZYMES.
51.3234521 GENERAL.
51.3234522 EFFECT ON AMINO ACIDS.
51.3234524 EFFECT ON ENZYMES.
51.323453 EFFECT ON LIPIDS.
51.323454 EFFECT ON CARBOHYDRATES, GLYCOLYSIS, KREBS CYCLE, ATP PRODUCTION, RESPIRATION, ENERGY TRANSFER AND HEAT TRANSFER IN GROWTH.
51.323455 EFFECT ON VITAMINS.
51.3235 PRECLINICAL TOXICOLOGY OF CANCER CHEMOTHERAPEUTIC AGENTS ANDCYTOTOXIC EFFECTS OF CHEMOTHERAPEUTIC AGENTS IN GENERAL.
EFFECT OF CHEMOTHERAPEUTIC AGENTS ON SPECIFIC TYPES OF NORMAL TISSUES AND ORGAN SYSTEMS.
SEE ALSO: 51.3234 FOR EFFECT ON CYTOLOGY, MORPHOLOGY, GROWTH, CELL DIVISION, AND CELL BIOCHEMISTRY AND EFFECT ON TISSUE CULTURES.
51.32351 GENERAL.
51.323511 OPEN.
51.323512 LETHAL DOSE STUDIES AND METHODS FOR MEASURING LETHAL DOSE.
STUDIES OF TOXICITY ON CULTURED CELLS IN VITRO.
51.323513 EFFECT ON RAPIDLY DIVIDING TISSUES (AS COMPARED WITH SLOWLY DIVIDING TISSUES) IN GENERAL.
EFFECT ON REGENERATING LIVER.
EFFECT ON WOUND HEALING.
51.323514 EFFECT ON IMMUNITY OF HOST TO STIMULATION OF IMMUNE MECHANISMS BY CHEMOTHERAPEUTIC AGENTS IN GENERAL.
51.32352 EFFECT OF CHEMOTHERAPEUTIC AGENTS ON CARDIOVASCULAR, HEMAPOIETIC, RETICULO-ENDOTHELIAL, AND LYMPHATIC SYSTEMS.
51.323525 EFFECT ON RETICULOENDOTHELIAL, HEMOPOIETIC AND LYMPHOPOIETIC CELLS AND LYMPHATIC SYSTEMS AND CELLS.
EFFECT OF CHEMOTHERAPEUTIC AGENTS ON PHAGOCYTOSIS.
51.323526 EFFECT ON HEPATIC CELLS, BONE MARROW AND SPLEEN MEGALOBLASTOSIS.
SEE ALSO: 51.323514 FOR EFFECT ON HOST IMMUNITY.
51.32353 TOXIC EFFECTS OF CHEMOTHERAPEUTIC AGENTS ON MUSCLE.
51.32354 TOXIC EFFECTS OF CHEMOTHERAPEUTIC AGENTS ON KIDNEY, URINARY TRACTS, AND BLADDER.
51.323552 TOXIC EFFECTS ON LUNG.
51.323553 TOXIC EFFECTS ON LIVER.
51.323554 TOXIC EFFECTS ON GASTROINTESTINAL TRACT.
51.323555 TOXIC EFFECTS ON GONADS AND REPRODUCTIVE SYSTEM.
51.323556 TOXIC EFFECTS ON OTHER ENDOCRINE SYSTEMS.
51.32356 TOXIC EFFECTS ON NERVOUS SYSTEM AND BRAIN.
51.323572 TOXIC EFFECTS ON EYES AND VISION.
51.323573 TOXIC EFFECTS ON EARS AND HEARING.
51.323582 TOXIC EFFECTS ON CONNECTIVE TISSUES AND RELATED STRUCTURES (JOINTS).
51.323583 TOXIC EFFECTS ON SKIN.
51.323584 TOXIC EFFECTS ON BONES, TEETH, AND MINERALIZED STRUCTURES IN GENERAL.
51.3235842 TOXIC EFFECTS ON BONES.
51.3236 EFFECT OF CANCER CHEMOTHERAPEUTIC AGENTS IN UNUSUAL SYSTEMS.
SEE ALSO: 51.3224 FOR USE OF THESE EFFECTS TO SCREEN FOR ANTICANCER AGENTS.
51.323601 EFFECT ON VIRUSES.
51.323602 EFFECT ON BACTERIOPHAGE.
ABILITY OF CHEMOTHERAPEUTIC AGENTS TO INDUCE LYSIS OF LYSOGENIC BACTERIA.

51.323603 EFFECT ON BACTERIA.
51.323604 EFFECT ON OTHER FUNGI (MOLDS, YEASTS).
51.323605 EFFECT ON PROTOZOA.
51.323606 EFFECT ON OTHER MICROBIAL SYSTEMS.
51.323607 EFFECT ON VARIOUS INVERTEBRATES (INCLUDING PARASITIC WORMS).
51.324 PRE-CLINICAL STUDIES OF ALKYLATING AGENTS (GENERAL ASPECTS ONLY).
THEIR EFFECTS ON TUMORS AND FACTORS AFFECTING THIS.
SEE ALSO: 46.33 FOR ALKYLATING AGENTS AS MUTAGENS, MECHANISM OF MUTAGENIC ACTIVITY, AND EFFECT ON NUCLEIC ACIDS.
51.32400 SELECTED BROAD TOPICS.
51.324001 OPEN.
51.324002 RELATION OF STRUCTURE TO ANTICANCER AND THEIR METABOLISM ACTIVITY AND MECHANISM OF ANTICANCER ACTION OF ALKYLATING AGENTS AND COMPARISON OF ALKYLATING AGENTS TO RADIATION.
51.324003 FACTORS AFFECTING THE ANTITUMOR ACTIVITY OF ALKYLATING AGENTS.
EFFECT OF HORMONES.
EFFECT ON CELL TRANSPORT.
51.324004 RESISTANCE TO ALKYLATING AGENTS AND MECHANISMS OF THIS RESISTANCE.
CROSS RESISTANCE OF TUMORS TO ALL ALKYLATING AGENTS AND TO REDUCTION IF THEY ARE RESISTANT TO ONE.
51.324005 PROTECTION OF NORMAL TISSUE AGAINST THE EFFECTS OF ALKYLATING AGENTS.
51.3240101 ANILINE MUSTARD.
51.3240102 AMINO ACID MUSTARDS (GENERAL).
51.3240103 ADL-4S (SEE NAMS).
51.3240104 AGN 1414 (NET NBL ETC; 5-BROMO-3-BENZO THIENYL METHYLAMINE HYDROCHLORIDE).
51.3240105 1,6-AZIRIDINE STEROIDAL ALKYLATING AGENTS.
51.3240201 BCNU (1,3-BIS-(2-CHLOROETHYL)-1-NITROSOUREA).
SEE ALSO MCNU FOR MONO DERIVATIVE.
51.3240202 BUSULFAN (MYLERAN).
51.3240203 P BENZOQUINONE.
51.3240301 CHLORAMBUCIL (LEUKERAN).
51.3240302 CYCLOPHOSPHAMIDE (ENDOXAN; CYTOXAN); NATURE OF THE ANTICANCER METABOLITES OF CYTOXAN.
CYTOXAN - SEE CYCLOPHOSPHAMIDE.
ENDOXAN - SEE CYCLOPHOSPHAMIDE.
HN2 - SEE MECHLORETHAMINE.
LEUKERAN - SEE CHLORAMBUCIL.
51.3240303 CB-1850.
51.3240304 CFNU (3-CYCLOHEXYL-1,1-(2-FLUOROETHYL)-1-NITROSOUREA.
51.3240305 N,N-BIS(2-CHLOROETHYL)ANILINE.
51.3240306 CCNU; 1(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA.
51.3240401 DDUG; 4,4'-DIACETYLDIPHENYLUREA-BIS(GUANYL HYDRAZONE).
POTENTIATION OF THIS AGENT BY HYDROXYSTILBAMIDINE (DHSB).
TOXICITY DUE TO FLUOROACETATE PRODUCTION FROM CFNU.
51.3240402 DIPINE (TETRAETHYLENIMIDE-N-N-PIPERAZINE DIPHOSPHORIC ACID).
51.3240403 DAAP; DIALLYL BAZIRIDINOPROPIONAMIDE.
51.3240901 ISOPROPYLMETHANE SULFATE.
51.3241301 MANNOMUSTINE.
51.3241301 MECHLORETHAMINE ("NITROGEN MUSTARD"; HN2).
MELPHALAN - SEE PHENYLALANINE MUSTARD.
MYLERAN - SEE BUSULFAN.
"NITROGEN MUSTARD"; SEE MECHLORETHAMINE.
51.3241303 MANNITOL, DERIVATIVES AND OTHER ALKYLATING AGENTS AND SUGARS.
51.324130301 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL (DBD).
51.324130302 1,6-DIBROMO-1,6-DIDEOXY-D MANNITOL (DBM MYELOBROMOL).
51.324130303 TETRAMEZYL-MANNITOL R52 (CH3-SO2- ON POSITIONS 1,2,5,6 OF MANNITOL).
51.324130304 DEGRANOL.
51.324130305 MANNITOL-MYELERAN.
51.324130306 DIBROMOMANNITOL.
51.324130307 DIBROMODULCITOL.
51.3241304 METHYL BIS(3-MESYLOXY PROPYL)AMINE HYDROCHLORIDE.
51.3241305 BIS(3-MESYLOXY PROPYL)AMINE HYDROCHLORIDE.
51.3241306 MNU; METHYL NITROSO UREA.
51.3241307 METHYL METHANE SULFONATE.
51.3241308 1-METHYL-2-P(ISOPROPYLCARBAMOYL)BENZYL HYDRAZINE HYDROCHLORIDE (NATULAN).
51.3241309 MCNU; 1-MONO(2-CHLOROETHYL)-1-NITROSOUREA.
NAPTHYLAMINE MUSTARD.

51.3241401 OMF-59.
PAM - SEE PHENYLALANINE MUSTARD.
SEE ALSO: 51.3241602 FOR OMF-59.
51.3241402 NITROSOUREAS AS A CLASS.
SEE ALSO BCNU, CENU.
51.3241403 NAMS; N,N-BIS(2-METHYANOL SULFONOXYETHYL)P-NITROSOANILINE (ADL-50, NSC 79423).
51.3241404 NITROGEN MUSTARD N-OXIDE.
51.3241601 L-PHENYLALANINE MUSTARD (PAM; L-SARCOLYSIN; MELPHALAN; CB-3025).
SARCOLYSIN - SEE PHENYLALANINE MUSTARD.
51.3241602 PHOSPHORODIAMIDIC ACIDS (OMF-59 (N,N-BIS(2-CHLOROETHYL)PHOSPHORODIAMIDIC ACID)) OPEN-RING COGENER OF CYTOXAN).
51.32419191 S-191.
51.3241946 S-46.
51.3241973 S-73.
51.3242001 TRIETHYLENEMELAMINE (TEM).
51.3242002 TRIETHYLENETHIOPHOSPHORAMIDE (THIO-TEPA).
51.3242003 2,3,5-TRISETHYLENEIMINO-BENZOQUINONE (TRENIMON).
51.3242004 TRYPTOPHANE MUSTARD (5-BIS(2-CHLOROETHYL)AMINO TRYPTOPHANE).
51.3242101 URACIL MUSTARD.
51.3243 SPECIFIC CLASSES OF ALKYLATING AGENTS (TAKEN AS A GROUP).
51.32431 GENERAL.
51.32433 ETHYLENEIMINE (AZIRIDINE, EPIMINE) COMPOUNDS, AS A GROUP.
51.32434 PHOSPHOROUS ALKYLATING AGENTS.
51.32435 SULFONIC ACID ESTERS, AS A GROUP.
X 51.32436 HALOGENATED SUGARS (BROMOMANNITOLS).
51.325 PRE-CLINICAL STUDIES ON ANTIMETABOLITES AS RELATED TO THEIR ANTICANCER ACTIVITY.
51.3251 GENERAL.
51.3252 PRE-CLINICAL STUDIES ON NUCLEIC ACID ANALOGS AND OTHER NUCLEIC ACID ANTIMETABOLITES AS RELATED TO THEIR ANTICANCER PROPERTIES.
SEE ALSO: 51.3253 FOR GLUTAMINE ANTAGONISTS (DON ; AZASERINE) THAT INHIBIT PURINE BIOSYNTHESIS.
51.325200 GENERAL.
51.32520101 AZAURACIL.
51.32520102 ARABINOSYL 6MD.
51.32520103 ADENOSINE N-OXIDE.
SEE ALSO: 51.32520401 FOR DEOXYADENOSINE N-OXIDES.
51.32520104 6-AZAURIDINE.
51.32520105 ARABINOFURANOSYL ADENOSINE (ARA A) AND DERIVATIVES AND (ARA ATP).
51.32520106 5-AZACYTIDINE.
51.32520201 5-BROMO-5-FLUORO-6-METHOXY-DIHYDRO-2'-DEOXY URIDINE.
51.32520301 CYTOSINE ARABINOSIDE (ARA C).
1,BETA-D-ARABINOFURANOSYL CYTOSINE.
51.32520401 2' AND 3'-DEOXYADENOSINE DERIVATIVES AND THEIR N-OXIDES (SLOWLY REDUCED; USED TO GIVE PARENT COMPONENTS).
51.32520801 HYDROXYAMINO DERIVATIVES OF PYRIMIDINES, AS A GROUP.
51.32520601 5-FLUOROURACIL DEOXYRIBOSIDE (FUDR).
51.32521301 6MP.
SEE ALSO: 51.32520102 FOR ARABINOSYL 6MP.
51.32521306 6-METHYL MP AND 6-METHYL MR RIBOSIDE.
51.32522001 TRIFLUOROMETHYL URACIL.
51.32522002 TRIFLUOROMETHYL DEOXYURIDINE.
PRODUCTION OF HYPOCALCEMIA BY THIS AGENT.
51.3253 PRECLINICAL STUDIES OF AMINO ACID ANTIMETABOLITES AND AMINO ACIDS AS RELATED TO THEIR ANTICANCER PROPERTIES.
51.325300 GENERAL.
51.3253011 AZASERINE (O-DIAZOACETYL-L-SERINE) (A GLUTAMINE ANTAGONIST).
51.3253031 O-CARBAMYLSERINE (A GLUAMINE ANTAGONIST).
51.3253032 L-CYSTEINE USED TO INHIBIT MELANOMA GROWTH.
51.3253041 DON (6-DIAZO-5-OXO-L-NORLEUCINE) (A GLUTAMINE ANTAGONIST).
51.3253051 ETHIONINE.
51.3253071 GAMMA-GLUTAMYLHYDRAZIDE (A GLUTAMINE ANTAGONIST).
51.3253081 HYDROXYLYSINE (A GLUTAMINE ANTAGONIST).
51.3253131 METHIONINE SULFOXIMINE (A GLUTAMINE ANTAGONIST).
51.3253201 TRIFLUORLEUCINE.
51.3254 PRECLINICAL STUDIES OF ANTIFOLIC AGENTS (METHOTREXATE, AMETHOPLEREN) AS RELATED TO THEIR ANTICANCER PROPERTIES.
INCREASE IN DIHYDROFOLATE REDUCTASE AFTER TREATMENT OF TUMORS WITH ANTIFOLIC AGENTS.

ABSORPTION OF METHOTREXATE ON TUMOR CELL MEMBRANES AND EFFECT ON MEMBRANE PERMEABILITY.
UPTAKE OF METHOTREXATE INTO LEUKEMIC CELLS.
AMETHOPLEREN TRANSPORT BY TUMOR CELLS.
ANTICANCER ACTION OF HOMOFOLIC ACID.
STIMULATION OF UPTAKE OF METHOTREXATE BY TRIAMTERENE.

51.3255 PRE-CLINICAL STUDIES OF VITAMIN ANTIMETABOLITES AND OTHER VITAMIN-RELATED THERAPY (VITAMIN DEFICIENT DIETS) FOR CANCER.
51.32551 GENERAL ASPECTS OF VITAMIN-RELATED THERAPY OF CANCER.
51.32552 THERAPY RELATED TO VITAMIN A, K, AND D.
INHIBITION OF TUMORS BY HIGH DOSES OF VITAMIN A.
51.32553 THERAPY RELATED TO VITAMIN B6 AND NIACIN.
INHIBITION OF TUMORS BY 4-DEOXYPYRIDOXINE.
51.32554 THERAPY RELATED TO OTHER B VITAMINS AND B VITAMINS IN GENERAL.
51.325541 GENERAL.
51.325542 THERAPY RELATED TO RIBOFLAVIN ANTAGONISTS SUCH AS U-2112.
51.325543 THERAPY RELATED TO NICOTINAMIDE ANALOGS.
51.32555 THERAPY RELATED TO VITAMIN D.
51.3256 PRE-CLINICAL STUDIES OF ANTIMETABOLITES OF FATTY ACIDS AND OTHER LIPIDS AS RELATED TO ANTICANCER PROPERTIES.
51.3257 PRECLINICAL STUDIES OF ANTIMETABOLITES OF CARBOHYDRATES AND OTHER CARBOHYDRATE ANALOGS.
SEE ALSO: 51.1303 FOR ALKYLATING AGENTS, DERIVATIVES AND SUGARS.
SEE ALSO: 51.326105 FOR ANTICANCER ACTIVITY OF ALDEHYDES.

51.326 PRE-CLINICAL STUDIES OF OTHER SYNTHETIC ORGANIC COMPOUNDS AND INORGANIC COMPOUNDS.
51.3261 PRECLINICAL BIOLOGICAL STUDIES OF SPECIFIC SYNTHETIC ORGANIC COMPOUNDS.
SEE ALSO: 51.322 FOR SYNTHESIS AND SCREENING OF THESE COMPOUNDS.
SEE ALSO: 51.32745304 FOR NATURALLY OCCURRING ALDEHYDES.
SEE ALSO: 51.32610104 FOR ACRIDINE AND DERIVATIVES IN GENERAL.
51.326100 GENERAL.
ANTICOAGULANTS.
METAL COMPLEXES (COMPLEXES OF SUBSTITUTED SULFINIC ACIDS).
51.32610101 ACENAPHTHALENES AND RELATED COMPOUNDS (AZACENAPTHALENES, AZAPYRACENES).
51.32610102 ACETOXYOXAMIDE.
51.32610103 6'-AMINOCHRYSENE (CHRYSENEX).
51.32610104 ACRIDINE AND DERIVATIVES.
SEE ALSO: 51.32610401 FOR DMMA, 1-NITRO-9-AMINO ACRIDINE, CC 283.
51.32610105 ALDEHYDES (GENERAL).
51.32610106 ALLYL UREAS AND DIALLYLUREAS.
51.32610107 ANTICOAGULANTS.
51.32610301 CHLOROQUINE.
51.32610302 COAGULANTS, CEAN, CAPROIC TROSYLOL, THROMBOPLASTIN.
51.32610801 HYDROXYUREA AND ITS DERIVATIVES.
51.32610802 HEXADIMETHRINE BROMIDE.
51.32611001 JANUS GREEN B; INHIBITION OF ABILITY OF CULTURED CELLS TO PRODUCE TUMORS IF INHIBITED WITH JGB.
51.32611101 KTS (U-7726; NSC 82116) (A COPPER CHELATING AGENT WITH BIS THIOSEMICARBAONE.
KETHOXAL BIS(THIOSEMICARBAZONE).
51.32611301 MALEURIC ACID AND ITS ESTERS (MALEYLUREA).
51.32611302 METHYL METHANE SULFONATE (NSC 50256).
CURE OF LYMPHOMA 8 BY THIS AGENT.
51.32611303 METHYL HYDRAZINES.
51.3261130301 NATULAN (PROCARBAZINE).
51.32611304 METAL CHELATORS (GENERAL).
SEE ALSO: 51.32610403 FOR DITHIZONE AND OTHER METAL CHELATERS.
51.32611305 METAL CHELATES.
51.32611306 MIH, N-ISOPROPUL-ALPHA(2-METHYLHYDRAZINO)-P-TOLUAMIDE, NATULAX, PROCARBAZIDE.
51.32611307 1-METHYLNITROSOUREA.
51.32611401 NITROMIN.
51.32611601 PHTHALANILIDES, PHTHALAMIDINES, AND TEREPHTHALANILIDES AND OTHER CYCLIC IMIDES.
FORMATION OF LIPID COMPLEXES BY THESE AGENTS.
2-CHLOROTEREPHTHALANILIDE.
51.32611602 POLYANIONS (POLYCARBOXYLIC ACIDS; POLY-AROMATIC PHOSPHATES).
51.32611603 PHENANTHRIDINIUM (DIMIDIUM, ETHIDIUM, METAMIDINIUM, ISOMETAMIDIUM (IMDM)).

5

51.32611604 PERATHIEPINE.
51.32612001 TRIPARANOL.
51.32612002 THIOSEMICARBAZONES.
51.3261200201 PYRUVALDEHYDE (THIOSEMICARBAZONE) (PTS) AND ITS COPPER CHELATE.
51.3261200202 KTS (3-ETHOXY-2-OXOBUTYRALDEHYDE-BIS(THIOSEMICARBAZONE), KETHOXAL BIS(THIOSEMICARBAZONE).
51.3262 PRECLINICAL STUDIES ON INORGANIC CHEMICALS AND SELECTED ORGANO-METALLIC COMPOUNDS.
51.326200 GENERAL.
51.326201 EFFECT OF HYPEROXIA ON TUMORS.
EFFECT OF PEROXIDES (HYDROGEN PEROXIDE).
EFFECT OF HYPERBARIC OXYGEN OR INCREASED PO2.
51.326202 SELENIUM COMPOUNDS (SODIUM SELENITE; ORGANOSELENIUM COMPOUNDS).
51.326203 EFFECT OF CYANIDE ON TUMORS.
51.327 PRE-CLINICAL STUDIES OF CANCER CHEMOTHERAPEUTIC AGENTS FROM NATURAL SOURCES.
51.3270 GENERAL.
51.3271 PRE-CLINICAL STUDIES ON ANTI-CANCER SUBSTANCES FROM PLANTS.
51.32711 GENERAL.
51.3271200 GENERAL.
51.327120101 ARISTOLOCHIC ACID.
51.327120102 APOCANNOSIDE (FROM INDIAN DOGBANE OR AMERICAN INDIAN HEMP) (APOCYNUM CANNABINUM).
CATHARANTHUS ALKALOIDS: USE VINCA ALKALOIDS.
51.327120301 COLCHICINE AND DERIVATIVES (TRIMETHYL COLCHICINIC ACID).
SEE ALSO: 43.3632 FOR EFFECT OF COLCHICINE ON CELL DIVISION.
51.327120302 CALOTROPIN FROM RED MILKWEED EXTRACTS (ASCLEPIAS CURASSAVICA OR CANCERILLO).
51.327120303 CYMARIN (FROM INDIAN DOGBANE OR AMERICAN INDIAN HEMP (APOCYANUM CANNABINUM)).
51.327120304 CRINAMINE.
51.327120305 CRYPTOWOLLINE.
51.327120306 CUCURBITACINE (TRITERPENES), CURCURBITACIN B; INCLUDING ELATERICIN A.
51.327120307 CRINAMINE (NSC 88421).
51.327120308 CAMPTOTHECIN FROM CAMPTOTHECA ACAMINATA.
51.327120309 CONVALLARIA EXTRACTS.
51.327120310 COLUBRINA EXTRACTS.
51.327120401 DEOXYPODOPHYLLOTOXIN AND ELATERICIN.
SEE ALSO: 51.327120306 FOR CURCURBITACINS.
51.327120501 ELLIPTICINE (SEE ALSO METHOXYELLIPTICINE).
51.321720502 ELEPHANTIN AND ELEPHANTOPIN.
51.327120503 ELE.
51.327120801 HEMICHOLINIUMS.
51.327120802 HOLOCANTHONE FROM HOLOCANTHS.
51.327121201 LUNASINE.
51.327121202 LYCORINE.
51.327121203 LAPACHOL.
51.327121301 MONOCROTALINE.
51.327121302 METHOXYELLIPTICINE (SEE ALSO ELLIPTICINE).
51.327121303 5-METHOXYCANTHIN-6-ONE.
51.327121304 4-METHYLTHIOCANTHIN-6-ONE.
51.327121401 NERIIFOLIN FROM THEVETIA PERUVIANA.
51.327121402 NARCICLASINE FROM NARCISSUS.
51.327121601 PODOPHYLLIN AND PODOPHYLLOTOXIN AND DERIVATIVES (DEOXYPODOPHYLLOTOXIN).
51.327121602 PELTATIN (ALPHA AND BETA) FROM DIPHLLEIAL.
51.327121901 BETA SOLAMARINE (FROM SOLANUM DULCAMARA OR WOODY NIGHTSHADE OR BITTERSWEET).
51.327121902 BETA SITOSTEROL.
51.327122001 TYLOCREBRINE.
51.327122002 THALICARPINE FROM THALICTRUM DASYCORPUM.
51.327122002 TETRANDRINE.
51.327122004 TAXOL FROM TAXUS BREVIFOLIA.
51.327122201 VINCA ALKALOIDS FROM CATHARANTHUS.
51.3271222011 GENERAL.
51.3271222012 VINCRISTINE (LEUROCRISTINE, VCR) (ONCOVIN).
51.3271222013 VINBLASTINE (VINCALEUKOBLASTINE, VLB, VBR, VELBAN) AND DIHYDROVINBLASTINE (DHVLB).
INHIBITION OF CELL DIVISION DURING METAPHASE BY VLB.

51.3271222014 VINLEUROSINE (LEUROSINE).
51.3271222015 VINGLYCINATE SULFATE (VGL).
51.327122301 WITHAFERIN A.
51.32713 ANTICANCER EXTRACTS AND CRUDE PREPARATIONS FROM HIGHER PLANTS.
51.327130101 ABIES CONCOLOR.
51.327130102 AGAVE AMERICANA.
51.327130201 ROM BRYONIA ALBA L.
51.327130202 FROM BURSERA MICROPHYLLA.
51.327130301 CAESALPINIA GILLEISII.
51.327130701 GUTIERREZIA SAROTHRAE EXTRACTS.
51.327131301 MIRABILISMULTIFLORA.
51.327131501 OSTEOMELES SCHWERINAE.
51.327131801 RUMEX HYMENOSEPALUS.
51.327131901 SAVIN (FROM JUNIPERIS SABINA).
51.32714 ANTICANCER AGENTS FROM PLANTS WITH STRUCTURES RELATED TO CLASSES OF COMPOUNDS LISTED BELOW.
SEE ALSO: 51.327 AND 51.3276 FOR AGENTS WHICH COULD COME FROM PATIENTS OR ANIMALS OR MICROBES.
51.327141 ANTICANCER COMPOUNDS RELATED TO NUCLEIC ACIDS OR DERIVATIVES.
51.327142 ANTICANCER AMINO ACIDS OR PEPTIDES OR RELATED COMPOUNDS FROM PLANTS.
51.327143 ANTICANCER LIPIDS OR RELATED COMPUNDS (OTHER THAN STEROIDS) FROM PLANTS; LYSOLECITHIN.
51.327144 ANTICANCER STEROIDS FROM PLANTS.
CARDIAC GLYCOSIDES.
SAPONIN FROM ALER NEGUNDO.
SEE ALSO: 51.327122301 FOR WITHAFERIN A.
51.327145 ANTICANCER CARBOHYDRATES (INCLUDING NON-ALKALOID GLYCOSIDES) FROM PLANTS.
51.327146 ANTICANCER TERPENES AND TERPENOIDS FROM PLANTS (CUCURBITACINS, TRITERPENES).
51.3271471 QUINONES.
51.32715 OTHER TYPES OF ANTICANCER AGENTS FROM PLANTS.
51.3271501 COUMARINS (PENCEDAMIN AND ANALOGS).
51.3272 PRE-CLINICAL STUDIES ON ANTICANCER ANTIBIOTICS AND OTHER ANTICANCER FERMENTATION PRODUCTS.
SEE ALSO: 51.3252031 FOR CYTOSINE ARABINOSIDE.
SEE ALSO: 51.3253 FOR DON AND AZASERINE (GLUTAMINE ANTAGONISTS).
SEE ALSO: 51.33 FOR STEROID ANTIBIOTICS WHICH MAY BE LISTED THERE.
51.3272001 GENERAL.
51.32720011 ISOLATION AND TESTING OF NEW MATERIALS (AS SEPARATE FROM THE DETAILED STUDIES OF MECHANISM OF ACTION OF EXPERIMENTAL AGENTS.
51.3273 PRE-CLINICAL BIOLOGICAL STUDIES ON OTHER MICROBIAL AND FUNGAL SUBSTANCES (AND MICROBES) AS RELATED TO CANCER THERAPY.
SEE ALSO: 51.3275 FOR ANTICANCER ACTIVITY OF MICROBIAL ENZYMES.
51.327301 GENERAL.
51.327302 ANTICANCER ACTIVITY OF BACTERIAL POLYSACCHARIDES AND OTHER MICROBIAL ANTIGENS.
THE METHANOL-INSOLUBLE FRACTION OF TUBERCLE BACILLI (BCG STRAIN).
ANTICANCER ACTIVITY OF FREUNDS ADJUVANT.
51.327303 ONCOLYTIC BACTERIA AND OTHER ONCOLYTIC MICROBES (OTHER THAN VIRUSES).
USE OF CLOSTRIDIUM.
USE OF LEPTOSPIRAE.
51.327304 ANTICANCER ACTIVITY OF INTERFERONS AND OTHER AGENTS FROM VIRUSES.
USE OF INTERFERONS FOR ANTICANCER THERAPY.
INJECTION OF VIRUSES WHICH PRODUCE INTERFERONS IN THE HOST.
SEE ALSO: 51.45127 FOR INTERFERON IN RELATION TO VIRAL CARCINOGENESIS.
51.327305 ANTICANCER ACTIVITY OF OTHER AGENTS FROM VIRUSES.
51.327306 ONCOLYTIC VIRUSES.
EFFECT OF NEWCASTLE DISEASE VIRUS ON TUMORS.
BENNETTES' TUMOR-DESTROYING VIRUS.
ONCOLYSIS BY VACCINIA VIRUS, INFLUENZA VIRUS.
51.327307 ANTICANCER AGENTS FROM FUNGI.
51.32730700 GENERAL.
51.3273070901 ILLUDINS (FROM MUSHROOMS).
51.3273073 ANTICANCER AGENTS FROM MUSHROOMS (GENERAL).
51.3274 PRE-CLINICAL STUDIES ON TUMOR-INHIBITING EXTRACTS AND SUBSTANCES FROM ANIMAL SOURCES.
SEE ALSO: 51.3275 FOR ANTICANCER ACTIVITY OF IMMUNITY-RELATED SYSTEMS AND COMPLEMENT.
SEE ALSO: 51.744 FOR ANTICANCER ACTIVITY OF ANTIBODIES AND COMPLEMENT.

52

SEE ALSO: 51.3275 FOR ANTICANCER ACTIVITY OF ANIMAL ENZYMES.

51.32741 GENERAL.

51.32742 EXTRACTS FROM HUMAN AND MAMMALIAN SOURCES.

SEE ALSO: 51.74 FOR EFFECT OF SERA AND BLOOD ON TUMOR CELLS.

51.3274200 GENERAL.

51.3274201 ANTICANCER ACTIVITY OF NERVE EXTRACTS; PHOSPHOLIPIDS FROM NERVES.

51.3274202 ANTICANCER ACTIVITY OF RETINE AND LIVER EXTRACTS (SZENT-GYØRGYI).

SEE ALSO: 43.354181 FOR MORE GENERAL INFORMATION ABOUT RETINE.

51.3274203 GUINEA PIG SERUM AND ITS TUMOR INHIBITING PRINCIPLE (TIP).
IDENTITY OF TIP AS L-ASPARAGINASE.
SEE ALSO: 51.3275011 FOR ANTICANCER ACTIVITY OF ASPARAGINASE.

51.3274204 ANTICANCER ACTIVITY OF ELASTIN AND SUBSTANCES DERIVED FROM IT.

51.3274205 ANTICANCER ACTIVITY OF EXTRACTS (OTHER THAN ELASTIN) FROM CONNECTIVE TISSUES.

51.3274206 ANTICANCER ACTIVITY OF NUCLEIC ACIDS.

51.3274207 ANTICANCER ACTIVITY OF EXTRACTS FROM TUMORS AND TUMOR-BEARING HOSTS.

51.3274208 ANTICANCER ACTIVITY OF HEPARIN.

51.32743 EXTRACTS FROM VERTEBRATES OTHER THAN MAMMALS.

51.32744 EXTRACTS FROM INVERTEBRATES (MOLLUSC EXTRACTS).

SEE ALSO: 51.455304161 FOR INHIBITION OF VIRAL ONCOGENESIS BY MOLLUSC PADLINS.

51.327441301 INHIBITION OF TUMORS BY MERCENENE.

51.327443 EXTRACTS FROM INSECTS AND OTHER ARTHROPODS.

51.32745 SPECIFIC CLASSES OF ANTICANCER AGENTS FROM ANIMAL SOURCES.

51.327451 NUCLEIC ACIDS AND RELATED COMPOUNDS.
INHIBITION OF TUMOR CELLS BY DNA.

51.327452 AMINO ACIDS, PROTEINS (HISTONES), AND RELATED COMPOUNDS AND METABOLITES.
INHIBITION BY SPERMINE AND OTHER ALIPHATIC BASES.

51.327453 LIPIDS, PHOSPHOLIPIDS, STEROIDS, FATTY ACIDS, AND RELATED COMPOUNDS.

51.32745301 GENERAL.

51.32745302 ANTICANCER ACTIVITY OF IRRADIATED UNSATURATED FATTY ACIDS.

51.32745303 INHIBITION OF TUMORS BY GLYCERYL-PHOSPHORYL-CHOLINE AND PHOSPHORYL CHOLINE (ISOLATED FROM POST-COITAL FLUID AND FROM SEMINAL PLASMA OF RATS).

51.32745304 ANTICANCER ACTIVITY OF ALDEHYDES.
HEPATALDEHYDE.
CITRAL.
GLYCERALDEHYDE.
METHYL GLYOXAL.
2-OXOPROPANAL.
PYRUVALDEHYDE.

51.327454 CARBOHYDRATES, POLYSACCHARIDES, AND RELATED COMPOUNDS AND METABOLITES.
ANTICANCER ACTIVITY OF ANIMAL POLYSACCHARIDES (HEPARIN).
SEE ALSO: 51.3274208 FOR ANTICANCER EFFECTS OF HEPARIN.

51.3275 ANTICANCER ACTIVITY OF ENZYMES (FROM ANY SOURCE).

51.32750101 ANTICANCER ACTIVITY OF ASPARAGINASE.
SEE ALSO: 51.3274203 FOR TUMOR INHIBITION BY GUINEA PIG SERUM ASPARAGINASE.

51.32750301 EFFECT OF CATALASE ON TUMORS.

51.32750401 ANTICANCER ACTIVITY OF DISTREPTASE.

51.32750701 ANTICANCER ACTIVITY OF GLUTAMINASE.
SEE ALSO: 51.62218 FOR GLUTAMINE LEVELS AND METABOLISM IN TUMOR-BEARING HOSTS.

51.3275131 ANTICANCER ACTIVITY OF MYELOPEROXIDASE (FROM LEUKOCYTES) WHEN COMBINED WITH THIO-TEPA.

51.32761 NUCLEIC ACIDS.

51.32762 PROTEINS AND AMINO ACIDS.

51.32763 LIPIDS.

51.32764 CARBOHYDRATES.
SEE ALSO: 51.32745303 FOR INHIBITION OF TUMORS BY ALDEHYDES.

51.32765 VITAMINS.

51.3280 ANTICANCER ACTIVITY OF MISCELLANEOUS SUBSTANCES.

51.32801 ANTICANCER ACTIVITY OF ANESTHETICS AND OF PROLONGED ANESTHESIA.

53

51.33 PRE-CLINICAL ASPECTS OF HORMONE-RELATED THERAPY AND USE OF STEROIDS IN ANIMALS AND IN VITRO.
SEE ALSO: 51.47 FOR CARCINOGENIC ACTIVITY OF HORMONES AND ENDOCRINE-RELATED CARCINOGENESIS.

51.330 PRECLINICAL ASPECTS OF SPECIFIC TYPES OF CANCER.
GENERAL EFFECT OF HORMONES ON TUMOR GROWTH (GENERAL).
51.331 GENERAL.
51.3311 UPTAKE, TRANSPORT, AND METABOLISM OF EXOGENOUS AND/OR SYNTHETIC HORMONES BY TUMORS AND BY TUMOR-BEARING HOSTS.
METABOLISM OF DIETHYLSTIBESTROL.
SEE ALSO: 51.634 FOR BIOCHEMISTRY OF ENDOGENOUS AND/OR NORMAL STEROID HORMONES.
SEE ALSO: 51.7556 FOR EFFECTS OF CANCER ON THE ENDOCRINE ORGANS.
SEE ALSO: 51.76 FOR ENDOCRINE TUMORS AND RELATED ENDOCRINE PHYSIOLOGY.
51.3312 EFFECT OF HORMONE ANTAGONISTS AND ANTI-HORMONE SERA ON ANIMAL NEOPLASMS AND TUMOR CELLS IN VITRO.
51.3313 EFFECT OF REMOVING ENDOCRINE GLANDS (GENERAL) ON CANCER GROWTH.
51.3314 SCREENING METHODS INVOLVING HORMONE AND ENDOCRINE RELATED TUMORS.
DMBA-INDUCED AND TRANSPLANTABLE MMV ADENOCANCER.
R-35 MMV ADENOCARCINOMA (CANDWYENS).
11095 SQUAMOUS CELL CARCINOMA OF THE PROSTATE(CARCINOGENESIS AND PROGESTERONE DERIVATIVES).
R-3149 ACUTE MONOCYTIC LEUKEMIA (CORTICOIDS).
WR-6 ACUTE LYMPHOCYTIC LEUKEMIA.
LW/12 MYELOCYTIC LEUKEMIA.
51.3315 EFFECT OF HORMONES ON TUMOR METABOLISM.
51.332 EFFECT OF PITUITARY HORMONES OR THEIR ANTAGONISTS OR HYPOPHYSECTOMY.
USE OF ANTI-GROWTH HORMONE SERA.
51.333 EFFECT OF THYROID HORMONES OF THEIR ANTAGONISTS OR THYROIDECTOMY ON RATE OF CANCER GROWTH.
51.334 EFFECT OF PARATHYROID HORMONES OR THEIR ANTAGONISTS OR PARATHROIDECTOMY.
51.335 EFFECT OF ADRENAL HORMONES (CORTICOSTEROIDS) OR THEIR ANTAGONISTS, ADRENALECTOMY, OR ACTH.
51.3351 GENERAL.
51.3352 "LYMPHOCYTE DISSOLUTION" BY CORTICOSTEROIDS.
51.33521 GENERAL.
51.33522 REMOVAL OF LYMPHOCYTE CYTOPLASM BY "BUDDING" AND LOSS OF CYTOPLASM IN GENERAL.
51.33523 DESTRUCTION OF LYMPHOCYTE NUCLEI (LYMPHOCYTOKARYORRHEXIS) AND NUCLEAR "SHRINKAGE".
51.33524 SUPPRESSION OF MITOSIS.
51.33525 REGRESSION OF MOUSE LYMPHOMAS (P1798) AFTER CORTICOID TREATMENT.
51.3353 EFFECT ON CYTOLOGY AND HISTOLOGY OF OTHER TUMORS.
51.3354 EFFECT ON METABOLISM OF TUMORS AND TUMOR-BEARING HOSTS.
51.336 ANTICANCER EFFECT OF SEX HORMONES OR GONADOTROPHS OR THEIR ANTAGONISTS OR GONADECTOMY.
SEE ALSO: 44.132 FOR EFFECT OF HORMONES ON CELL DIVISION.
51.3361 GENERAL.
51.3362 EFFECT OF FEMALE SEX HORMONES (ESTROGENS, PROGESTINS) OR INHIBITING OF FEMALE SEX HORMONES SUCH AS U.11, 100 A, OR OF OVARIECTOMY.
SEE ALSO: 51.51654 FOR REDUCTION OF MULTINUCLEATION BY TUMOR CELLS.
SEE ALSO: 51.7702 FOR EFFECT OF PREGNANCY ON TUMOR DEVELOPMENT.
51.3363 EFFECT OF MALE SEX HORMONES (TESTOSTERONE) OR THEIR ANTAGONISTS OR OF CASTRATION (IN MALES).
51.33631 GENERAL.
51.33632 EFFECT OF MALE SEX HORMONES (TESTOSTERONE OR C^{1} TESTOLALACTONE).
51.33633 EFFECT OF CASTRATION AND ANTAGONISTS OF MALE SEX HORMONES ON TUMOR DEVELOPMENT.
51.3364 EFFECT OF GONADOTROPHINS.
51.337 ANTICANCER EFFECT OF SYNTHETIC STEROIDS (CYTOTOXIC STEROIDS)NOT INCLUDED ABOVE, AND OF STEROIDS IN GENERAL.
51.33700 GENERAL.
51.337C01 STRUCTURE-ACTIVITY RELATIONS OF ANTICANCER STEROIDS.
51.337211 U-18317 (CYTOTOXIC STEROID).
51.337212 U-14941 (CYTOTOXIC STEROID WITH UNSATURATED GAMMA-LACTONE RING).
51.338 ANTICANCER EFFECT OF OTHER ENDOCRINE AND NEUROENDOCRINE MATERIALS.
51.3382 EFFECT OF PINEAL HORMONES.
51.3383 EFFECT OF SEROTONIN AND RELATED TRYPTOPHAN DERIVATIVES.
51.3384 EFFECT OF HISTAMINE.

54

51.34 PRE-CLINICAL ASPECTS OF CANCER RADIATION THERAPY.
51.340 EFFECT OF TOXIC RADIATION ON TUMORS OF SPECIFIC ORGANS IN ANIMALS.
SEE ALSO: 35. FOR TOXIC EFFECT OF IRRADIATION ON VARIOUS TYPES OF TISSUES.
51.34025 PRECLINICAL RADIATION THERAPY OF LEUKEMIA/LYMPHOMA.
IRRADIATION SENSITIVITY OF L-1210 MURINE LEUKEMIA.
LACK OF CROSS-RESISTANCE TO IRRADIATION IN CELLS OF BACTERIA RESISTANT TO IRRADIATION.

51.34052 PRECLINICAL RADIATION THERAPY OF LUNG CANCER.
51.34065 RADIATION THERAPY OF BRAIN TUMOR IN ANIMALS.
51.341 GENERAL AND SELECTED BROAD TOPICS.
51.342 SPECIFIC TYPES OF RADIATION USED FOR NON-CLINICAL OR PRE-CLINICAL STUDIES.
51.3421 GENERAL.
51.3422 X-RAY; STUDIES OF X-IRRADIATION DOSAGE SCHEDULES AND MEASUREMENT OF DOSAGE.
SEE ALSO: 51.242 FOR CLINICAL DOSAGE STUDIES.
51.34221 GENERAL.
51.34222 IN VIVO X-RADIATION.
51.34223 EFFECT ON CANCER CELLS IN VITRO.
51.3423 ISOTOPES.
SEE ALSO: 51.34632 FOR USE OF BORON COMPOUNDS FOR NEUTRON-CAPTURE THERAPY.
USE OF TUMOR-SPECIFIC ANTIBODIES FOR THIS PURPOSE.
USE OF LABELLED PORPHYRINS.
USE OF NON-RADIOACTIVE ISOTOPES.
EFFECT OF D2O ON TUMORS.
51.342398 USE OF P32.
51.3424 NUCLEAR RADIATION FROM PARTICLE ACCELERATORS.
51.3425 LASERS AND OTHER USE OF VISIBLE LIGHT USED TO TREAT TUMORS.
PERFUSION OF DYES THROUGH TUMORS PRIOR TO LASER IRRADIATION AND OTHER METHODS OF PHOTOSENSITIZATION.
SEE ALSO: 35.91 FOR EFFECT OF LASER BEAMS ON BIOLOGICAL MATERIALS.
SEE ALSO: 56.1771 FOR USES OF LASERS IN MEDICINE (GENERAL).
51.343 EFFECT OF RADIATION ON TUMOR CELL BIOCHEMISTRY (CONSTITUENTS, METABOLISM, ENZYMES) IN VIVO AND IN VITRO.
51.3430 GENERAL.
51.3431 EFFECT ON NUCLEIC ACIDS, NUCLEIC ACID METABOLISM, AND RELATED ENZYMES.
51.3432 EFFECT ON PROTEINS AND AMINO ACIDS, ON PROTEIN AND AMINO ACID METABOLISM, AND RELATED ENZYMES.
51.3433 EFFECT ON LIPIDS, LIPID METABOLISM, AND RELATED ENZYMES.
INCREASE IN PHOSPHOLIPID SYNTHESIS AFTER IRRADIATION OF TUMORS.
51.3434 EFFECT ON CARBOHYDRATES AND CARBOHYDRATE METABOLISM (INCLUDING GLYCOLYSIS AND THE KREBS CYCLE) AND RELATED ENZYMES.
51.3435 EFFECT ON ENZYMES IN GENERAL AND ON LYSOSOMAL ENZYMES.
51.3437 EFFECT ON OTHER SPECIFIC COMPOUNDS.
51.343701 EFFECT ON SULFHYDRYL GROUPS.
51.344 RADIOSENSITIVITY AND REPAIR MECHANISMS; EFFECT OF RADIATION ON TUMOR CELL SURVIVAL, CELL DIVISION, AND CELL CYTOLOGY.
51.3441 GENERAL.
SEQUENCE OF POST-IRRADIATION EVENTS.
METHODS FOR MEASURING RADIOSENSITIVITY.
SENSITIVE AND RESISTANT TUMOR CELLS AND DIFFERENCES BETWEEN THEM.
51.3442 EFFECT OF RADIATION ON TUMOR CELL DIVISION.
RADIATION EFFECTS ON TUMORS AS A FUNCTION OF STAGE OF MITOTIC CYCLE AND OTHER BIOLOGICAL (CIRCADIAN) RHYTHYMS.
TUMOR CELL VIABILITY AFTER RADIATION AND METHODS FOR DETERMINING VIABILITY.
RADIOSENSITIVITY OF TUMOR CELLS IN VIVO AND IN VITRO.
51.3443 RECOVERY AND REPAIR PROCESSES AFTER IRRADIATION.
TIME COURSE OF THE RECOVERY PROCESS.
RECOVERY CURVES AND SURVIVAL KINETICS.
REPAIR OF SUBLETHAL RADIATION DAMAGE.
51.3444 GROWTH AND TRANSPLANTABILITY OF TUMORS AFTER IRRADIATION.
SEE ALSO: 51.3454 FOR EFFECT OF IRRADIATING THE HOST.
51.34441 GENERAL.
51.34442 EFFECT OF NON-VIABLE IRRADIATED CELLS ON THE "TAKE" AND GROWTH OF VIABLE CELLS.
THE "REVESZ EFFECT" (INHIBITION OF "TAKE" BY SMALL NUMBERS OF IRRADIATED CELLS AND STIMULATION BY LARGE NUMBERS OF IRRADIATED CELLS).
51.34443 EFFECT OF RADIATION ON THE ANTIGENICITY OF TUMOR CELLS AND ON ANTIBODY RESPONSE OF THE HOST.
SEE ALSO: 51.743 FOR TUMOR ANTIGENS (GENERAL).
SEE ALSO: 51.7435 FOR OTHER AGENTS WHICH MODIFY TUMOR ANTIGENICITY AND OTHER CYTOLOGICAL ALTERATION.
51.34444 EFFECT OF DOSE FRACTIONATION ON TUMOR TAKES.
51.3445 CHROMOSOME ABNORMALITIES AND OTHER CYTOLOGICAL ALTERATION RESULTING FROM IRRADIATION.
SEE ALSO: 51.512 FOR TUMOR CHROMOSOMES IN GENERAL.
51.34451 GENERAL.
51.34452 CHROMOSOME DAMAGE.
51.344521 GENERAL

51.344522 MECHANISM OF CHROMOSOME DAMAGE INDUCED BY RADIATION.
51.3446 SELECTED CELL TYPES RESULTING FROM IRRADIATION AND DIFFERENTIAL EFFECTS OF RADIATION ON DIFFERENT CELL LINES PRESENT IN TUMORS.
51.34461 GENERAL.
51.34462 RADIATION-INDUCED GIANT CELL FORMATION.
51.345 EFFECT OF RADIATION ON TUMOR HISTOLOGY AND MORPHOLOGY AND RELATED EFFECTS ON THE HOST.
51.3451 GENERAL.
51.3452 EFFECT ON BLOOD SUPPLY TO THE TUMOR.
EFFECT ON TUMOR MICROCIRCULATION.
RADIATION-INDUCED "SUPER-VASCULARIZATION" OF THE TUMOR.
"TUMOR-BED EFFECT".
SEE ALSO: 51.735 FOR MORE GENERAL ASPECTS OF BLOOD SUPPLY TO TUMORS.
51.3453 EFFECT OF RADIATION ON TUMOR SIZE.
51.3454 EFFECT OF IRRADIATING HOST ON THE "TAKE" AND GROWTH OF TRANSPLANTED TUMORS.
SEE ALSO: 51.3444 FOR THE EFFECT OF IRRADIATING TUMORS AND TUMOR CELLS.
SEE ALSO: 35. FOR EFFECT OF RADIATION ON SPECIFIC ORGANS.
51.345524 PRECLINICAL RADIATION THERAPY OF BREAST CANCER.
51.346 PRE-CLINICAL ASPECTS OF SENSITIZERS AND ADJUVANTS THAT INCREASE THE EFFECT OF RADIATION ON TISSUES.
51.3461 GENERAL.
METHODS OF ADMINISTERING THESE COMPOUNDS.
51.3462 INCREASED OXYGEN TENSION FOR SENSITIZING TUMORS.
USE OF INCREASED PRESSURE AND HYBAROXIC TECHNIQUES.
USE OF HYDROGEN PEROXIDE.
STUDIES OF OXYGEN TENSION IN TUMORS AND SURROUNDING AREAS.
SEE ALSO: 53.27 FOR OXYGENATION OF TISSUES (GENERAL).
51.3463 PRE-CLINICAL STUDIES OF NEUTRON-CAPTURE TECHNIQUES.
51.34631 GENERAL.
51.34632 USE OF BORON COMPOUNDS FOR BRAIN TUMORS IN EXPERIMENTAL ANIMALS.
51.3464 PRE-CLINICAL STUDIES OF HALOGENATED PYRIMIDINES AND OTHER DRUGS.
51.346400 GENERAL.
51.3464021 BROMOURIDINE DEOXYRIBOSIDE (BUDR).
51.3464081 OH UREA.
51.34641901 SH-BINDING AGENTS (N-ETHYL MALEIN IMIDE).
51.34641601 PORPHYRINS (COPPER COMPLEXES OF CRUDE HEMATOPORPHYRINS).
51.3465 USE OF PHYSICAL FORCES AND MODIFICATION OF PHYSICAL ENVIRONMENT DURING IRRADIATION OF EXPERIMENTAL ANIMAL TUMORS.
51.34651 GENERAL.
51.34652 USE OF INCREASED TEMPERATURE.
51.34653 USE OF MAGNETIC FIELDS DURING TUMOR IRRADIATION.
51.347 PRECLINICAL STUDIES OF AGENTS WHICH PREVENT IRRADIATION DAMAGE AND PROTECT NORMAL TISSUES AGAINST IRRADIATION (CYTOPROTECTANTS).
USE OF TESTOSTERONE TO PROTECT AGAINST HEMATOLOGIC DEPRESSION INDUCED BY P32.
51.34701 GENERAL.
51.34702 USE OF SUCH COMPOUNDS.
51.34703 USE OF BONE MARROW AND OTHER CELL TRANSPLANTATION.
51.3483 PRECLINICAL RADIATION THERAPY OF SKIN CANCER.

51.35 SURGICAL REMOVAL OF CANCERS IN EXPERIMENTAL ANIMALS.
51.351 GENERAL.
51.352 SURGICAL REMOVAL OF CANCER FROM SPECIFIC REGIONS.
51.353 METHODS FOR PREVENTING RECURRENCE OR METASTASIS OF SUGICALLY REMOVED TUMORS.

51.36 PRE-CLINICAL STUDIES OF COMBINATION THERAPY.
ADJUNCT OR ADJUVANT THERAPY.
SEE ALSO: 51.376 FOR COMBINATION THERAPY INVOLVING IMMUNOTHERAPY.
51.361 GENERAL.
51.362 COMBINATIONS OF RADIATION AND SURGERY.
51.363 COMBINATIONS OF CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES) AND SURGERY.
51.364 COMBINATIONS OF RADIATION AND CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES).
ACTINOMYCIN D AND IRRADIATION.
51.365 COMBINATIONS OF RADIATION, SURGERY, AND CHEMOTHERAPEUTIC AGENTS (INCLUDING HORMONES).
ACTINOMYCIN D AND RADIATION.
SEE ALSO: 51.34025 FOR COMPOUNDED SENSITIVITY OF LEUKEMIA CELLS TO IRRADIATION BY BACTERIA RESISTANT TO CHEMOTHERAPEUTIC AGENTS.
51.366 COMBINATIONS OF RADIATION AND HORMONES.
51.367 COMBINATIONS OF HORMONES AND OTHER CHEMOTHERAPEUTIC AGENTS.

51.368 COMBINATIONS OF THREE TYPES OF TREATMENT.
51.3681 GENERAL.
51.3682 RADIATION, SURGERY, CHEMOTHERAPEUTIC AGENTS.
51.3683 SURGERY, CHEMOTHERAPEUTIC AGENTS, HORMONES.
51.3684 CHEMOTHERAPEUTIC AGENTS, HORMONES, RADIATION.
51.3685 HORMONES, RADIATION, SURGERY.
51.369 COMBINATIONS INVOLVING ALL FOUR BASIC METHODS OF TREATMENT.

51.37 PRE-CLINICAL NON-VIRAL IMMUNOTHERAPY AND RELATED IMMUNE PROCEDURES; USE OF ANTIBODIES AND MODIFIED TUMOR TISSUE (AND OTHER IMMUNOLOGICAL PROPHYLAXIS) TO INHIBIT TUMOR GROWTH OF NON-VIRUS-INDUCED TUMORS.
INJECTION OF TUMOR CELLS OR TISSUES.
METHODS FOR MODIFYING SUCH CELLS OR TISSUES BEFORE INJECTION.
INFECTION OF TUMOR CELLS WITH VIRUSES IN TISSUE CULTURE.
CYTOSIDAL ACTION OF NORMAL HUMAN SERUM.
EFFECT OF COMBINING IMMUNIZING PROCEDURES WITH CANCER CHEMOTHERAPEUTIC AGENTS.
USE OF IMMUNE COMPETENT CELLS AND DRUGS.
SEE ALSO: 51.45125 FOR IMMUNE METHODS USED TO INHIBIT VIRUS-INDUCED TUMORS.
SEE ALSO: 51.32325 FOR IMMUNOCHEMOTHERAPY (USE OF ANTIBODIES TO CARRY CHEMOTHERAPEUTIC AGENTS TO THE TUMOR).
SEE ALSO: 51.32725 FOR USE OF MICROBIAL ANTIGENS.
SEE ALSO: 51.32726 FOR USE OF INTERFERONS AND THE INJECTION OF INTERFERON-PRODUCING VIRUSES.
SEE ALSO: 51.743 FOR ANTIBODIES AGAINST TUMOR ANTIGENS AGAINST SPECIFIC HORMONES.
SEE ALSO: 51.33 FOR USE OF ANTISERUM.
SEE ALSO: 51.74 FOR TUMOR IMMUNITY (GENERAL).
SEE ALSO: 51.74232 FOR EFFECT OF MODIFIED TUMOR CELLS AND TISSUES ON REJECTION BY THEIR BEING TRANSPLANTED OR INJECTED INTO HOSTS.
SEE ALSO: 51.45127 FOR IMMUNOTHERAPY AGAINST TUMORS INDUCED BY VIRUSES.
51.371 GENERAL.
51.372 EFFECT OF PRE-IMMUNIZATION OF ANIMALS BY ONE TUMOR ON THE SUBSEQUENT DEVELOPMENT OF SPONTANEOUS AND CARCINOGEN-INDUCED TUMORS.
51.373 DEVELOPMENT OF DNA-SPECIFIC ANTIBODIES AND DNA COMBINING AGENTS.
51.374 INHIBITION OF CARCINOGENESIS BY IMMUNE METHODS.
51.375 IMMUNIZATION AGAINST TRANSPLANTABLE TUMORS.
51.376 COMBINATION THERAPY INVOLVING IMMUNOTHERAPY AND DRUGS OR RADIATION OR SURGERY.

51.38 NOVEL METHODS OF TREATING CANCER AND EFFECTS OF PHYSICAL FORCES.
SEE ALSO: 36.3 FOR EFFECT OF THESE FORCES ON BIOLOGICAL MATERIALS (GENERAL).
SEE ALSO: 51.3425 FOR USE OF LASER BEAMS.
SEE ALSO: 51.3272 FOR ONCOLYTIC BACTERIA AND VIRUSES.
51.381 EFFECT OF MAGNETIC FIELDS.
51.382 USE OF TEMPERATURE CHANGES (HEAT OR COLD) TO DESTROY TUMORS.
INCREASED SENSITIVITY OF TUMORS TO HEAT.
EFFECT OF COLD ON TUMOR GROWTH.
51.3821 GENERAL.
51.3822 EFFECT OF HEAT ON TUMORS.
INCREASED SENSITIVITY OF TUMORS TO HEAT.
DESTRUCTION OF LYMPH NODE METASTASES IN ANIMALS BY HYSTERESIS HEATING (WITH FLUCTUATING MAGNETIC FIELD) OF IRON PARTICLE.
EFFECT OF HEATING TUMORS WHILE COOLING REST OF BODY.
THERMAL SENSITIZATION OF CANCER CELLS FOR VITAMIN COMBINATIONS AND METHYLENE BLUE.
SEE ALSO: 51.51115 FOR EFFECT OF HEAT ON TUMOR HISTOLOGY.
SEE ALSO: 51.314 FOR USE OF GENERAL HYPOTHERMIA WHILE TREATING LOCALLY WARMED TUMORS IN ANIMALS.
51.3823 EFFECT OF COLD ON TUMORS.
51.383 EFFECT OF DIETS ON ANIMAL TUMORS.
SEE ALSO: 51.32543 FOR VITAMIN DEFICIENT DIETS.
SEE ALSO: 51.3255 FOR EFFECT OF VITAMIN ANTIMETABOLITES ON TUMORS.
51.384 EFFECT OF STRESS OR TRAUMA ON TUMOR GROWTH.
51.38401 GENERAL.